



Planet Depos[®]
We Make It *Happen*[™]

Transcript of Stylianos Bournazos, Ph.D.

Date: December 11, 2025

Case: CSPC Megalith Biopharmaceutical Co., Ltd -v- Shanghai Miracogen Inc.

Planet Depos

Phone: 888.433.3767

Email: transcripts@planetdepos.com

www.planetdepos.com

Transcript of Stylianos Bournazos, Ph.D.
 Conducted on December 11, 2025

<p>1 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE</p> <p>2 BEFORE THE PATENT TRIAL AND APPEAL BOARD</p> <p>3</p> <p>4 CSPC MEGALITH) BIOPHARMACEUTICAL CO., LTD.,)) 5 Petitioner,) Case No.) IPR2025-00685 6 vs.)) U.S. Patent No. 7 SHANGHAI MIRACOGEN INC.,) 10,792,370) 8 Patent Owner.) 9)</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15 REMOTE DEPOSITION OF</p> <p>16 STYLIANOS BOURNAZOS, Ph.D.</p> <p>17 THURSDAY, DECEMBER 11, 2025</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24 Reported Stenographically By: Cody Knacke, RDR, CSR No. 13691 25 Job No.: 610717 Pages: 1-161</p>	<p>1 I - N - D - E - X</p> <p>2 EXAMINATION BY: PAGE</p> <p>3 BY MR. QIU 6</p> <p>4 AFTERNOON SESSION 74</p> <p>5</p> <p>6</p> <p>7 E - X - H - I - B - I - T - S</p> <p>8 MARKED DESCRIPTION PAGE</p> <p>9 Exhibit 2020 HHS Public Access author 141 manuscript entitled "Signaling 10 by Antibodies: Recent Progress"</p> <p>11</p> <p>12 PREVIOUSLY MARKED EXHIBITS</p> <p>13 MARKED DESCRIPTION PAGE</p> <p>14 Exhibit 7 Petitioners' Response to 152 Patent Owner's Request for Discretionary Denial of Institution</p> <p>16 Exhibit 1002 Expert Declaration of 15 Stylianos Bournazos, Ph.D.</p> <p>18 Exhibit 1005 United States Patent 74 Application Publication No. US 2015/0071923, Wei, et al.</p> <p>20 Exhibit 1006 World Intellectual Property 91 Organization Publication No. WO 2014/152199 A1</p> <p>22 Exhibit 1007 China National Intellectual 100 Property Administration Invention Patent Application 23 Publication No. CN 103772504 A (Chinese version)</p> <p>24</p> <p>25</p>
<p>1 REMOTE DEPOSITION OF STYLIANOS BOURNAZOS,</p> <p>2 Ph.D., taken before Cody Knacke, RDR, CSR No. 13691,</p> <p>3 a Certified Shorthand Reporter for the State of</p> <p>4 California, commencing on Thursday,</p> <p>5 December 11, 2025, at 8:00 a.m., Pacific time.</p> <p>6</p> <p>7 (All Appearances Via Videoconference.)</p> <p>8 APPEARANCES OF COUNSEL:</p> <p>9 For the Petitioner:</p> <p>10 SHEPPARD MULLIN</p> <p>11 BY: FANGZHOU FRED QIU, ESQ. ALEX NIE, ESQ. 1540 El Camino Real Menlo Park, California 94025 650.815.2652 fqi@sheppardmullin.com anie@sheppardmullin.com</p> <p>14 For the Patent Owner:</p> <p>15 FOX ROTHSCHILD</p> <p>16 BY: HOWARD SUH, ESQ. ERXIN DU, ESQ. 101 Park Avenue, 17th Floor New York, New York 10178 212.878.7914 hsuh@foxrothschild.com edu@foxrothschild.com</p> <p>19 Also Present:</p> <p>21 Drew Schueler, Remote Technician</p> <p>22</p> <p>23</p> <p>24</p> <p>25</p>	<p>1 I N D E X</p> <p>2 (Continued)</p> <p>3 PREVIOUSLY MARKED EXHIBITS</p> <p>4 MARKED DESCRIPTION PAGE</p> <p>5 Exhibit 1008 China National Intellectual 100 Property Administration Invention Patent Application Publication No. CN 103772504 A (English version)</p> <p>8 Exhibit 1009 World Intellectual Property 120 Organization Publication No. WO 2015/000062 A1</p> <p>10 Exhibit 1021 Article published in Nature 69 Reviews Drug Discovery entitled "Fresh from the Pipeline - Brentuximab vedotin," written by Younes, et al., dated January 2012</p> <p>13 Exhibit 1101 Article entitled, "A Study of 153 SYS6010 and Platinum-based Chemotherapy in Patients With EGFR-mutated NSCLC"</p> <p>16 Exhibit 1102 Article entitled, "Clinical 153 Trial of SYS6010 SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors"</p> <p>18 Exhibit 1103 Article entitled, "A Phase 1 153 Study of CP0301 in Adult Patients with Advanced or Metastatic Solid Tumors"</p> <p>20 Exhibit 2015 United States Patent 95 Application Publication No. US 2011/0076232, Old, et al.</p> <p>22</p> <p>23</p> <p>24</p> <p>25</p>

Transcript of Stylianos Bournazos, Ph.D.
Conducted on December 11, 2025

2 (5 to 8)

5	7
<p>1 THURSDAY, DECEMBER 11, 2025 2 8:00 A.M. 3 REMOTE TECHNICIAN: Thank you to everyone 4 for attending this proceeding remotely, which we 5 anticipate will run smoothly. Please remember to 6 speak slowly and do your best not to talk over one 7 another. Please be aware that we are recording this 8 for backup purposes. Any off-the-record discussions 9 should be had away from the computer. Please 10 remember to mute your mic for those conversations. 11 Please have your video enabled to help the 12 reporter identify who is speaking. We will provide 13 a complimentary, unedited recording of this 14 deposition with the purchase of a transcript. 15 I apologize in advance for any 16 technical-related interruptions. 17 Thank you. 18 THE STENOGRAPHER: This is Cody Knacke, 19 CSR 13691. This deposition is being recorded 20 stenographically. 21 STYLIANOS BOURNAZOS, Ph.D., 22 called as a witness, having been first duly sworn, 23 testified as follows: 24 /// 25 ///</p>	<p>1 speaker -- 2 A. It's in front of me, so I'll do my best. 3 Q. It's right -- okay. Okay. Thank you. 4 A. I can move it closer. 5 Okay. Hope it's better now because I have 6 moved it closer. 7 Q. Okay. Thank you. 8 And we can take breaks today when you need 9 to. I just ask that when we take a break, there's 10 no question pending. Is that fair? 11 A. Yes. 12 Q. Do you understand you're not allowed to 13 discuss your testimony with your counsel during 14 breaks today? 15 A. Yes, I do. 16 Q. If you don't understand a question, let me 17 know, and I will rephrase. Unless you say 18 otherwise, I will assume you understand the 19 question. 20 Is that fair? 21 A. Yes, I do. 22 Q. You have to answer my questions today 23 unless your attorney instructs you otherwise. 24 Understood? 25 A. Yes.</p>
6	8
<p>1 EXAMINATION 2 BY MR. QIU: 3 Q. Good morning, Dr. Bournazos. 4 A. Good morning. 5 Q. So let's start the deposition. 6 Have you been deposed before? 7 A. No. It's my first time. 8 Q. So let's go over a few ground rules just to 9 get things started. 10 So you understand you are under oath to 11 tell the truth today? 12 A. I do. 13 Q. We need verbal responses for today's 14 deposition because this is being transcribed today. 15 We need to make sure the court reporter can get your 16 responses. 17 A. Yes. And if at some point the court 18 reporter cannot understand me, I can speak more 19 slowly or you can let me know. 20 Q. Great. 21 A. Can you hear me well? 22 Q. I'm sorry? 23 A. Can you hear me well? 24 Q. It's a little, slightly unclear. Don't 25 know if you have a microphone near, other than the</p>	<p>1 Q. Are you on any medication today? 2 A. No. 3 Q. Any reason that you wouldn't be able to 4 provide accurate and truthful testimony today? 5 A. No. 6 Q. Are you here to give testimony in the 7 Inter Partes Review proceedings involving 8 U.S. Patent Number 10,792,370? 9 A. Yes. 10 Q. Today, we will refer to that patent as the 11 '370 patent. 12 Is that all right? 13 A. Yes, that's correct. 14 Q. What documents do you have with you? 15 A. Nothing. I can see only the exhibits on my 16 left side. 17 Q. And are you referring to the exhibits that 18 was in the box that we mailed to you? 19 A. Yes, those exhibits. 20 Q. Okay. Do you have a computer in front of 21 you? 22 A. No. Just my cell phone. 23 Q. Okay. So one of the things that we are 24 probably going to talk about today is the concept of 25 person of ordinary skill in the art.</p>

9	11
<p>1 Are you familiar with that phrase?</p> <p>2 A. Yes.</p> <p>3 Q. If we use the term POSA, that's spelled,</p> <p>4 P-O-S-A, will you understand that that refers to the</p> <p>5 person of ordinary skill in the art?</p> <p>6 A. Yes. You mean the acronym?</p> <p>7 Q. Yes, yes.</p> <p>8 A. Yes.</p> <p>9 Q. Are there any errors in your declaration or</p> <p>10 anything you want to change?</p> <p>11 A. I don't think so.</p> <p>12 Q. How much time did you spend preparing your</p> <p>13 declaration?</p> <p>14 A. Quite many hours. I don't recall the exact</p> <p>15 number of hours.</p> <p>16 Q. Can you give me a ballpark estimate?</p> <p>17 A. I would say maybe 20, 30 hours. But I</p> <p>18 don't really keep time.</p> <p>19 Q. What did you review when preparing your</p> <p>20 declaration?</p> <p>21 A. Can you repeat your question?</p> <p>22 Q. I'm sorry? Can I repeat --</p> <p>23 A. Can you repeat your question?</p> <p>24 Q. So my question is, when you were preparing</p> <p>25 your declaration, what did you review -- what</p>	<p>1 you reviewed for preparing the declaration but was</p> <p>2 not listed in the declaration?</p> <p>3 MR. SUH: Objection. Asked and answered.</p> <p>4 THE WITNESS: I don't recall any. It's</p> <p>5 been almost a year, so I cannot remember every</p> <p>6 single paper that I reviewed back then.</p> <p>7 BY MR. QIU:</p> <p>8 Q. Did you draft your expert declaration in</p> <p>9 this proceeding?</p> <p>10 A. Can you repeat the question, please?</p> <p>11 Q. Did you draft the declaration that you</p> <p>12 signed for this proceeding?</p> <p>13 A. I reviewed the draft.</p> <p>14 Q. You reviewed the draft.</p> <p>15 A. Yeah, I worked on the draft.</p> <p>16 Q. So you didn't draft the initial declaration</p> <p>17 yourself.</p> <p>18 MR. SUH: Objection. Form.</p> <p>19 Sorry. Same objection.</p> <p>20 THE WITNESS: I don't remember having</p> <p>21 prepared the first draft of the declaration. But</p> <p>22 there were several versions that I went through and</p> <p>23 edited.</p> <p>24 BY MR. QIU:</p> <p>25 Q. What did you do to prepare for this</p>
10	12
<p>1 documents did you review?</p> <p>2 A. Lots of documents, including patents,</p> <p>3 abstracts, conference abstracts, prior publications,</p> <p>4 sequences. Quite a few materials.</p> <p>5 Q. Is there any document that you reviewed</p> <p>6 that was not listed in the list of exhibits shown in</p> <p>7 your declaration?</p> <p>8 A. I believe we reviewed lots of different</p> <p>9 documents, papers, patents, and would include the</p> <p>10 most relevant ones. Yes. So during the process we</p> <p>11 reviewed many things.</p> <p>12 Q. And some of the things were not listed in</p> <p>13 the exhibit list; is that right?</p> <p>14 MR. SUH: Objection -- sorry. Objection to</p> <p>15 form.</p> <p>16 You can answer, Doc.</p> <p>17 THE WITNESS: Okay. I don't recall</p> <p>18 exactly, the type of materials and what exact</p> <p>19 materials we were going through.</p> <p>20 BY MR. QIU:</p> <p>21 Q. Right.</p> <p>22 A. But at the end, we decided these are the</p> <p>23 most relevant for the case and for the -- for the</p> <p>24 arguments.</p> <p>25 Q. Okay. Can you remember any document that</p>	<p>1 deposition?</p> <p>2 A. I reviewed the materials, I refreshed my</p> <p>3 memory, because it's been a year, and had a good</p> <p>4 night's sleep.</p> <p>5 Q. How long did you spend preparing for this</p> <p>6 deposition with counsel?</p> <p>7 A. A few hours.</p> <p>8 Q. Did you review any documents for preparing</p> <p>9 for this deposition?</p> <p>10 A. Yes. I mentioned already I reviewed my</p> <p>11 declaration and then what it was included with the</p> <p>12 declaration previously.</p> <p>13 Q. So in total, how much time have you spent</p> <p>14 reading and reviewing the '370 patent?</p> <p>15 MR. SUH: Objection. Lacks foundation.</p> <p>16 You can answer if you understand.</p> <p>17 THE WITNESS: No, it's fine.</p> <p>18 Total from the -- total number of hours or</p> <p>19 in preparation for the deposition?</p> <p>20 BY MR. QIU:</p> <p>21 Q. Yes, yes. Total number of hours.</p> <p>22 A. I don't recall.</p> <p>23 Q. Can you give an estimate for that?</p> <p>24 A. No. I would say many hours.</p> <p>25 Q. Have you ever reviewed the entire</p>

13	<p>1 specification of the '370 patent? 2 A. What do you mean if I reviewed? 3 Q. Do you know the meaning of the 4 specification in the context of a patent? 5 A. The claims. 6 Q. So you -- so your understanding is that the 7 specification of a patent are the claims? 8 MR. SUH: Objection to form. 9 THE WITNESS: Can you rephrase your 10 question or make it clearer? 11 BY MR. QIU: 12 Q. Sure. 13 Have you reviewed the entirety of the 14 '370 patent? 15 A. Yes. 16 Q. Do you know what the specification of the 17 '370 patent refers to? 18 MR. SUH: Objection to form. Vague. 19 You can answer if you understand the 20 question. 21 THE WITNESS: What do you mean by 22 specification? You mean the claims? 23 BY MR. QIU: 24 Q. Okay. Yeah, so by the specification, I 25 mean the, yes, the content in the patent that goes</p>	15	<p>1 February 2015 that qualified you to be a POSA? 2 A. My experiences are outlined in the 3 deposition -- in the declaration, sorry. And I 4 believe I fulfill these requirements as a POSA. 5 Q. What experiences listed in your declaration 6 qualifies you to be a POSA? 7 A. Can I have a copy of the declaration -- of 8 the declaration? 9 Q. Sure. You can open the declaration. 10 MR. SUH: Fred, do you want to mark it as 11 an exhibit? 12 MR. QIU: Yeah. So the declaration is 13 already marked as Exhibit 1002, I believe. 14 MR. SUH: All right. We're looking for it. 15 Okay. 16 So, Fred, did you say this was marked 17 already as an exhibit? 18 MR. QIU: Yeah. So this declaration is 19 Dr. Bournazos's declaration that has been filed and 20 stamped as Exhibit 1002 in this case. 21 (Exhibit 1002 was previously marked by the 22 Certified Shorthand Reporter, and a copy is 23 attached hereto.) 24 MR. SUH: Okay. Thank you. 25 And we're using the same exhibit numbers</p>
14	<p>1 before the claims, you know, the paragraphs. 2 A. Oh, the text. 3 Q. Uh-huh. Yeah. 4 A. Yes. 5 Q. Do you believe you have an adequate 6 understanding of the '370 patent? 7 A. I think so. 8 Q. Is there anything you think is unclear 9 about the '370 patent? 10 A. No. 11 Q. In your opinion, what qualifications does a 12 person need to have to be a POSA? 13 A. According to my opinion, a POSA would be a 14 person, as the name suggests, of ordinary skill in 15 the art that will have a Ph.D. in immunology, 16 molecular biology, biochemistry, or a related 17 discipline, and at least five years of experience in 18 research in the field of antibodies, antibody 19 therapeutics, or any related field. It can also be 20 an MD that has research experience as well. And I 21 believe these were included in the petition as a 22 definition of POSA. 23 Q. Did you qualify as a POSA in February 2015? 24 A. I believe so. 25 Q. What experiences did you have prior to</p>	16	<p>1 that were actually used in the actual filing of the 2 papers? 3 MR. QIU: Yeah. I think that's -- that's a 4 convenient way to do it, unless you have some other 5 proposal. So for the -- 6 MR. SUH: That's fine. 7 MR. QIU: Okay. 8 THE WITNESS: Okay. That's good. Thanks. 9 So do you have a copy of the declaration? 10 BY MR. QIU: 11 Q. I do, yeah. 12 A. Okay. Good. So then in Section 1, 13 paragraphs 2 through 9, I have listed all my 14 qualifications that are relevant to this case. 15 Q. Are all those qualifications relevant for 16 determining whether you qualify as a POSA? 17 A. Yeah. 18 Q. Have you worked with any anti-EGFR antibody 19 in your research? 20 A. Briefly, yes. 21 Q. Can you describe that experience? 22 A. It's an ongoing project, and I cannot 23 really describe ongoing projects for this purpose. 24 MR. SUH: Yeah, and I just want to note for 25 the record that, Doctor, to the extent that you have</p>

<p style="text-align: right;">17</p> <p>1 confidentiality agreements with respect to work that 2 you currently have, that you do not disclose those. 3 BY MR. QIU: 4 Q. Do you have -- 5 A. And don't -- yeah. No, sorry. 6 Q. Do you have any publications about 7 anti-EGFR antibodies? 8 A. No. 9 Q. Have you worked with cetuximab in your 10 research? 11 A. Yes. 12 Q. Is that something you can describe? 13 A. In very broad terms, yes. 14 Q. So can you please describe your experience 15 researching about cetuximab. 16 A. So we have used cetuximab in the project 17 that is still ongoing to assess the activity of the 18 Fc domain in vivo and in vitro. 19 Q. Have you worked with antibody drug 20 conjugates in your research? 21 A. Yes. 22 Q. Can you please describe your research about 23 antibody drug conjugates. 24 A. Yes, of course. So one publication that 25 was some years ago was in collaboration with a group</p>	<p style="text-align: right;">19</p> <p>1 page. 2 Q. Okay. Is it the eleventh -- oh, it's -- is 3 it the eleventh from the end of that section? Like 4 before -- 5 A. Yeah. 6 Q. -- before Review Articles; right? 7 A. Before the Review Articles. So in the 8 research. 9 Q. So it's the last article on the previous 10 page. 11 A. Yeah, exactly. 12 Q. One-pot conversion of free sialoglycans to 13 functionalized -- 14 A. That's the one, yes. 15 MR. SUH: I just want to make sure that 16 we're not talking over each other for the court 17 reporter's purposes. 18 THE STENOGRAPHER: Thank you. 19 BY MR. QIU: 20 Q. So what is the title of this article? 21 A. What is that? 22 Q. What is the title of this article? 23 A. One-pot conversion of free sialoglycans to 24 functionalized glycan oxazolines and efficient 25 synthesis of homogenous antibody-drug conjugates</p>
<p style="text-align: right;">18</p> <p>1 at University of Maryland. So if you -- you have a 2 copy of my CV; right? 3 Q. Yes. 4 A. Yeah. So -- or even in declaration. So 5 page -- so publication in 2021 listed as One-pot 6 conversion of free sialoglycans to functionalized 7 glycan oxazolines. So this one was used in this 8 publication, so actually -- 9 (Speaking simultaneously.) 10 BY MR. QIU: 11 Q. On what page is that publication? 12 A. Is -- if you go to my CV, you see that? 13 Bibliography, Research Articles. 14 Q. Yes, yes. Research articles, yes. 15 A. So then you scroll to 2021. It's the last 16 publication on the page before the end. Above the 17 Review Articles. 18 Q. Okay. 19 A. So Ou, Li, Zhang, Yang, Zong, Dai, Francis, 20 Bournazos, Ravetch, Wang, 2021. 21 Q. Is that at the top of that page or middle? 22 A. Because this is not marked. 23 Q. ELISA? 24 A. It's the eleventh publication from the end 25 of the recent articles, the last on the previous</p>	<p style="text-align: right;">20</p> <p>1 through site-specific chemoenzymatic glycan 2 remodeling. 3 Did you see? 4 Q. Can you briefly describe the subject of 5 that research. 6 A. Yes. So this is basically testing 7 different approaches of generating conjugation 8 strategies of ADC to -- or conjugation strategies of 9 the drug to the antibody and assessing the impact in 10 vitro in the capacity of these antibodies to induce 11 cell death. 12 Q. Do you have any other publications about 13 ADCs? 14 A. The last one in 2024, this is -- again, 15 it's not directly ADCs, but it's antibody drug and 16 radioisotopes. Same chemistry, different approach. 17 Q. And can you -- sorry. 18 A. And there are also ongoing projects that 19 I'm involved in direct assessing the activity of 20 ADCs in vivo. 21 Q. Can you state the name of the -- this 22 publication for the record in 2024? 23 A. Oh, the one I mention? Rodriguez. It's 24 the last one on the list. 25 Q. Yeah, can you please state the title of</p>

<p style="text-align: center;">21</p> <p>1 this article?</p> <p>2 A. Exploring the Interplay</p> <p>3 Between Radioimmunoconjugates and Fc Gamma Receptors</p> <p>4 in Genetically Engineered Mouse Models of Cancer.</p> <p>5 Q. Thank you.</p> <p>6 A. Thank you.</p> <p>7 THE STENOGRAPHER: Excuse me, Counsel. May</p> <p>8 we go off the record, please.</p> <p>9 (Recess.)</p> <p>10 BY MR. QIU:</p> <p>11 Q. Dr. Bournazos, can you please explain the</p> <p>12 differences between mouse antibody, chimeric</p> <p>13 antibody, and humanized antibody?</p> <p>14 A. Mouse antibody is an antibody that has been</p> <p>15 produced in mouse and 100 percent of the sequence is</p> <p>16 mouse.</p> <p>17 Your next question was chimeric?</p> <p>18 Q. Yes.</p> <p>19 A. Chimeric, as the name suggests, is an</p> <p>20 antibody that has sequence from a mouse or another</p> <p>21 species -- from two different species. Usually,</p> <p>22 when we -- specifically for this case, when we refer</p> <p>23 chimeric means that some part is mouse and the vast</p> <p>24 majority of the rest is human. So typically, the</p> <p>25 variations can be mouse because the antibody has</p>	<p style="text-align: center;">23</p> <p>1 system against something else.</p> <p>2 So one of the benefits of humanization is</p> <p>3 actually to reduce the potential of immunogenicity.</p> <p>4 Is it clear?</p> <p>5 BY MR. QIU:</p> <p>6 Q. Do all humanized antibodies exhibit the</p> <p>7 same benefits over all chimeric antibodies?</p> <p>8 A. What do you mean by "benefit"?</p> <p>9 Q. You have just explained the benefits of</p> <p>10 humanization; correct?</p> <p>11 A. I mentioned immunogenicity specifically.</p> <p>12 Q. Okay. So do all humanized antibodies</p> <p>13 exhibit this same benefit over all chimeric</p> <p>14 antibodies?</p> <p>15 MR. SUH: Objection. Vague.</p> <p>16 THE WITNESS: In principle, yes. So any</p> <p>17 antibody that is closer to humans is expected to</p> <p>18 have lower immunogenicity.</p> <p>19 BY MR. QIU:</p> <p>20 Q. Are there any other benefits of</p> <p>21 humanization?</p> <p>22 MR. SUH: Objection. Vague.</p> <p>23 THE WITNESS: What other benefits do you</p> <p>24 have in mind?</p> <p>25 ///</p>
<p style="text-align: center;">22</p> <p>1 been originated from a mouse, and then the rest is</p> <p>2 human.</p> <p>3 And then your last -- your last question</p> <p>4 was humanized.</p> <p>5 Q. Correct.</p> <p>6 A. Humanized is usually an antibody that has</p> <p>7 as much human sequence as possible. It's not</p> <p>8 entirely human, but it has as high sequence</p> <p>9 similarity to humans as possible.</p> <p>10 There is -- in the declaration, there is a</p> <p>11 nice cartoon -- cartoon that actually illustrates</p> <p>12 this. And it's very helpful. So if you go, for</p> <p>13 example, on page 22, you will see this.</p> <p>14 Q. What are the benefits of humanization?</p> <p>15 MR. SUH: Objection. Vague.</p> <p>16 You can answer if you understand.</p> <p>17 THE WITNESS: Benefits? So if you have a</p> <p>18 forwarding sequence from another species that is</p> <p>19 given to human, there is always going to be a</p> <p>20 reaction to that because the body is going to see</p> <p>21 this as a foreign object.</p> <p>22 Think about in the context of</p> <p>23 transplantation. It's a foreign thing that is also</p> <p>24 immunogenic. So this process is called</p> <p>25 immunogenicity. So it's a reaction of the immune</p>	<p style="text-align: center;">24</p> <p>1 BY MR. QIU:</p> <p>2 Q. Dr. Bournazos, I'm asking you a question.</p> <p>3 So my question is, are there any other benefits of</p> <p>4 humanization?</p> <p>5 MR. SUH: Same objection. Vague.</p> <p>6 THE WITNESS: Humanization, depending on</p> <p>7 how it's done, it can change the properties of the</p> <p>8 antibodies. It can lead to some benefits -- you can</p> <p>9 call them benefits. In my opinion, it's a change of</p> <p>10 property, but it really depends on the context of</p> <p>11 the antibody. But in principle, the main reason of</p> <p>12 humanization is to reduce immunogenicity.</p> <p>13 BY MR. QIU:</p> <p>14 Q. Is there any other property of an antibody</p> <p>15 that will be resulted from a humanization process?</p> <p>16 A. It depends on what change is introduced</p> <p>17 during humanization.</p> <p>18 (Stenographer clarification.)</p> <p>19 THE WITNESS: On what changes, what</p> <p>20 modifications you introduced during the humanization</p> <p>21 process, and each process is different for each</p> <p>22 antibody.</p> <p>23 BY MR. QIU:</p> <p>24 Q. Can you give me an example of a property</p> <p>25 other than immunogenicity that's changed by the</p>

<p>25</p> <p>1 process of humanization? 2 A. So using the humanization invokes changes 3 in the site where the antibody recognizes the 4 antigen. So when you introduce these changes, you 5 can also introduce variables that will influence the 6 way that the antibody binds the antigen. 7 (Stenographer clarification.) 8 THE WITNESS: That the antibody recognizes 9 the antigen. 10 BY MR. QIU: 11 Q. If you compare the humanized version of a 12 first antibody and the chimeric version of a second 13 antibody, will you always find the first antibody to 14 have lower immunogenicity than the second antibody? 15 A. What is the first antibody and what is the 16 second? 17 Q. They are two different antibodies. 18 A. Ah. Two different, we cannot make a 19 comparison in two different antibodies. 20 Q. And why is that? 21 A. Because its antibody, if they are 22 different, will organize different antigens. 23 Q. What if the two antibodies target the same 24 antigen, but they are different antibodies? 25 A. Again, even if they target the same</p>	<p>27</p> <p>1 Q. Does 2004 sound right to you, in the right 2 time frame? 3 A. I believe so. I believe so. 4 Q. Was it right that cetuximab was initially 5 approved for medical use in the U.S. in 2004? 6 A. I think so. 7 Q. To your knowledge, approximately how many 8 anti-EGFR antibodies have been developed or 9 described in the scientific literature? 10 A. Quite many. 11 Q. Do you have a ballpark estimate? 12 A. I would say hundreds. If we go over 13 papers, literature, abstracts, patents, there are 14 hundreds of antibodies out there. 15 Q. Are you familiar with efforts to create 16 variants of cetuximab? 17 A. Yes. 18 Q. Why do researchers create variants of 19 cetuximab? 20 A. Several reasons. 21 Q. Can you elaborate on the reasons? 22 A. One of the many reasons, for example, is a 23 topic that we briefly discussed today about 24 immunogenicity. So cetuximab is a chimeric 25 antibody. So one of the efforts was to create</p>
<p>26</p> <p>1 antigen, they can be from different clones. So 2 binding different areas of the antigen, different 3 epitopes. So we cannot make the assumptions that 4 they are identical because they are different. You 5 said they are different antibodies. 6 Q. Can you describe the history of anti-EGFR 7 antibodies in clinical use? 8 MR. SUH: Objection. Vague. Lacks 9 foundation. 10 You can answer if you understand, Doctor. 11 THE WITNESS: I understand the question, 12 but I cannot really comment on the history or give 13 you an overview, a very detailed overview that will 14 be 100 percent scientifically accurate at this 15 point. I'm not writing a review. I can give you a 16 very -- like, what is EGFR, why antibodies used 17 against EGFR, and so on, but to give you the history 18 of EGFR, this is a subject of -- first of all, I 19 will need to review literature on that, and I don't 20 have anything in front of me. And it's also a 21 subject of discussion that can take hours and hours. 22 BY MR. QIU: 23 Q. When did anti-EGFR antibodies first become 24 available for clinical use? 25 A. I don't recall the exact year.</p>	<p>28</p> <p>1 humanized versions of cetuximab to reduce the 2 potential for immunogenicity. 3 Q. Any other reason you can think of? 4 A. You always want to make an antibody better. 5 Q. What do you mean by "better" in this case? 6 A. And this -- and this is true for every 7 other therapeutic antibody out there. So you want 8 to increase the potency and reduce -- and improve 9 the safety profile. 10 Q. Are there any other reason why researchers 11 create variants of cetuximab? 12 A. There might be other reasons. 13 Q. Can you think of any at this point? 14 A. I can only speculate. If I'm allowed to do 15 that, I can say cetuximab is owned by another 16 company, so you want to make variants of that. 17 Q. What I would you -- strike that. 18 Was it common for researchers to create 19 many cetuximab variants and then screen them for 20 antibodies with desired properties? 21 MR. SUH: Objection. Vague. 22 THE WITNESS: Exactly what do you mean? 23 MR. QIU: Counsel, I have seen a pattern of 24 you making an "Objection, vague," and then the 25 witness will ask what I mean.</p>

<p>29</p> <p>1 According to the Board's rules, "Objection, 2 vague" is not allowed as an objection for 3 depositions. So I advise you to abstain from using 4 that objection in this session. 5 MR. SUH: Well -- well, I'll ask you to 6 articulate your questions more clearly. 7 MR. QIU: The Board has clear rules that 8 speaking objections are not allowed in depositions 9 for IPRs and -- 10 MR. SUH: I don't believe -- I don't 11 believe -- 12 MR. QIU: And the Trial Practice Guide -- 13 MR. SUH: I don't believe I've been making 14 speaking objections. 15 MR. QIU: And the Trial Practice Guide 16 explicitly states that "Objection, vague" is not 17 allowed. 18 MR. SUH: Okay. We can discuss this off 19 the record if you want to. 20 MR. QIU: Okay, yeah, let's go off the 21 record and discuss this. 22 THE STENOGRAPHER: Off the record. 23 (Recess.) 24 THE STENOGRAPHER: Back on the record. 25 THE WITNESS: Can you please repeat your</p>	<p>31</p> <p>1 it a generally common practice? I don't 2 understand -- generally, I don't understand your 3 question. 4 Q. Oh, the time frame. 5 Before 2015. 6 A. There is evidence that people were doing 7 this. Now, how common, extensive, or how many 8 groups were working on this, I cannot comment. 9 Q. When were ADCs initially invented? 10 A. When? 11 Q. Yes. At what time? 12 A. I don't recall -- I don't recall the exact 13 year. 14 Q. Is it correct that the FDA approved an ADC 15 for the first time in 2000? 16 A. I'm not sure. 17 Q. Does that time frame sound right to you? 18 A. Sounds a bit early, but it might be right. 19 I cannot be 100 percent sure. 20 Q. Can you briefly explain the role of each 21 component of an ADC molecule? 22 A. Yes. That's easy. So as the name 23 suggests, it's antibody drug conjugates, so it's an 24 antibody that has been conjugated to a drug, and 25 usually the drug is a chemotherapy agent. But</p>
<p>30</p> <p>1 question? 2 BY MR. QIU: 3 Q. Yes. Let me do that. 4 Was it a common approach for researchers to 5 create a number of cetuximab variants and then 6 screen the variants to identify ones that have 7 desirable properties? 8 MR. SUH: Objection. Unclear. 9 THE WITNESS: So your question is if it's 10 common to create variants of cetuximab? Is that 11 correct? 12 BY MR. QIU: 13 Q. So my question is -- so there's a research 14 approach of creating a number of variants and 15 screening the variants to identify ones that have 16 desirable properties. 17 And my question is whether that was a 18 common approach. 19 MR. SUH: Objection. That question lacks 20 foundation. 21 THE WITNESS: At what time frame you are 22 referring to? 23 BY MR. QIU: 24 Q. Sorry? 25 A. At what time frame you are referring to is</p>	<p>32</p> <p>1 that's commonly used. 2 There are also later-on efforts to have 3 other drugs instead of chemotherapy agents for other 4 diseases, not neoplastic. 5 Q. What is the process of an ADC killing a 6 tumor cell once it is administered to a patient? 7 A. Process? The mechanism, you mean? 8 Q. Sure. Mechanism. 9 A. So the first way that ADC act is to deliver 10 the drug to tumor cells. So the exact mechanism, we 11 still don't know. And there are several components 12 that contribute to this antitumor process. 13 But basically, a very, very -- a very 14 simplistic interpretation of how ADCs mediate 15 antitumor activity is that they recognize a receptor 16 on a tumor cell, commonly an extracellular 17 membrane-expressed antigen, they recognize that, the 18 receptor becomes internalized, and then the drug is 19 released intracellularly in the tumor cell. 20 So this is a very simplistic way of how an 21 ADC works, but we know that this process is much 22 more complicated than we think, than this simplistic 23 interpretation. 24 Q. What is the -- what is the main purpose of 25 the antibody portion of an ADC?</p>

Conducted on December 11, 2025

<p style="text-align: right;">33</p> <p>1 A. Most of the set -- in the context of tumor, 2 most of the drugs that are used in the drug 3 component of the ADC is very toxic to use it in 4 humans. So you cannot administer these drugs in 5 humans without killing the patient. 6 So what the ADC does, it brings this drug 7 primarily to the tumor site. Think about 8 chemotherapy but in a more targeted approach. 9 Q. So is it correct to say that the primary 10 role of the antibody is to recognize and bind to 11 target cells via specific antigens? 12 MR. SUH: Objection to form. 13 THE WITNESS: Can you repeat your question? 14 BY MR. QIU: 15 Q. Is it correct to say that the primary role 16 of the antibody is to recognize and bind to target 17 cells? 18 A. In the context of an ADC? 19 Q. Yes. 20 A. For most examples, yes, but there are 21 always exceptions to the rule. 22 Q. What exceptions do you have in mind? 23 A. Of the antibody, in addition to do this 24 function, to perform other functions. 25 Q. What other functions do you have in mind?</p>	<p style="text-align: right;">35</p> <p>1 antibody or -- 2 Q. Let me repeat my question. 3 A. Yeah, yeah, sorry, sorry. 4 Q. What are the important considerations when 5 selecting an antibody for use in an ADC? 6 A. So selecting the antibody, there are 7 several considerations that include among them the 8 target that you are -- the target molecule that you 9 are aiming to so that the antibody would be 10 recognizing. And then it has to do primarily with 11 the quality and the nature of the target. 12 Q. What is the main purpose of the linker 13 within ADC? 14 A. So the linker, as the name suggests, links, 15 in most cases, covalently the antibody to the 16 cytotoxin, to the cytotoxic compound. 17 Q. How does the process of an ADC killing a 18 tumor cell differ between ADCs with cleavable and 19 noncleavable linkers? 20 A. The process of killing is -- depends on the 21 cytotoxin, not on the linker. But the linker can 22 influence when and where the cytotoxin will be 23 released. 24 Q. How does a linker influence when and where 25 the cytotoxin will be released?</p>
<p style="text-align: right;">34</p> <p>1 A. It depends -- 2 MR. SUH: Objection. 3 Sorry. Objection. Asked and answered. 4 You can go ahead. 5 THE WITNESS: It depends on the context on 6 what receptor is targeted, what is not targeted, the 7 nature of the receptor, the signaling downstream of 8 the receptor, and so on. And this is mainly on the 9 Fab portion of the antibody. Fc can also have 10 effects. 11 BY MR. QIU: 12 Q. Can you give me an example of such other 13 functions? 14 A. Yeah. We can -- I can give you an example 15 specifically from the case, like cetuximab. It 16 binds and blocks the activity of EGFR. So you see, 17 in addition to blocking the receptor and 18 internalizing the receptor, it can also block the 19 signaling activity of the receptor. 20 Q. What are the important considerations when 21 selecting an antibody for an ADC? 22 A. Too many. Selecting an antibody, you mean, 23 or constructing an ADC? 24 Q. Yes. 25 A. The former or the latter? Selecting of the</p>	<p style="text-align: right;">36</p> <p>1 A. It does influence because of the nature of 2 the linker. So you can have linkers that are 3 cleavable and noncleavable. And among the cleavable 4 linkers, it will also influence how these linkers 5 are cleaved and under what conditions are cleavable. 6 And this process will influence whether or not and 7 to where the cytotoxin will be released. 8 Q. How does a cleavable linker and a 9 noncleavable linker function differently in this 10 mechanism? 11 A. In this? Can you repeat the last part of 12 your question? 13 Q. How does a cleavable linker and a 14 noncleavable linker function differently in the 15 mechanism of the ADC? 16 A. It depends on the chemical nature of the 17 linker. So I avoid using a global term of 18 "cleavable linker" because even with this category, 19 you can have linkers that can be cleaved under 20 different conditions. And each different condition 21 will influence how and when and where the tumor 22 cell -- the cytotoxin will be released. 23 Q. If we use the same antibody and payload but 24 either are cleavable or noncleavable linker, which 25 ADC will generally be more potent?</p>

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

<p style="text-align: right;">37</p> <p>1 MR. SUH: Objection. Unclear. 2 THE WITNESS: Do you mean by having this 3 exact same antibody and the exact same cytotoxin? 4 BY MR. QIU: 5 Q. That's correct. 6 A. It will really depend on the nature of the 7 linker. So as I mentioned previously, I would avoid 8 making the label of "cleavable linker" just to 9 having a blank statement or designation of cleavable 10 versus noncleavable because it depends on how the 11 linker will be cleaved. 12 Q. What is the main therapeutic function of 13 the payload in an ADC? 14 A. The main therapeutic function is to kill 15 malignant cells. But it depends, again, on what 16 this drug is. So I cannot comment on the mechanism 17 of these drugs if I don't know the drug that you are 18 referring to. 19 Q. What are the important considerations when 20 selecting a payload for use in an ADC? 21 A. You always want to go with as potent as 22 possible, but there are multiple considerations that 23 you need to take into account when selecting a 24 payload. But it's always a combination of the 25 payload with a linker and with a target that you</p>	<p style="text-align: right;">39</p> <p>1 A. It depends on the context. 2 Q. In what situations does ADC not provide 3 increased efficacy in tumor eradication compared 4 with unconjugated antibodies? 5 A. It depends on the target. So there -- 6 there are examples of ADCs not conferring any 7 benefit over naked antibodies. But it all depends 8 on the context. Generally, having an ADC is 9 expected to have better antitumor activity. But as 10 I mentioned, a very -- some important consideration 11 is the target. It all depends on what these 12 antibodies or ADCs are targeting. I cannot -- we 13 cannot really draw a conclusion and say ADCs are 14 always better than antibodies. 15 Q. Is it correct to say that an antibody -- 16 sorry. Strike that. 17 Is it correct to say that an ADC and 18 antibody mainly provides the specificity and that 19 the cytotoxic payload mainly performs the killing of 20 tumor cells? 21 A. We already -- 22 MR. SUH: Objection. I'm sorry. 23 Objection. Lacks foundation. 24 You can answer. 25 THE WITNESS: We already discussed this.</p>
<p style="text-align: right;">38</p> <p>1 want to target. So it's not a one payload fits 2 everything. 3 Q. What are the common payloads used in 4 FDA-approved ADCs and those candidate ADCs in 5 clinical trials? 6 A. I can refer to two. So one is DM-1 and the 7 other is MMAE, also known as vedotin. These are the 8 most commonly used, but there are several others. 9 Q. How do ADCs differ from unconjugated 10 antibodies in terms of their components and 11 mechanisms of action? 12 A. So antibody drug conjugates have a drug 13 that's conjugated to the antibody. The other 14 antibodies don't. So in terms of mechanism, ADCs 15 will also bring any cytotoxic activities that come 16 from the payload. Or cytotoxic or immunostimulator. 17 So that's the main difference between antibodies and 18 ADCs. 19 Q. Has ADC -- 20 A. But not the only one. 21 Q. Sorry. 22 A. Yeah, go ahead. 23 Q. Does ADC provide increased efficacy in 24 tumor eradication compared with unconjugated 25 antibodies?</p>	<p style="text-align: right;">40</p> <p>1 BY MR. QIU: 2 Q. So you agree with my statement; correct? 3 A. We already discussed this. So your 4 question is that if it merely provides binding to 5 the enzyme. I mentioned before that this is not one 6 single function of the antibody. 7 Q. What properties of the antibody determines 8 the binding specificity to target cells? 9 A. So the antibodies don't bind directly to 10 target cells. They bind to molecules that are 11 expressed by target cells, if you mentioned this. 12 Properties would be through a protein-protein 13 interactions between the Fab atom of the antibody 14 and the antigen that they recognize, the epitope 15 that they recognize. 16 (Stenographer clarification.) 17 THE WITNESS: So the primary determiner 18 would be how the Fab, F-A-B, the main atom antibody 19 would recognize the epitope on the antigen that's 20 expressed by the target cell. Is that clear? 21 THE STENOGRAPHER: Thank you. 22 THE WITNESS: Perfect. Thanks. 23 BY MR. QIU: 24 Q. Is binding specificity dictated by the 25 structure of the antibody's variable region?</p>

Conducted on December 11, 2025

41	<p>1 A. Correct, along with sometimes</p> <p>2 post-translation modifications of this. So</p> <p>3 sometimes it's not protein-protein structure, but it</p> <p>4 can also have glycoproteins or glycans that are</p> <p>5 involved in this process.</p> <p>6 Q. What properties of the antibody determines</p> <p>7 the binding affinity for a particular antigen?</p> <p>8 A. I would -- properties? Did you mean</p> <p>9 determinants?</p> <p>10 Q. Sure.</p> <p>11 A. So the interaction is primarily through</p> <p>12 protein-protein context, but as I mentioned before,</p> <p>13 sometimes you can have glycans that participate in</p> <p>14 this interface.</p> <p>15 Q. Does the binding of an antibody to cell</p> <p>16 surfaces depend on the expression level of antigen</p> <p>17 on cell surface?</p> <p>18 MR. SUH: Objection. Lack of foundation.</p> <p>19 You can answer if you understand.</p> <p>20 THE WITNESS: Depends on the context. You</p> <p>21 can have high expression, but the antibody might not</p> <p>22 be able to bind. Or you can have very low</p> <p>23 expression, and the antibody can be binding really</p> <p>24 well.</p> <p>25 ///</p>	43
42	<p>1 BY MR. QIU:</p> <p>2 Q. In what situation can an antibody not bind</p> <p>3 well when you have high expression?</p> <p>4 A. I can give you an example from SARS-CoV-2.</p> <p>5 So the spike protein has different components: The</p> <p>6 RBD, the NTD, and the S2 domains. So we know</p> <p>7 that -- how the spike protein, the S protein of</p> <p>8 SARS-CoV-2 is expressed by infected cells can</p> <p>9 influence how the antibody binds. This is because</p> <p>10 primarily of accessibility of the epitope, secondary</p> <p>11 structure or of how the spike is organized in the</p> <p>12 membrane, contact with other surface receptors,</p> <p>13 glycosylation, steric hindrance. There are many,</p> <p>14 many determinants that can determine how an antibody</p> <p>15 can bind to the antigen when the antigen is</p> <p>16 expressed on the cell surface.</p> <p>17 Q. For a certain antibody, does its binding to</p> <p>18 cell surfaces depend on the expression level of</p> <p>19 antigen on the cell surface?</p> <p>20 A. Not necessarily. I just mentioned the</p> <p>21 example of SARS-CoV-2. So you can have antibodies</p> <p>22 against a spike protein that might not bind very</p> <p>23 well to the spike. It depends on the antigen, it</p> <p>24 depends on the antibody and where the antibody</p> <p>25 binds.</p>	44
41	<p>1 So overexpression or expression of</p> <p>2 something doesn't necessarily mean that the antibody</p> <p>3 is still able to bind to that.</p> <p>4 Q. If an antigen is expressed at a very low --</p> <p>5 at a very low level, is it accurate that even</p> <p>6 high-affinity antibodies may not bind efficiently?</p> <p>7 A. No, that's not true. Because keep in</p> <p>8 mind --</p> <p>9 Q. Because --</p> <p>10 (Speaking simultaneously.)</p> <p>11 A. No, go ahead.</p> <p>12 Q. No, sorry. Please continue your answer.</p> <p>13 A. Antibodies have two arms. So even if you</p> <p>14 don't have enough expression or you have very low</p> <p>15 affinity, avidity effects can compensate for that.</p> <p>16 That's why the context, the antibody, and the</p> <p>17 epitope matters when we discuss issues like that.</p> <p>18 Q. So your opinion is if an antigen is</p> <p>19 expressed at a very low level, antibodies will still</p> <p>20 bind efficiently always?</p> <p>21 A. No.</p> <p>22 MR. SUH: Objection to form.</p> <p>23 THE WITNESS: I already explained that it</p> <p>24 depends on the antibody, the target, and the</p> <p>25 molecule. It's all dependent on the context. I</p>	44

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

Conducted on December 11, 2025

45	<p>1 expression. One antibody can bind, another antibody 2 cannot bind despite recognizing the same antigen. 3 BY MR. QIU: 4 Q. Does the expression level have an impact on 5 how efficiently an antibody will bind to cells with 6 an antigen? 7 A. Can you repeat the question? 8 Q. Does the expression level of an antigen 9 have an impact on how efficiently an antibody can 10 bind to cells with an antigen? 11 A. I explained this already. So the 12 expression cannot guarantee binding because every 13 antibody, every epitope is unique. 14 Q. Does the expression level of an antigen 15 have an impact on how efficiently an antibody can 16 bind to cells with an antigen other than 17 guaranteeing binding? 18 A. Can you clarify your question because I 19 think it's the same as your previous one. 20 Q. Sure. 21 I want to understand whether the expression 22 level of an antigen have any impact on how 23 efficiently an antibody can bind to cells with the 24 antigen. 25 Your earlier answer talks about</p>	47	<p>1 cell surface antigen, it can -- it's not necessarily 2 a function of expression level because it can be 3 influenced because where the antibody binds, which 4 epitope and so on, it all depends on the context. 5 Is it clear? 6 BY MR. QIU: 7 Q. Is there any case where the binding is a 8 function of the expression level of antigen? 9 A. I'm sure there is a case. But every 10 situation is unique. It's biology. Every system is 11 so complex. It has evolved in this way. 12 MR. SUH: Fred, we've gone for more than an 13 hour. Is this a good time for a break? 14 MR. QIU: Sure. Yeah, we can take a break. 15 MR. SUH: And if we could go off the 16 record, we can talk about... 17 (Recess.) 18 BY MR. QIU: 19 Q. Is there a minimum of density of surface 20 antibody binding required to trigger internalization 21 of the target cell? 22 A. No, not an absolute minimum. 23 Q. For a specific antibody and the specific 24 antigen being targeted, can a POSA determine an 25 amount of density required to trigger</p>
46	<p>1 guaranteeing binding. So that's one way the 2 expression level can impact. 3 But I'm asking about whether there are 4 other impacts that the expression level of an 5 antigen can have on how efficiently an antibody can 6 bind to cells with an antigen? 7 A. What do you mean -- 8 MR. SUH: Objection. Form. Misrepresents 9 the testimony. 10 Go ahead, Doctor. 11 THE WITNESS: What do you mean other 12 impacts? Other factors? 13 BY MR. QIU: 14 Q. Is the binding of an antibody to cells with 15 an antigen in any way influenced by the expression 16 level of the antigen on the cell. 17 MR. SUH: Objection. Asked and answered. 18 THE WITNESS: But I have already explained 19 this. So you are asking me -- and I'm sorry if I 20 don't get it. But you are asking me if the 21 expression level can influence how efficiently the 22 antibody can bind. 23 I have already explained that the level, 24 the expression level of the antigen, it depends -- 25 so how well -- how efficient the antibody binds to a</p>	48	<p>1 internalization by the target cell? 2 A. Can you please repeat the question? 3 Q. Sure. 4 For a specific antibody and a specific 5 antigen, can a POSA determine an amount of density 6 required to trigger internalization by the target 7 cell? 8 A. What do you mean "specific"? Is it a 9 specific example or for an antibody -- an antigen? 10 Q. Yes. 11 So my question is if the POSA knows what 12 the antibody is and what the antigen is, would the 13 POSA have been able to determine the amount of 14 density of a surface antibody binding that is 15 required for internalization to happen? 16 A. Oh, okay. Got it. Thanks for clarifying. 17 It depends if the POSA knows the targeting 18 antibody. Without this information, it's -- I don't 19 think -- without knowing which antibody, which 20 target is it, we cannot make the assumption about 21 density. 22 Q. What antibody properties influence the 23 threshold of binding required for internalization? 24 A. Let's take a step back. Antibody binding 25 doesn't equate to internalization. You understand</p>

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

<p style="text-align: right;">49</p> <p>1 that?</p> <p>2 Q. That's correct.</p> <p>3 So my question is -- sorry. Strike that.</p> <p>4 Let me rephrase my question.</p> <p>5 A. Thank you.</p> <p>6 Q. What properties of the antibody influence a</p> <p>7 threshold of binding density required for</p> <p>8 internalization to occur?</p> <p>9 A. So I explained this. So antibody binding</p> <p>10 doesn't equate to internalization. So we cannot</p> <p>11 have properties of an antibody that will dictate</p> <p>12 whether or not an antibody will be internalized.</p> <p>13 Q. Is antibody binding in any way related to</p> <p>14 internalization?</p> <p>15 A. No. I just explained that. It depends on</p> <p>16 the enzyme that the antibody is targeting.</p> <p>17 Q. When an antibody binds to an antigen, is</p> <p>18 binding with a single arm sufficient?</p> <p>19 MR. SUH: Objection. Lacks foundation.</p> <p>20 THE WITNESS: It depends on the context.</p> <p>21 For same-cell magnets [phonetic], it is sufficient.</p> <p>22 For others, it's not. For others -- for some</p> <p>23 antibodies, it is sufficient. For other antibodies,</p> <p>24 it is not sufficient.</p> <p>25 ///</p>	<p style="text-align: right;">51</p> <p>1 while sparing normal cells with low expression?</p> <p>2 A. Can you repeat the question? I didn't get</p> <p>3 the first part.</p> <p>4 Q. Sure.</p> <p>5 Would lowering the binding affinity of the</p> <p>6 antibody result in the antibody preferentially</p> <p>7 binding to and being internalized by cells with</p> <p>8 higher antigen expression, such as tumor cells,</p> <p>9 while sparing normal cells with lower expression?</p> <p>10 MR. SUH: Objection. Lacks foundation.</p> <p>11 THE WITNESS: I don't like the</p> <p>12 generalization that you make. So as I mentioned,</p> <p>13 binding doesn't equate to internalization.</p> <p>14 Everything depends on the target and the antibody</p> <p>15 and epitope that this antibody is recognizing. So I</p> <p>16 cannot comment on this.</p> <p>17 BY MR. QIU:</p> <p>18 Q. Would you agree that one key scenario where</p> <p>19 affinity is intentionally lowered for an antibody is</p> <p>20 when the target antigen is expressed on both tumor</p> <p>21 and normal cells but at much higher levels on</p> <p>22 tumors?</p> <p>23 MR. SUH: Objection to form.</p> <p>24 THE WITNESS: Would I agree with -- can you</p> <p>25 please repeat or rephrase, if necessary?</p>
<p style="text-align: right;">50</p> <p>1 BY MR. QIU:</p> <p>2 Q. When an antibody binds to a cell surface</p> <p>3 antigen, is binding via a single Fab typically</p> <p>4 sufficient to induce internalization, or is</p> <p>5 cross-linking generally required?</p> <p>6 MR. SUH: Objection. Lacks foundation.</p> <p>7 THE WITNESS: It depends on the target.</p> <p>8 BY MR. QIU:</p> <p>9 Q. Can adjusting an antibody's affinity alter</p> <p>10 the selectivity for cancer cells over normal cells</p> <p>11 based on differences --</p> <p>12 (Speaking simultaneously.)</p> <p>13 A. The antibody --</p> <p>14 Q. Sorry.</p> <p>15 A. No, no, sorry. Go ahead.</p> <p>16 Q. Can adjusting the antibody's affinity alter</p> <p>17 the selectivity for cancer cells over normal cells</p> <p>18 based on their differences in antigen expression</p> <p>19 levels?</p> <p>20 A. It can and cannot. Again, it depends on</p> <p>21 what antigen you're targeting and what antibodies.</p> <p>22 Q. Would lowering the binding affinity of the</p> <p>23 antibody result in the antibody preferentially</p> <p>24 binding to and being internalized by cells with</p> <p>25 higher antigen expression, such as tumor cells,</p>	<p style="text-align: right;">52</p> <p>1 BY MR. QIU:</p> <p>2 Q. One scenario in ADC development that often</p> <p>3 occurs is that binding affinity of the antibody is</p> <p>4 intentionally lowered when the target antigen is</p> <p>5 expressed on both tumor and normal cells but at much</p> <p>6 higher levels on tumors; is that correct?</p> <p>7 MR. SUH: Objection to form.</p> <p>8 THE WITNESS: So you are talking about a</p> <p>9 scenario -- I don't think I get the question</p> <p>10 correctly. So you are talking about a scenario</p> <p>11 where the affinity is lower and you -- what's the</p> <p>12 question? If I --</p> <p>13 BY MR. QIU:</p> <p>14 Q. Let me try to ask another question to make</p> <p>15 more sense.</p> <p>16 In cases of ADCs with higher toxic --</p> <p>17 sorry. Strike that.</p> <p>18 In cases of ADCs with highly toxic</p> <p>19 payloads, would higher binding affinity increase the</p> <p>20 risk of the drug being delivered to normal tissues</p> <p>21 expressing low levels of the antigen?</p> <p>22 A. Not necessarily. Also, keep in mind that</p> <p>23 ADCs have very toxic drugs.</p> <p>24 Q. Would you agree that in the context of ADCs</p> <p>25 with highly toxic payloads, lowering antibody</p>

Conducted on December 11, 2025

53	<p>1 affinity is an established strategy to limit 2 off-tumor toxicity? 3 A. Can you repeat the question, please? 4 Q. Would you agree that in the context of ADCs 5 with highly toxic payloads, lowering antibody 6 affinity is an established strategy to limit 7 off-tumor toxicity? 8 A. I'm not aware that this being -- that this 9 is an established strategy. 10 Q. If an ADC is found to be too toxic due 11 to -- due to its payload being delivered to both 12 tumor and normal cells, does increasing the 13 antibody's binding affinity increase or decrease the 14 risk of tumor toxicity? 15 A. It's very hard to speculate because 16 everything depends on the expression level, on the 17 dose. There are so many determinants. 18 Q. Are you aware of any case in the field 19 where an ADC -- that it was too toxic with the 20 initial antibody, was improved by switching to an 21 antibody that has a higher binding affinity? 22 A. Compared to the parental [phonetic] 23 antibody? 24 Q. Correct. 25 A. I'm not aware of any studies that have</p>	55	<p>1 window"? 2 A. It is the time where you have the 3 opportunity to treat the patient. 4 Q. Do you understand what widening the 5 therapeutic window means? 6 A. Yeah, I do. 7 Q. What does that mean? 8 A. To extend the time that you can treat the 9 patient, if we are referring to the timing. 10 Q. Do you know the meaning of the term 11 "therapeutic index"? 12 A. I'm not entirely sure what you mean. Can 13 you please explain? 14 Q. So the term "therapeutic index" does not 15 sound familiar to you; is that right? 16 A. I've heard it, but not in isolation as a 17 single term. 18 Q. So do you understand the meaning of 19 "therapeutic index"? 20 A. In general terms, yes. 21 Q. What is the meaning? 22 A. How a drug can be applied in the clinic, 23 provide therapy against a disease. 24 Q. What are the factors that affect the 25 likelihood of success of an ADC?</p>
54	<p>1 done -- assessed clinical efficacy and safety 2 comparing antibodies with higher or lower affinity 3 as ADCs. 4 Q. Is there a scientific rationale for 5 expecting that switching to a higher affinity 6 antibody will make an already too-potent and a 7 too-toxic ADC less toxic to normal tissues? 8 A. It depends on the target. I won't exclude. 9 It as a scenario, but everything needs to 10 be considered, having in mind the nature of the 11 antibody, the nature of the target, and the 12 properties of the target. 13 Q. If an ADC is observed to be too toxic at 14 therapeutic doses due to off-tumor targeting, would 15 widening the therapeutic window be a primary goal in 16 altering the ADC design? 17 MR. SUH: Objection. Foundation. 18 THE WITNESS: What do you mean, "widening 19 of the therapeutic window"? Can you please define? 20 BY MR. QIU: 21 Q. Do you understand the term -- the meaning 22 of the term "therapeutic window"? 23 A. Yes, I do, but not in the context of your 24 question. 25 Q. What is the meaning of the "therapeutic</p>	56	<p>1 A. Can you please define "success"? 2 Q. Do you understand what the phrase -- what 3 the term "success" means in the field of ADC 4 creation? 5 A. I do, but not in the context of your 6 question. 7 Q. Can you please explain what you understand 8 "success" to mean? 9 A. If a drug provides therapeutic benefit to 10 the patient, I would personally consider it as a 11 success. But this is my personal opinion. A 12 company would consider it if it has a commercial 13 success. So it's a very vague term. 14 How do you define "success" in your context 15 of your question? 16 Q. Can you please go to -- can you please open 17 your declaration, which is Exhibit 1002. 18 A. Yeah. 19 Q. And go to paragraph 35 of that exhibit. 20 A. Yes. 21 Q. Can you please read the first sentence of 22 that paragraph. 23 A. "ADC research has revealed several factors 24 that affect the likelihood of success." 25 Q. What does the term "success" mean in that</p>

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

<p>57</p> <p>1 sentence?</p> <p>2 A. In this -- in this context, it's not</p> <p>3 referring to a clinical benefit. It mostly refers</p> <p>4 to the antitumor activity of an ADC, because we can</p> <p>5 define success at different stages: Preclinical,</p> <p>6 clinical, post-market.</p> <p>7 Q. So what does "success" mean in the context</p> <p>8 of creating an ADC?</p> <p>9 A. In the context of paragraph 35 is for the</p> <p>10 ADC to exert antitumor activity.</p> <p>11 Q. In determining whether there's a reasonable</p> <p>12 expectation of success in making an ADC, what</p> <p>13 factors would a POSA typically consider?</p> <p>14 MR. SUH: Lack of foundation. Objection.</p> <p>15 THE WITNESS: Can you please repeat the</p> <p>16 question?</p> <p>17 MR. QIU: Can the court reporter read back</p> <p>18 my question.</p> <p>19 THE STENOGRAPHER: Yes.</p> <p>20 (The previous question was read back by the</p> <p>21 court reporter as follows:</p> <p>22 "QUESTION: In determining</p> <p>23 whether there's a reasonable</p> <p>24 expectation of success in making an</p> <p>25 ADC, what factors would a POSA</p>	<p>59</p> <p>1 that list.</p> <p>2 A. Yeah. So for example, it can be the</p> <p>3 antigen that's targeted, if it can be internalized</p> <p>4 or not. It can be the selection of the drug itself.</p> <p>5 It can be the antigen, if it's expressed, where it</p> <p>6 is expressed, and when it is expressed. It can be</p> <p>7 the antibody.</p> <p>8 So each component of the ADC we can -- we</p> <p>9 can specify a number of factors that can influence</p> <p>10 the likelihood of success. These are the three</p> <p>11 main, but there are several others.</p> <p>12 Immunogenicity. That's another.</p> <p>13 Q. What are some issues or obstacles that can</p> <p>14 make the effort of creating an ADC unsuccessful?</p> <p>15 A. Can you repeat the question, please.</p> <p>16 MR. QIU: Can the court reporter repeat the</p> <p>17 question.</p> <p>18 THE STENOGRAPHER: Yes.</p> <p>19 (The previous question was read back by the</p> <p>20 court reporter as follows:</p> <p>21 "QUESTION: What are some</p> <p>22 issues or obstacles that can make</p> <p>23 the effort of creating an ADC</p> <p>24 unsuccessful?")</p> <p>25 THE WITNESS: It can be toxicity, it can be</p>
<p>58</p> <p>1 typically consider?")</p> <p>2 MR. SUH: Same objection.</p> <p>3 THE WITNESS: So the factors that are</p> <p>4 outlined primarily in section 35, paragraph 35. So:</p> <p>5 "First, the selected antigen should provide</p> <p>6 substantial tumor selectivity. Second, the</p> <p>7 cytotoxic drug should be highly potent as only a</p> <p>8 small amount of the ADC will reach the target</p> <p>9 cells." And: "Third, linker technologies are</p> <p>10 needed that result in stability of the ADC in</p> <p>11 circulation while also permitting efficient release</p> <p>12 of the cytotoxic drug following its internalization</p> <p>13 into target cells or localization in the tumor."</p> <p>14 These are some of the factors that we -- a</p> <p>15 POSA would need to increase the likelihood of</p> <p>16 success.</p> <p>17 BY MR. QIU:</p> <p>18 Q. Are there any other factors that a POSA</p> <p>19 would have considered?</p> <p>20 A. Yes, of course, but these are the main</p> <p>21 factors that I believe are important.</p> <p>22 Q. Can you please provide a list of the other</p> <p>23 factors that the POSA would have considered.</p> <p>24 A. It can be an extensive list.</p> <p>25 Q. Can you please provide an example factor on</p>	<p>60</p> <p>1 an antigen that is not internalized, poor selection</p> <p>2 of antigen, unstable antibody, not efficient drug.</p> <p>3 These are some of the factors that I can think of,</p> <p>4 but there are several others.</p> <p>5 BY MR. QIU:</p> <p>6 Q. If a POSA knows the components that are</p> <p>7 used in an ADC, would the POSA would have been able</p> <p>8 to predict whether the ADC is likely to be</p> <p>9 successful?</p> <p>10 A. Yes. Based on prior art, you can -- you --</p> <p>11 a POSA will have the ability to determine whether a</p> <p>12 target is suitable, whether an antibody is suitable,</p> <p>13 whether a linker is suitable, whether a drug is</p> <p>14 suitable to increase the likelihood of success.</p> <p>15 Q. What analysis would the POSA have performed</p> <p>16 to determine whether the ADC is likely to be</p> <p>17 successful?</p> <p>18 A. By reading articles, by seeing</p> <p>19 publications, by attending conferences, by going</p> <p>20 over patent literature, see what other people have</p> <p>21 done before, check the nature of the target, be</p> <p>22 informed about advances in the technologies of</p> <p>23 payloads, of linkers. These are a few examples that</p> <p>24 a POSA can -- steps that the POSA can take to</p> <p>25 increase the likelihood -- likelihood of success.</p>

<p>61</p> <p>1 Q. Are there ways that a POSA can use to tell 2 whether an anti-EGFR antibody is useful for use in 3 an ADC? 4 A. Can you please repeat the question? We 5 have some noise here. 6 Q. Sure. 7 Are there ways that a POSA can use to tell 8 whether an anti-EGFR antibody is suitable for use in 9 an ADC? 10 A. Are there ways that a POSA -- I believe so. 11 Q. What are they? 12 A. For example, selecting the right linker, 13 the right payload, the right antibody, the right 14 target, EGFR in that case. So all these factors 15 would -- a POSA would consider for selecting and 16 designing an ADC against an EGFR. 17 Q. What analysis would a POSA have performed 18 to select the right antibody? 19 MR. SUH: Objection. Asked and answered. 20 THE WITNESS: Yeah, I believe I already 21 answered that. 22 Again, understanding more about the 23 antibodies, the target, seeking different sources of 24 information, publications, patents, conference 25 proceedings, be as informed as possible.</p>	<p>63</p> <p>1 the target. So the expressed -- the molecule, the 2 antigen itself, not where in the antigen. 3 Q. It is your opinion that all antibodies that 4 binds to a target are suitable to be used in an ADC; 5 correct? 6 A. Not at all because, as I mentioned, you 7 need -- a requirement for an ADC to work would be 8 that the target becomes internalized upon antibody 9 binding. 10 Q. What properties of an antibody, other than 11 whether it binds to the target, will decide -- will 12 help a POSA to determine whether the antibody is 13 suitable to use in an ADC? 14 A. Other than binding the antigen? 15 Q. Correct. 16 A. If the antibody triggers internalization. 17 That's one important component. 18 Q. It is your opinion that all antibodies that 19 binds to the target and triggers internalization are 20 suitable to be used in an ADC; correct? 21 A. I believe so, unless this internalization 22 is low or not efficient. But again, it depends on 23 the context and the target. So expression density 24 of a target and so on. 25 Q. Do you believe ADCs are useful tools for</p>
<p>62</p> <p>1 BY MR. QIU: 2 Q. Would a POSA have analyzed the properties 3 or characteristics of an antibody to determine 4 whether it is the right antibody to use in an ADC? 5 A. How do you define "right"? 6 Q. You mentioned that, "the right antibody," 7 in your earlier answer to my question. 8 A. Oh, okay. 9 Q. So I am asking you in that sense. 10 A. So the question was? 11 Q. Would a POSA have analyzed the properties 12 or the characteristics of an antibody to determine 13 whether it is the right antibody to use in an ADC? 14 A. Yes. Antibody is a critical component of 15 an ADC. By analysis of the properties of the 16 antibodies -- I believe that by analyzing the 17 properties of the antibodies and selecting the right 18 antibody is critical for the success of an ADC. 19 Q. How would a POSA have selected an antibody 20 by analyzing its properties? 21 A. The most important is to know where it 22 binds, the target. 23 Q. How does where an antibody binds to the 24 target determine whether it is the right antibody? 25 A. No, no. I mentioned if it -- if it binds</p>	<p>64</p> <p>1 therapy? 2 A. Absolutely. 3 Q. Do you know whether companies have been 4 trying to develop anti-EGFR ADCs? 5 A. I'm not 100 percent familiar with the field 6 and what have -- what the efforts have been. But I 7 believe that there are a few candidates of EGFR 8 ADCs. 9 Q. When did researchers start to develop 10 anti-EGFR ADCs? 11 A. I'm not entirely sure. 12 Q. Has any anti-EGFR ADC received regulatory 13 approval? 14 A. I don't think so. 15 Q. Can you explain why no anti-EGFR ADCs have 16 been approved in the 20 years since cetuximab was 17 known? 18 A. Millions of -- it can be millions of 19 factors. I cannot speculate. 20 Q. What do you think are the challenges 21 preventing successful development of anti-EGFR ADCs? 22 A. Scientific challenges. 23 Q. Can you please provide a list of the 24 scientific challenges that you have in mind. 25 A. I cannot speak list of challenges because</p>

Conducted on December 11, 2025

<p style="text-align: right;">65</p> <p>1 there have been studies showing the in vivo efficacy 2 of anti-EGFR ADCs. Now, why -- are these real 3 challenges that have -- have prevented the clinical 4 development of EGFR ADCs or not. 5 Scientifically, it's a very -- if I have to 6 comment in a scientific basis, it's a very neat 7 approach. 8 (Stenographer clarification.) 9 THE WITNESS: Neat, elegant. 10 BY MR. QIU: 11 Q. Sorry. 12 A. Yes? 13 Q. What are you referring to as a "neat 14 approach"? 15 A. To develop ADCs as -- EGFR ADCs, the 16 clinical development of EGFR ADCs. To me, based on 17 existing literature and previous clinical studies, 18 it seems a sophisticated approach. 19 Q. So what are the scientific challenges that 20 prevent successful development of the anti-EGFR 21 ADCs? 22 A. So I already answered this question. So to 23 me, in reviewing the literature, going over the 24 progress of anti-EGFR ADCs, and seeing the 25 clinical -- them, the antitumor efficacy in</p>	<p style="text-align: right;">67</p> <p>1 benefit you see from cetuximab, along with the drug 2 conjugate, to my opinion and based on preclinical 3 data I have seen, it seems a nice therapeutic 4 approach. 5 Q. Are there any characteristics of the EGFR 6 antigen that would have motivated researchers to 7 develop an ADC-targeted -- 8 A. Sorry. Give me a second. 9 MR. SUH: Sorry. We have to go off the 10 record. There's, like, some commotion going on 11 outside. If we can just take a minute. 12 (Recess.) 13 BY MR. QIU: 14 Q. Are there any characteristics of the EGFR 15 antigen that would have motivated researchers to 16 develop an ADC targeting this antigen? 17 A. Yes. So it's if -- and that's the reason 18 of why initially, EGFR was selected as a target for 19 cetuximab. So it is abundantly expressed, 20 abundantly expressed by multiple tumor types. And 21 it's a receptor that, when targeted by cetuximab, 22 can be internalized. 23 So naturally, it makes a lot of sense to 24 generate now a cetuximab-based ADC. 25 Q. Do you think there has long been a need for</p>
<p style="text-align: right;">66</p> <p>1 preclinical models, I don't really see major 2 scientific challenges that have prevented the 3 clinical development on the anti-EGFR ADCs. It is 4 an attractive target and I believe would have very 5 good therapeutic benefits to patients. 6 Q. Why do you think ADCs for other targets 7 have been developed sooner than anti-EGFR ADCs? 8 A. Again, a million of factors. It can be -- 9 because we are talking about companies. Each 10 company will have its own pipeline, its own 11 strategy, what therapeutic areas to prioritize or 12 not. 13 Yes, there are -- we still have cancer, so 14 there is still cancer cases. And as a scientific 15 community, we are trying to get the best out of 16 that. 17 Now, why new drugs don't enter the market 18 or targets that we believe are good do not enter the 19 market, that's beyond me to comment. 20 Q. Why is it meaningful to develop an ADC 21 based on anti-EGFR antibodies? 22 A. As my personal opinion, I would say it's a 23 nice approach because we know the target, EGFR. 24 Cetuximab has been in clinical use for so many 25 years. And by combining cetuximab, the clinical</p>	<p style="text-align: right;">68</p> <p>1 anti-EGFR ADCs that's approved for clinical use? 2 A. What do you mean by "improved"? Like, 3 improved compared to cetuximab? 4 Q. Let me repeat the question. 5 A. Yeah, yes. 6 Q. Do you think there has long been a need for 7 anti-EGFR ADCs that are approved for clinical use? 8 A. I'm not aware of any EGFR ADCs that have 9 been approved. 10 Now, your question is if there is a need 11 for that? 12 Q. Correct. 13 A. Any drug is useful. People are still dying 14 from cancer. So any drug, even if it extends the 15 life of a patient by a few months, it's useful. 16 Q. Can you scroll to paragraph 35 of your 17 declaration. 18 A. Yes. 19 Q. Which is Exhibit 1002. 20 Please let me know when you are there. 21 A. Yeah, I'm here. 35, you said? 22 Q. Yes. 23 In that paragraph, you stated there are -- 24 you listed three factors that control -- affect the 25 likelihood of success; correct?</p>

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

<p>69</p> <p>1 A. Yes. 2 Q. And those factors are from Exhibit 1021; 3 correct? 4 A. Yes. Can we get Exhibit 1021? 5 MR. QIU: Yeah. Can you please get 6 Exhibit 1021. 7 MR. SUH: Here we go. 8 THE WITNESS: Yeah. Got it. Yes. 9 (Exhibit 1021 was previously marked by the 10 Certified Shorthand Reporter, and a copy is 11 attached hereto.) 12 BY MR. QIU: 13 Q. Are you familiar with Exhibit 1021? 14 A. Yeah. 15 Q. Exhibit 1021 is concerned with the 16 CD30 antigen; correct? 17 A. Exactly. 18 Q. Are you familiar with the CD30 antigen? 19 A. Yep. 20 Q. How does the EGFR antigen compare to the 21 CD30 antigen in terms of their differentials of 22 expression level between cancer cells and normal 23 cells? 24 A. I believe there are differences, but these 25 differences don't really extend to that. IF CD30</p>	<p>71</p> <p>1 least two or three, I believe, ADCs that are against 2 HER2. 3 Another example is NECTIN4. NECTIN4 is 4 expressed, I believe, by skin, primarily, and in 5 some endothelial cells but overexpressed in bladder 6 cancer and has been developed as a very successful 7 ADC for the management of urothelial cancer. 8 Q. Is there any additional issue a POSA would 9 have considered for creating an EGFR ADC but not for 10 creating a CD30 ADC? 11 A. No. Given the success of other ADCs that 12 target antigens that are expressed also by normal 13 cells in physiological tissues, a POSA wouldn't 14 really see a concern about this expression because 15 by the time, like in 2015 Herceptin as an ADC has 16 been developed, actually approved by FDA, and 17 several others like NECTIN4 ADCs have been in 18 clinical development. 19 Q. How does EGFR compare to CD -- strike that. 20 Are you familiar with the CD33 antigen? 21 A. Yes. 22 Q. How does EGFR compare to CD33 in terms of 23 their differentials of expression level between 24 cancer cells and normal cells? 25 A. I believe CD33 is expressed primarily by</p>
<p>70</p> <p>1 and ADCs for CD30 target liquid cancers, EGFR 2 primarily would target solid tumors. 3 Q. CD30 has higher expression difference 4 between tumor and normal cells than EGFR; correct? 5 A. Correct. 6 Q. Given that EGFR has a smaller expression 7 difference between the tumor and normal cells than 8 CD30, that makes it harder to create an EGFR ADC 9 than a CD30 ADC; correct? 10 MR. SUH: Objection to form. Foundation. 11 THE WITNESS: What do you mean "harder"? 12 Like, the manufacturing would be challenging? 13 BY MR. QIU: 14 Q. By "harder," I'm referring to the 15 difficulty of creating a useful ADC. 16 A. Ah, I see your point because CD30 is 17 expressed only in tumors, whereas EGFR is expressed 18 on tumors and also by normal cells, you mean. Is 19 that correct? 20 Q. Correct. 21 A. No, not necessarily because EGFR -- we have 22 to think a little bit out of the context between 23 these two, CD30 and EGFR. HER2, HER2 is expressed 24 on tumor cells, breast or gastric tumor, but it's 25 also expressed on normal cells. But we have at</p>	<p>72</p> <p>1 hematopoietic cells, whereas EGFR is expressed 2 primarily by cells of endothelial origin -- 3 epithelial origin, sorry. 4 Q. CD33 has higher expression difference 5 between tumor and normal cells than EGFR; correct? 6 A. I haven't -- I'm not 100 percent sure. 7 I -- I can do an analysis to see. I can do a 8 database to check expression, but I cannot 9 comment -- I don't remember the answer on the top of 10 my head. 11 Q. Can you please access Exhibit 1002, your 12 declaration, and go to paragraph 108. Please let me 13 know when you are there. 14 A. On the declaration? 15 Yes. 16 Q. There, you mentioned that: "The background 17 of the '370 patent recognizes 'it is highly complex 18 and unpredictable whether an antibody drug conjugate 19 becomes a safe and effective drug depending on a 20 variety of factors." 21 Correct? 22 A. Yes. 23 Q. Do you agree with this statement in the 24 '370 patent? 25 A. I have not made it there. Give me a</p>

<p>73</p> <p>1 second. 2 Yes, I do agree with this statement. 3 Q. In the same paragraph, you listed five 4 factors from the '370 patent; correct? 5 A. Yeah. 6 Q. Do you agree that these factors affect the 7 likelihood of successfully creating an ADC? 8 A. Yeah. All of them sound reasonable. 9 MR. SUH: Fred, sorry. Yeah, it's -- it's 10 1:20 here. 11 MR. QIU: Yeah, I was about to ask for -- 12 whether you wanted a break as well. 13 MR. SUH: Yeah, sure. It's getting kind of 14 late for a lunch, so if we could maybe just take a 15 quick lunch, like 30 minutes. 16 MR. QIU: 30 minutes, okay. Sounds good. 17 So it is 1:20 your time, and we come back at 1:50 18 Eastern time. 19 MR. SUH: We'll try, yeah. 20 (Luncheon recess taken at 10:19 a.m.) 21 22 23 24 25</p>	<p>75</p> <p>1 So if you go to paragraph 246, it has a 2 description of the antibody. So Figure 1A and B, 3 this is the "alignments of the exemplary heavy and 4 light chains of cetuximab." So the sequences are 5 there depicted in Figure 1A and B, and also, you can 6 see them as SEQ ID NO: 5, for example, which is the 7 heavy chain variable domain. 8 Q. So it's SEQ No. 5; correct? 9 A. I'm not 100 percent sure. Let me check. 10 Searching sequences on a piece of paper is not easy. 11 I believe -- give me a second, because I'm 12 a little lost with all the sequences. 13 I cannot comment on that because on the 14 exhibit, I don't have a copy of the sequence 15 listing. So I'm not 100 percent sure which specific 16 sequence is there. 17 Q. Did you analyze the sequence of Wei's Y104D 18 antibody as part of your analysis for creating the 19 declaration? 20 A. I believe so. 21 Q. How is Wei's Y104D antibody different from 22 cetuximab? 23 A. So this particular variant, 104D, is a 24 replacement of a tyrosine on position 104 using 25 aspartic acid.</p>
<p>74</p> <p>1 THURSDAY, DECEMBER 11, 2025 2 10:51 A.M. 3 STYLIANOS BOURNAZOS, Ph.D., 4 having been previously duly sworn, 5 was examined and testified as follows: 6 BY MR. QIU: 7 Q. Dr. Bournazos, are you familiar with 8 Exhibit 1005 in this case, which is the Wei 9 reference? 10 A. Yes. I have it in front of me. 11 MR. QIU: Let me upload this reference for 12 the court reporter. 13 (Exhibit 1005 was previously marked by the 14 Certified Shorthand Reporter, and a copy is 15 attached hereto.) 16 BY MR. QIU: 17 Q. So what is Wei's Y104D antibody? 18 A. It is a clone that is related to cetuximab. 19 Q. Can you point me to the sequence of this 20 antibody? 21 A. Yeah. I believe the sequence is provided 22 on Figure 1A. 23 Q. Figure 1A. 24 A. For the heavy chain, and then Figure 1B -- 25 give me a second, because I'm looking --</p>	<p>76</p> <p>1 Q. Why did Wei try to modify cetuximab? 2 A. Modify the sequence, you mean, or to 3 express it and formulate it as an ADC? 4 Q. Modify the sequence. 5 A. Modify the sequence. 6 So Wei made a few modifications. One among 7 them is the Y104D. He also made some modifications 8 actually to humanize it. And as we mentioned 9 previously, humanization leads to reduced 10 immunogenicity. So I believe among one of the 11 motives was also to make a more appropriate and 12 suitable cetuximab antibody by reducing 13 immunogenicity. 14 Q. So it is your opinion that the Y104D 15 antibody is a humanized; correct? 16 A. No. He made several versions. So if you 17 read the patent, he made 104D -- actually, they. 18 They made 104D, several other mutations and also a 19 class of humanized antibodies based on cetuximab. 20 Q. So why did Wei try to modify cetuximab to 21 arrive at the Y104D antibody? 22 A. His main rationale, you mean? 23 Q. Correct. 24 A. Yeah. So as Wei states, and we can see 25 this in the background, for example: "The objects</p>

<p style="text-align: right;">77</p> <p>1 herein provide improved anti-EGFR antibodies that 2 exhibit increased EGFR binding activity in a tumor 3 microenvironment compared to in a nontumor 4 environment." This is the objective of this 5 application. 6 Q. Does that mean that the Y104D antibody has 7 more selectivity than cetuximab in terms of 8 targeting tumor cells rather than normal cells? 9 MR. SUH: Objection to form. 10 THE WITNESS: From the data that I have 11 reviewed in the patent, I don't see that there is 12 enough evidence to support this. So in my opinion, 13 no. 14 BY MR. QIU: 15 Q. Is it true that the Y104D antibody exhibit 16 greater activity under conditions of acidic pH than 17 under conditions of neutral pH? 18 A. To my opinion, no, and I don't think -- if 19 you can point me out -- point out evidence that 20 supports this, please do so. 21 Q. So in your opinion, is there any difference 22 between the properties of the Y104D antibody and 23 cetuximab? 24 A. There are obvious differences. To start 25 with, there is an amino acid substitution. So there</p>	<p style="text-align: right;">79</p> <p>1 Q. Is that your answer to the question? 2 A. No, no. I'm asking for a clarification. 3 Do you refer to the variants that Wei 4 describes or generally, are any variants of 5 cetuximab are expected to have different properties? 6 Q. Let's talk about the variants that Wei 7 describes. 8 Do they all have the same properties? 9 A. No. 10 Q. What are their differences in properties? 11 A. I expect that some of them might have 12 different stabilities used, express differently, and 13 they have differences. Wei also made humanized 14 versions of this antibody, so I expect that the 15 humanized versions of these antibodies will have 16 reduced immunogenicity in humans compared to 17 cetuximab, since cetuximab is a chimeric antibody. 18 Q. Wei makes a large number of chimeric 19 variants of cetuximab; correct? 20 A. Yes, correct. 21 Q. Is it true that they all differ from 22 cetuximab by one amino acid? 23 A. I believe so. He lists many, many 24 variants. 25 Q. Is it fair to say that the change of one</p>
<p style="text-align: right;">78</p> <p>1 are differences in the amino acid sequence between 2 cetuximab and the 104D variant. 3 Q. Other than the difference between their 4 sequences, is there any difference between their 5 properties? 6 A. So Wei reports differences in some of the 7 properties, but this is expected because it's -- any 8 time that you make a difference, you expect -- and 9 changes in the amino acid sequence, you expect 10 differences. 11 Now, are these differences biologically 12 meaningful? I doubt. 13 Q. So it is your opinion there is no 14 biologically meaningful difference between Wei's 15 Y104D antibody and cetuximab? 16 A. Yes. Upon a review of the data, I believe 17 that Y104D does not have any significant biological 18 differences compared to cetuximab. 19 Q. Does Y104D represent the only way to modify 20 cetuximab? 21 A. No. There are millions of ways that you 22 can modify cetuximab. 23 Q. So do all of the variants of cetuximab have 24 the same properties? 25 A. The variants that Wei describes?</p>	<p style="text-align: right;">80</p> <p>1 amino acid in the sequence of an antibody can 2 substantially change its properties? 3 MR. SUH: Objection to form. 4 THE WITNESS: Hard to predict. 5 BY MR. QIU: 6 Q. Why did Wei screen a large number of 7 antibodies and decide to use the Y104D antibody? 8 A. For specifically Y104D, I don't know 9 because I don't think -- I need to read it more 10 carefully, but I don't think that we have data for 11 all the variants presented in the Wei patent. But I 12 might be wrong. I can check, if you'd like. 13 Q. Can you please go to -- take out 14 Exhibit 1002, which is your declaration. 15 A. Yes. 16 Q. And go to paragraph 62. 17 A. Yep. 18 Q. Please let me know when you are there. 19 A. Yeah, I'm here. 20 Q. Can you please read that paragraph for the 21 record. 22 A. Paragraph 62: "Wei states that these 23 cetuximab variants 'exhibit greater activity 24 (binding affinity) under conditions of acidic pH, 25 such as present in a tumor microenvironment, than</p>

<p style="text-align: right;">81</p> <p>1 under conditions of neutral pH, such as exists in 2 non-tumor tissue.'" 3 Then there is a reference. 4 "Wei further states that, 'By virtue of the 5 pH-selective activity, the anti-EGFR antibodies 6 provided produce fewer or lesser undesirable 7 side-effects and/or exhibit improved efficacy in a 8 treated subject by virtue of the ability to 9 administer higher doses.'" 10 So that's paragraph 62. 11 Q. Based on reading this paragraph, do you 12 want to change any of the testimony you have given 13 just now? 14 A. No. These are statements that Wei makes, 15 not me. 16 Q. Is it your opinion that these statements by 17 Wei are incorrect? 18 A. According to the presented evidence in the 19 Wei patent, I don't think that there is enough 20 evidence to support these claims. 21 Q. Is it your opinion that a POSA reading Wei 22 would have understood that these statements by Wei 23 were incorrect? 24 A. Yeah, a POSA with understanding of the 25 scientific process and being able to interpret the</p>	<p style="text-align: right;">83</p> <p>1 things – other differences as well. What I see is 2 if you go to Table 42, for example. 3 Q. Table 42? 4 A. Mm-hmm. Table 42, yeah. Maybe there are 5 other changes – it's a big patent, so maybe there 6 are other differences. But from what I see here on 7 Table 42, in Table 42, is that Y104D-MMAE versus 8 human, huY104D-MMAE and this is continuing on page 9 128, so there is some difference in the clinical – 10 in the tumor growth efficacy in this model. And 11 this model is described in Figure – I believe it's 12 in paragraph 1118. 13 Then another difference that we see is also 14 on Table 44. So this is comparing Y104D-MMAD versus 15 human 104D-MMAD, same dose. Now it appears that the 16 humanized version of the 104D has better activity 17 than the chimeric. In the previous one it appeared 18 that it has comparably maybe worse activity. 19 These are the two tables or external data 20 that I see there is some difference between 104D and 21 human 104D. 22 Q. Does the humanization of Y104D have any 23 impact on the pH selectivity of the antibody? 24 A. I haven't seen some evidence, but give me a 25 second. I can go back and then check again.</p>
<p style="text-align: right;">82</p> <p>1 data, the presented data as presented in the Wei 2 patent, would have agreed with me. 3 Q. So it is your opinion that a POSA reading 4 Wei would have understood that the Y104D antibody 5 does not have higher pH selectivity than -- 6 A. Yes, correct. 7 Q. -- cetuximab? 8 A. Correct. 9 Q. Would a POSA -- sorry. Strike that. 10 Wei also disclosed a humanized version of 11 the Y104D antibody; correct? 12 MR. SUH: Objection to form. 13 THE WITNESS: Correct, yes. 14 BY MR. QIU: 15 Q. And that antibody is named huY104D; 16 correct? 17 A. Correct, yes. 18 Q. Is there any difference between the 19 properties of the Y104D and the huY104D antibody? 20 A. I believe there are differences. 21 Q. What are the differences? 22 A. I need to check to be double sure -- 23 double-check to be sure. Sorry. 24 Q. Yes, please check. 25 A. So from a quick look, maybe there are other</p>	<p style="text-align: right;">84</p> <p>1 Sorry, it's a big patent and it might take 2 a while. 3 You meant pH selectivity between 104D and 4 humanized 104D; right? 5 Q. Yes, mm-hmm. 6 A. Yes. It does appear that humanization 7 resulted in difference in the pH binding of 104D to 8 EGFR as assessed by ELISA. 9 Q. What is your basis in saying that? 10 A. So this is -- so if you go to Table 24. 11 Q. 1024? Okay. 12 A. Table 24. 13 Q. Table 24. 14 A. So this data described in Table 24 through 15 27. Without understanding the exact experimental 16 procedures, you cannot really definitively say there 17 is a difference in the pH selectivity between 104D 18 and the humanized version of 104D. 19 If we take the conclusion of the -- of Wei 20 that is in paragraph 1008 or 1007. 21 So Wei says that: "The results show that 22 all tested variants exhibit a higher EC50 and hence 23 weaker binding, at pH 7.4 than at pH 6.5 or pH 6.0." 24 So I'm not sure what are the units that 25 they are measuring. If I take the statement as is,</p>

<p style="text-align: right;">85</p> <p>1 then it appears that there is a difference in pH 2 selectivity that was better with humanization. 3 Q. Why do you agree with this statement of Wei 4 but do not agree with the other statement of Wei 5 that states that Y104D antibody has higher pH 6 selectivity than cetuximab? 7 MR. SUH: Objection. Mischaracterizes 8 testimony. 9 THE WITNESS: No. This one -- so we see 10 Table 24. Y104D. And we assume that EC50 is a 11 surrogate for pH selectivity, how well the antibody 12 binds to EGFR. 13 So we see that it has an EC50 value. 14 Again, I don't know the unit of that, so I'm not 15 entirely sure how reproducible these results are, 16 what's the intra-experimental variability. But we 17 see that 104D has an EC50 of 8.33. 18 You see that? In Table 24. 19 BY MR. QIU: 20 Q. Please continue with your answer. 21 A. Yeah. Then the humanization, which is D-h 22 has an EC50 of 30.2. 23 Without being able to comment how 24 biologically significant this difference is, the 25 8.33 versus 30.2, I believe that is some difference.</p>	<p style="text-align: right;">87</p> <p>1 was substantially weaker at pH 7.4 than at pH 6.5 or 2 pH 6.0 as evidenced by a higher EC50 under the 3 neutral pH tested conditions than the acidic pH 4 tested conditions. Thus, each of the mutants 5 exhibit a greater ratio of binding at acidic pH 6.0 6 or 6.5 than at pH 7.4." 7 Q. Do you want to change any of your testimony 8 provided in this deposition after reading Table 21 9 and paragraph 0994? 10 A. If we see at the values of pH 7.4, the 11 binding of the wild-type and the 104 mutants, I 12 consider this difference to be negligent, whereas in 13 the humanization, the difference are a little bit 14 more substantial. 15 So I still maintain the opinion that the 16 introduction of the 104D mutation doesn't really 17 influence its selectivity of cetuximab. 18 Q. Do you think pH selectivity is a positive 19 property for an antibody for use in ADC? 20 A. It's neutral. I cannot comment on that. 21 It can be positive, it can be negative. What it 22 really matters is, is the new antibody better than 23 cetuximab? And the results from the Wei patent are 24 conflicting. 25 So in one tumor model the humanization made</p>
<p style="text-align: right;">86</p> <p>1 Now, why I don't think that the 2 introduction, the replacement of the 104D does not 3 generate a variant with a better pH selectivity 4 comes from the fact that seeing, for example, on 5 Table 18, wild-type versus 104D variants, the 6 difference is from 3.3 to 5.07 or 6.18. 7 To me it appears that these differences are 8 well within the experimental level. 9 Q. Can you please go to page 102 of Wei. 10 A. 102? 11 Q. Yes. 12 Can you please read Table 21 and the 13 paragraph 0994. 14 A. How can I read Table 21? 15 MR. SUH: Do you want him to read it for 16 the record? 17 BY MR. QIU: 18 Q. You can review them or you can read them to 19 yourself. 20 A. So 994, you said. 21 Q. Yes. 22 A. "The results show that at pH 7.4, the 23 wild-type cetuximab antibody exhibited a slightly 24 higher EC50 than at pH 6.5 or pH 6.0. In contrast, 25 for the Y104 mutants and the FDP-h3 control, binding</p>	<p style="text-align: right;">88</p> <p>1 it better. In another tumor model, it made it 2 worse. 3 Q. Do you think -- what do you think is the 4 reason why humanization can enhance the pH 5 dependency of the antibody in Wei? 6 A. I can only speculate. So humanization 7 introduces changes to the amino acid sequence. Some 8 of the changes might result in the recognition of 9 the antigen with different affinity at different 10 pHs. It's a chemical property of amino acids. 11 Q. Do you think this effect applies generally 12 to humanization of chimeric antibodies? 13 A. I don't know if it applies generally. What 14 I know is that any change that you introduce to the 15 variable region of an antibody -- because remember 16 humanization involves changes to the amino acid 17 backbone of the antibody and to areas that recognize 18 the antigen or participate directly or indirectly to 19 this recognition. 20 So any of the changes might have impact on 21 any function, including pH sensitivity recognition 22 of an antigen. 23 Q. So it is your opinion that humanization 24 always increases the pH selectivity of an antibody? 25 MR. SUH: Objection.</p>

Transcript of Stylianos Bournazos, Ph.D.
Conducted on December 11, 2025

23 (89 to 92)

<p>89</p> <p>1 THE WITNESS: No, I didn't say that. 2 BY MR. QIU: 3 Q. Is that correct? 4 A. No, I didn't say that. Humanization might 5 change the prop- -- the how the antibody will 6 recognize the antigen at different pH conditions. 7 Not always. And we've seen this with Wei. So he 8 humanized another antibody. It's not an absolute, 9 like, every time that you humanize it will change 10 the pH sensitivity. 11 Q. Would you say that Wei was successful in 12 creating an ADC with the Y104D antibody? 13 A. Yeah. It showed potent antitumor activity. 14 Q. I want to turn to the Leanna reference, 15 which is Exhibit 1006. Let me first upload that. 16 Actually, before moving on to -- to Leanna, 17 let me -- let me ask some more questions on Wei. 18 So just to confirm, is it your opinion that 19 Wei was successful in creating an ADC with the 20 chimeric Y104D antibody? 21 A. Yes. I believe that Wei generated an ADC 22 based on Y104D or in EGFR variants that have 23 antitumor activity. 24 Q. Is it -- why do you believe it is -- why do 25 you believe it is successful?</p>	<p>91</p> <p>1 A. Yes. 2 Q. What is the basis of your opinion? 3 A. But -- and that's what I was -- I wanted to 4 follow up. 5 So by saying "successful," my personal 6 opinion is that if this molecule has antitumor 7 activity in vivo. And what we see from Wei is that 8 this molecule, one -- as an ADC, as an MMAE, it does 9 have antitumor activity in vivo in different models 10 that were -- that was tested. 11 Q. Do you believe -- strike that. 12 Let's move on to Leanna's -- Leanna, which 13 is Exhibit 1006. I think I have uploaded a copy of 14 that. 15 (Exhibit 1006 was previously marked by the 16 Certified Shorthand Reporter, and a copy is 17 attached hereto.) 18 BY MR. QIU: 19 Q. Actually, before moving on to Leanna, I 20 want to ask a question? 21 So Dr. Bournazos, during the breaks, 22 including the earlier ten-minute break and the lunch 23 break, did you communicate with any person? 24 A. I called my sister. 25 Q. Is that all?</p>
<p>90</p> <p>1 A. Because of the demonstrated antitumor 2 activity. 3 Q. You earlier testified that Wei's Y104D 4 antibody has no biologically meaningful difference 5 from cetuximab; correct? 6 A. Correct, correct. 7 Q. Is it your opinion that if Wei replaced the 8 Y104D antibody with cetuximab, it will result in a 9 successful ADC? 10 A. Yes. 11 Q. If we replace Wei's Y104D antibody with 12 other cetuximab variants that Wei created, is it 13 your opinion that the resulting ADC would have been 14 successful? 15 A. If you can specifically mention one 16 variant, I can look on the properties of his variant 17 according to the data that Wei provides and then 18 provide an opinion on that. But I don't believe 19 that any of the variants that Wei created will be 20 equally good as cetuximab. 21 Q. But Wei also created an ADC with humanized 22 Y104D antibodies; correct? 23 A. Correct. 24 Q. Would you say that Wei was successful in 25 creating that ADC?</p>	<p>92</p> <p>1 A. Yeah, that's all. 2 Q. Okay. And you did communicate with 3 counsel? 4 A. With who? 5 Q. With counsel present in your -- in the room 6 that you were in. 7 A. We did communicate, like, what options for 8 lunch we have. 9 This is acceptable; right? 10 Q. Okay. 11 A. Okay. Just to make sure. 12 Q. Yeah. I just want to make sure you didn't 13 communicate about anything about this case. 14 A. No. 15 Q. What is Leanna's Antibody 1? 16 A. It's an antibody against EGFR. 17 Q. Does it have a name or sequence you can 18 point me to? 19 A. No, I don't believe the sequence is 20 provided in Leanna's reference. 21 Q. So to render your opinion you did not 22 analyze Leanna's -- the sequence of Leanna's 23 Antibody 1; correct? 24 MR. SUH: Objection to form. 25 THE WITNESS: I believe I did, but I'm not</p>

Transcript of Stylianos Bournazos, Ph.D.
Conducted on December 11, 2025

24 (93 to 96)

<p style="text-align: right;">93</p> <p>1 100 percent sure. 2 BY MR. QIU: 3 Q. If the sequence is not provided in the 4 Leanna reference, where did you obtain the sequence? 5 A. So as I mentioned on paragraph 79 of the 6 declaration, so Antibody 1 was previously described 7 in WO 2011/041319. So I believe the sequence is 8 there. 9 Now, I don't recall whether or not I have 10 done any analysis of the sequence of Antibody 1 in 11 preparation of the declaration. 12 Q. Do you believe analyzing the sequence of 13 the Antibody 1 is relevant to rendering your 14 opinion? 15 A. Not really. 16 Q. Does Leanna's Antibody 1 display tumor 17 selectivity? 18 A. It's an antibody against EGFR, so it is 19 specific for tumors. 20 Q. Does Leanna's Antibody 1 display higher 21 activity against tumor cells than normal cells? 22 A. I'm not familiar with Antibody 1 to be able 23 to make a conclusion of that. I haven't reviewed 24 what is Antibody 1. 25 Q. Please go to paragraph 79 of your</p>	<p style="text-align: right;">95</p> <p>1 MR. SUH: We actually have -- we have a set 2 of 2015. Would you allow me to hand that over to 3 the witness -- 4 MR. QIU: Yeah, that'd be great. Is it -- 5 MR. SUH: For the record, it's a clean 6 copy, there's no notes or anything. 7 MR. QIU: Oh, that's perfect. Thank you. 8 MR. SUH: Okay. 9 THE WITNESS: Yeah, thanks. 10 Oh, that's big. 11 MR. QIU: Yeah. 12 (Exhibit 2015 was previously marked by the 13 Certified Shorthand Reporter, and a copy is 14 attached hereto.) 15 BY MR. QIU: 16 Q. Can you please go to this exhibit, 17 Exhibit 2015. 18 Do you recognize this reference? 19 A. Looks familiar. I'm not sure if I have 20 reviewed or not. 21 Q. Is it one of the -- 22 A. Yeah. 23 Q. Is it one of the references that you have 24 mentioned in your paragraph 79? 25 A. Yes. The number matches, yes.</p>
<p style="text-align: right;">94</p> <p>1 declaration, which is -- which is Exhibit 1002. 2 A. Yes. Do you need me to read it out loud? 3 Q. No. 4 A. Okay. 5 Q. There you mentioned that Antibody 1 is 6 described in WO 2011/041319 and US20110076232; 7 correct? 8 A. Yes, correct. 9 Q. Can you please open Exhibit 2015. 10 A. 2015, you said? 11 Q. Yes. I believe it's in the package that we 12 sent. 13 MR. SUH: 13, 14... it's not in this pile, 14 Fred, but I'm going to look at the other pile. 15 MR. QIU: Okay. Thank you. If it's not in 16 there I'll... 17 MR. SUH: So we have 2002, 2003, 2004, 18 2005, 2006, 2007, 2008, 2009, 2011, 2012, 2013, 19 2014, and it skips to 2016. 20 MR. QIU: Oh, okay. In that case, let's -- 21 let's have this exhibit electronically. 22 I have uploaded to the upload link. It 23 would be great if you can download it. 24 MR. SUH: Fred? 25 MR. QIU: Yeah.</p>	<p style="text-align: right;">96</p> <p>1 Q. Please go to paragraph 177 of Exhibit 2015. 2 A. 177. Give me a second because it's missing 3 pages. What page is it? It might be easier to find 4 like that. 5 Q. So it's on page 11. 6 A. Oh, okay. Paragraph? 7 Q. Yeah, paragraph 177 on page 11. 8 A. Got it. 9 Q. Can you please review that paragraph. 10 A. "Figures 55A and 55B show the hu806" -- 11 MR. SUH: Dr. Bournazos, I think he wants 12 you to review it. 13 THE WITNESS: Oh, review. Okay. 14 Yes. Let me go to the figures as well. 15 BY MR. QIU: 16 Q. So that paragraph indicates that the 17 antibodies shown in Figure 55 is hu806 antibody; 18 correct? 19 A. Correct. 20 Q. Can you please go to paragraph 15 of 21 Exhibit 2015. 22 A. Paragraph 15. 23 Q. And that paragraph is on page 3. 24 A. Got it. Got it. Yes, I'm here. 25 Q. Can you please read paragraph 15 to</p>

<p style="text-align: right;">97</p> <p>1 yourself. You don't need to read it out loud. 2 A. Yeah, okay. 3 Yes. 4 Q. Does reading this paragraph change your 5 opinion about whether Leanna's Antibody 1 is tumor 6 selective? 7 A. I don't think it's -- don't -- give me a 8 second. 9 These antibodies are different. I won't 10 classify them as tumor selective, as you mentioned. 11 And the reason for this opinion is that -- read 12 paragraph 15. So it says: "Additionally, while 13 these antibodies do not recognize the EGFR when 14 expressed on the cell surface of a glioma cell line 15 expressing normal amounts of EGFR..." 16 Gliomas are tumors. So based on this 17 evidence, yeah, from what I read, Antibody 1 and the 18 other antibodies recognize the surface of tumors 19 while maintaining very low binding to normal -- they 20 don't bind significantly to normal tissues. 21 But I wouldn't classify them as tumor 22 selective because glioma cells are tumors. 23 Q. After reading this paragraph, do you now 24 believe that Leanna's Antibody 1 has a higher 25 activity on tumor cells than on normal cells?</p>	<p style="text-align: right;">99</p> <p>1 anti-EGFR antibody as an example. 2 In this respect, yes. They were successful 3 in creating an antibody against EGFR that is -- 4 has -- is ADC, so it has a vcMMAE or vcMMAF drug. 5 Q. Would cetuximab bind to the mutant EGFR 6 that Antibody 1 targets? 7 A. Do you mean the deletion 2-7? 8 Q. I'm sorry? 9 A. Do you mean the variant DDE2-7 mutant? 10 Q. Yes. 11 A. I believe this is the same, I might be 12 wrong, but I believe that this is the variant 3 of 13 EGFR, and cetuximab has activity against that 14 variant. 15 MR. QIU: Okay. So, Doctor and Howard, the 16 deposition has continued for, I think, more than an 17 hour. 18 MR. SUH: Okay. 19 MR. QIU: I want to offer a break if you 20 want to take one. 21 MR. SUH: Yes. Yes, thank you. 22 MR. QIU: Shall we take a break and come 23 back ten minutes after 3:00 p.m. Eastern time? 24 MR. SUH: Yes. Thank you. 25 MR. QIU: Okay.</p>
<p style="text-align: right;">98</p> <p>1 MR. SUH: Objection. Mischaracterizes the 2 testimony. 3 THE WITNESS: On the contrary. By reading 4 this paragraph, as I mentioned before, is that it 5 appears, as they mentioned, I need to review the 6 experiments. It appears that while this -- and I'm 7 just citing what is in there in paragraph 15. These 8 antibodies do not recognize the EGFR when expressed 9 on the cell surface of a glioma cell line. Glioma 10 cells are tumors. 11 So it appears to me that these antibodies 12 bind but only to a subset of tumors. 13 So I would say tumor -- restricted to 14 certain tumor types. Not selective. 15 BY MR. QIU: 16 Q. Do you agree that Antibody 1 is better at 17 distinguishing tumor cells from normal cells than 18 cetuximab? 19 A. I cannot comment on this because I haven't 20 seen a head-to-head comparison between cetuximab and 21 Antibody 1. 22 Q. Would you say that Leanna was successful in 23 creating an ADC with Antibody 1? 24 A. So Leanna's objective was to describe the 25 method of generating an ADC using a humanized</p>	<p style="text-align: right;">100</p> <p>1 (Recess.) 2 BY MR. QIU: 3 Q. Doctor, did you communicate with anyone 4 during this past break? 5 A. No. 6 Q. Are you familiar with the reference Liu, 7 which is 1007 and 1008 in this case? 8 A. Yes. 9 (Exhibit 1007 and Exhibit 1008 were 10 previously marked by the reporter, and 11 copies are attached hereto.) 12 BY MR. QIU: 13 Q. Can you point me to the sequence of Liu's 14 BA03 antibody? 15 A. So Exhibit 1008, sequence of BA03 is, for 16 the heavy chain, is sequence ID number 5, and for 17 the light chain, sequence ID number 13. 18 So these sequences appear on Exhibit 1007 19 on page 19. So 5 and 6. 5 is there on page 19, 20 20 and sequence ID 15 is page 22. I believe it's also 21 on the translated on page 12 and 13. 22 Q. How is Liu's antibody BA03 antibody 23 different from cetuximab? 24 A. I believe it's a humanized version of 25 cetuximab.</p>

<p style="text-align: right;">101</p> <p>1 Q. Is there any -- are there any variations 2 other than humanization? 3 A. No. The humanization introduced changes. 4 So the goal was to generate a humanized version. So 5 the changes are amino acid changes from cetuximab to 6 BA03. 7 Q. So it is your opinion that the BA03 8 antibody was created by humanizing cetuximab without 9 any other variations? 10 MR. SUH: Objection to form. 11 THE WITNESS: So BA03 was constructed based 12 on cetuximab. So they have introduced changes with 13 the aim to humanize it. 14 Now, if these changes have resulted in 15 humanization, some of them mice, some them not, have 16 they changed the properties, if this is what you are 17 asking, perhaps. But the goal was humanization. 18 BY MR. QIU: 19 Q. Is Liu's BA03 antibody substantially the 20 same as Wei's humanized Y104D antibody? 21 A. Substantially the same. They both 22 originate from the same clone from cetuximab. So 23 they are related. So cetuximab is the parent. 24 These are the siblings. 25 Now, the similarity between BA03 and Wei's,</p>	<p style="text-align: right;">103</p> <p>1 differences in the properties of these two 2 antibodies, I don't know, mostly because there is no 3 head-to-head comparison between these two antibodies 4 that will enable me to say with confidence that BA03 5 differs from Liu's antibodies -- Liu's antibodies 6 differs from Wei's. 7 Q. So you are not aware of any difference 8 between the properties of Liu's BA03 antibody and 9 Wei's humanized Y104D antibody; correct? 10 A. Because I don't have the data that can 11 provide me with a head-to-head comparison between 12 those two antibodies. 13 Q. Have you ever tried to determine the 14 differences between the properties of Liu's BA03 15 antibody and Wei's humanized Y104D antibody? 16 A. No. That will require experimentation. 17 Q. Can you please go to paragraph 187 of 18 Exhibit 1002, which is your declaration. 19 A. Yes. 187, you said? 20 Q. Mm-hmm. Yes. 21 A. Do I need to read this out loud? 22 Q. You don't. 23 Is it true that you stated that the 24 humanized Y104D antibody and the BA03 antibody are 25 substantially identical?</p>
<p style="text-align: right;">102</p> <p>1 I'm not sure what degree of similarity would have. 2 Q. How is Liu's BA03 antibody different from 3 Wei's humanized Y104D antibody? 4 A. Sequence, I presume. 5 Q. Are you aware of -- so how -- how do their 6 sequences different -- sorry. Strike that. 7 How do the sequence of Liu's BA03 antibody 8 differ from Wei's humanized Y104D antibody? 9 A. Hard to tell. I -- give me a second. 10 I cannot comment on how different they are, 11 but they are not 100 percent identical. That's what 12 I can say. 13 Q. Have you analyzed how the properties of 14 Liu's BA03 antibody differ from those of Wei's 15 humanized Y104D antibody? 16 A. Can you please define what do you mean by 17 "property"? Is any specific aspect that you are 18 interested in? 19 Q. Have you analyzed how any property of Liu's 20 BA03 antibody differ from Wei's humanized Y104D 21 antibody? 22 A. What I know by reviewing the Wei and the 23 Liu patents is that both of them target the same 24 epitope, they are clonal variants or variants of 25 cetuximab. If there are any other changes or</p>	<p style="text-align: right;">104</p> <p>1 A. Yes. And that's what I said previously. 2 They come from the same clone, cetuximab. So they 3 are related. So the parent cetuximab, siblings are 4 Y104D and BA03. 5 Q. Is it your opinion that all cetuximab 6 variants are substantially identical to each other? 7 A. All the variants disclosed by Wei. 8 Q. Is it your opinion that the BA03 antibody 9 was created by Wei? 10 A. Can you rephrase -- can you repeat your 11 question, please? 12 Q. Sure, sure. 13 It is your opinion that the BA03 antibody 14 was created by Wei; correct? 15 A. By Liu. BA03 is Liu. Wei has the Y104D. 16 Q. So it is your opinion that all variants of 17 cetuximab, regardless of who created them, are 18 substantially identical to each other; correct? 19 MR. SUH: Objection. Mischaracterizes the 20 testimony. Also object to the form. 21 THE WITNESS: Depends on which variant. So 22 I can go ahead and generate a variant of cetuximab 23 that has replaced all the amino acids. I wouldn't 24 consider this to be substantially identical. A 25 single amino acid substitution, it is substantially</p>

Conducted on December 11, 2025

105	<p>1 identical. It's -- again, it refers to the degree</p> <p>2 of changes.</p> <p>3 BY MR. QIU:</p> <p>4 Q. What is your basis in you saying that the</p> <p>5 BA03 antibody is substantially identical to the</p> <p>6 humanized Y104D antibody other than the fact that</p> <p>7 both are variants of cetuximab?</p> <p>8 MR. SUH: Objection. Asked and answered.</p> <p>9 THE WITNESS: Because they originate from</p> <p>10 the same parent. The parent is cetuximab.</p> <p>11 Humanized 103, 104D, BA03 are related from the same</p> <p>12 family, from the same parent. So that makes them</p> <p>13 substantially identical.</p> <p>14 BY MR. QIU:</p> <p>15 Q. So all embodiments -- strike that.</p> <p>16 All antibodies that are generated from the</p> <p>17 same parent, like cetuximab, are substantially</p> <p>18 identical to each other, according to your opinion;</p> <p>19 correct?</p> <p>20 MR. SUH: Objection. Mischaracterizes the</p> <p>21 testimony.</p> <p>22 THE WITNESS: Not all of them. As I</p> <p>23 mentioned, if I go ahead and take cetuximab and I</p> <p>24 change everything, 99 out of 100 amino acids, it's</p> <p>25 not going to be substantially identical.</p>	107	<p>1 the BA03 antibody and the Y104D antibody made you</p> <p>2 believe that they are substantially identical?</p> <p>3 A. Because they come from the same parent with</p> <p>4 the cetuximab. They have very maintained binding to</p> <p>5 the target, which is EGFR.</p> <p>6 Q. So it is your opinion that as long as two</p> <p>7 antibodies -- as long as two humanized antibodies</p> <p>8 come from the same parent, regardless of their</p> <p>9 humanization process, they are substantially</p> <p>10 identical; correct?</p> <p>11 MR. SUH: Objection. Mischaracter- -- I'm</p> <p>12 sorry.</p> <p>13 Objection. Mischaracterizes the testimony.</p> <p>14 THE WITNESS: If they maintain binding</p> <p>15 properties, the same affinity or comparable affinity</p> <p>16 with a parent, if they maintain antigen specificity,</p> <p>17 I would consider them substantially identical</p> <p>18 compared to any other clone because the process of</p> <p>19 generating antibody diversity can lead to an</p> <p>20 infinite number antibodies in the combinations that</p> <p>21 you can have.</p> <p>22 So in this very diverse spectrum of</p> <p>23 antibodies, even if there are changes from the</p> <p>24 parent, me, personally, I would consider them</p> <p>25 substantially identical.</p>
106	<p>1 Based on what I've seen from the 104D and</p> <p>2 BA03, the changes that have been introduced are</p> <p>3 not -- they haven't changed the characteristics of</p> <p>4 the antibody. The antibody still binds to EGFR.</p> <p>5 They are still related to cetuximab.</p> <p>6 BY MR. QIU:</p> <p>7 Q. Is it your opinion that all humanized</p> <p>8 antibodies generated from the same parent are</p> <p>9 substantially identical to each other?</p> <p>10 A. Depends on the humanization strategy.</p> <p>11 (Stenographer clarification.)</p> <p>12 BY MR. QIU:</p> <p>13 Q. Is it your opinion that all humanized</p> <p>14 versions of cetuximab are substantially identical to</p> <p>15 cetuximab?</p> <p>16 A. It depends on the humanization strategy.</p> <p>17 But in principle, any humanization strategy will aim</p> <p>18 to maintain the least number of differences. So</p> <p>19 then it doesn't mess up with -- on cell binding.</p> <p>20 Q. How many amino acids are -- strike that.</p> <p>21 Sorry.</p> <p>22 Have you compared the humanization process</p> <p>23 of BA03 and Y104D?</p> <p>24 A. No, I haven't.</p> <p>25 Q. What aspect of the humanization process for</p>	108	<p>1 BY MR. QIU:</p> <p>2 Q. Does the BA03 antibody have a higher or</p> <p>3 lower binding affinity than the humanized Y104D</p> <p>4 antibody?</p> <p>5 A. I believe Liu never tested head-to-head</p> <p>6 BA03 with Y104D. So I cannot comment on that.</p> <p>7 Q. Does Liu's BA03 antibody have a higher or</p> <p>8 lower antigen specificity as compared to the</p> <p>9 humanized Y104D antibody in Wei?</p> <p>10 A. I believe I already answered this question.</p> <p>11 So there is no direct comparison between BA03 and</p> <p>12 humanized 104D or Y104D or any of the variants that</p> <p>13 Wei generated that would allow me to say that one</p> <p>14 has had affinity, has binding specificity over the</p> <p>15 other for EGFR.</p> <p>16 Q. If two antibodies have different pH</p> <p>17 selectivity, will that make them substantially</p> <p>18 different from each other?</p> <p>19 A. It depends on the definition of</p> <p>20 "substantially different." In the context of the</p> <p>21 paragraph 187, substantially -- my definition of</p> <p>22 substantially identical refers to the clone because</p> <p>23 we have endless possibility of generating antibody</p> <p>24 clones, these two are substantially identical.</p> <p>25 Changing the pH or changing any other</p>

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

Conducted on December 11, 2025

109	<p>1 function it won't make them substantially different.</p> <p>2 (Stenographer clarification.)</p> <p>3 THE WITNESS: Any other properties will not</p> <p>4 make them.</p> <p>5 BY MR. QIU:</p> <p>6 Q. Is Liu's BA03 antibody substantially the</p> <p>7 same as Wei's chimeric Y104D antibody?</p> <p>8 A. Can you please repeat the question?</p> <p>9 MR. QIU: Can the court reporter help read</p> <p>10 the question.</p> <p>11 THE STENOGRAPHER: Yes.</p> <p>12 (The previous question was read back by the</p> <p>13 court reporter as follows:</p> <p>14 "QUESTION: Is Liu's BA03</p> <p>15 antibody substantially the same as</p> <p>16 Wei's chimeric Y104D antibody?")</p> <p>17 THE WITNESS: I believe so. Both of them</p> <p>18 originate from the same clone, so this makes them</p> <p>19 substantially similar.</p> <p>20 BY MR. QIU:</p> <p>21 Q. Is there any difference between Liu's BA03</p> <p>22 antibody and Wei's Y104D antibody?</p> <p>23 A. Yes. They have differences in sequence, to</p> <p>24 begin with.</p> <p>25 Q. Did you compare the sequence of Liu's BA03</p>	111	<p>1 Wei's Y104D.</p> <p>2 Q. Have you ever analyzed whether Liu's BA03</p> <p>3 antibody has a higher or lower immunogenicity than</p> <p>4 Wei's Y104D antibody, either chimeric or humanized?</p> <p>5 A. If I have done the experiment by myself,</p> <p>6 you're asking?</p> <p>7 Q. No. I'm asking for any type of analysis</p> <p>8 that you have performed.</p> <p>9 A. Wei doesn't report immunogenicity, as far</p> <p>10 as I remember.</p> <p>11 Q. So you do not know whether Liu's BA03</p> <p>12 antibody has a higher or lower immunogenicity than</p> <p>13 Wei's Y104D antibody, either humanized or chimeric;</p> <p>14 correct?</p> <p>15 A. Correct, because Wei doesn't provide any</p> <p>16 analysis on immunogenicity. So I cannot comment on</p> <p>17 something like that.</p> <p>18 Q. Have you analyzed whether Liu's BA03</p> <p>19 antibody has a higher or lower level of inhibitory</p> <p>20 activity in blocking interactions between EGFR and</p> <p>21 the EGF than Wei's Y104D antibody, either chimeric</p> <p>22 or humanized?</p> <p>23 A. There is no head-to-head comparison between</p> <p>24 BA03 and Wei's Y104D that would allow me to draw any</p> <p>25 conclusions.</p>
110	<p>1 antibody and the sequence of Wei's chimeric Y104D</p> <p>2 antibody?</p> <p>3 A. I don't think I did.</p> <p>4 Q. Have you analyzed how the properties of</p> <p>5 Liu's BA03 antibody differ from those of Wei's</p> <p>6 chimeric Y104D antibody?</p> <p>7 A. Again, we don't have a direct comparison</p> <p>8 between these two antibodies. So by comparing data</p> <p>9 from one patent to the other, it's not possible for</p> <p>10 us to lead to any conclusions in differences in any</p> <p>11 of the properties of these antibodies.</p> <p>12 Q. Did you compare the properties of Liu's</p> <p>13 BA03 antibody and Wei's chimeric Y104D antibody in</p> <p>14 any way, including comparing data or other</p> <p>15 knowledge?</p> <p>16 A. I cannot compare the activity or datasets</p> <p>17 that are generated by Wei and Liu because these</p> <p>18 differences, these experiments were done separately.</p> <p>19 So it won't allow me to draw any conclusions that</p> <p>20 one is different than the other.</p> <p>21 Q. Have you analyzed whether Liu's BA03</p> <p>22 antibody has a higher or lower binding affinity than</p> <p>23 Wei's Y104D antibody, either chimeric or humanized?</p> <p>24 A. I cannot comment on that. There is no</p> <p>25 direct comparison in experiments between BA03 and</p>	112	<p>1 Q. Do you know whether Liu's BA03 antibody has</p> <p>2 a stronger or weaker antibody in inhibiting</p> <p>3 phosphorylation of EGFR than Wei's Y104D antibody?</p> <p>4 A. It's the same answer as before.</p> <p>5 Q. Can you please provide the answer?</p> <p>6 A. There is no direct comparison between BA03</p> <p>7 in Liu's and Wei's Y104D in respect to this aspect.</p> <p>8 So what Liu has done, and this is across</p> <p>9 different experiments that are described in Liu</p> <p>10 patent, is that BA03 has increased -- so they</p> <p>11 compared it only to cetuximab. So what I can do, if</p> <p>12 this is helpful, is to refer everything back to</p> <p>13 cetuximab. So BA03 has stronger activity in</p> <p>14 inhibiting phosphorylation of EGFR. It has higher</p> <p>15 ADCC activity. It has significantly lower</p> <p>16 immunogenicity compared to cetuximab.</p> <p>17 I cannot comment on any of these aspects</p> <p>18 compared to Wei's antibodies because I don't know</p> <p>19 how they behave. They are different than cetuximab.</p> <p>20 They are substantially identical, but this change</p> <p>21 might influence one or some aspects.</p> <p>22 Q. Have you analyzed whether Liu's BA03</p> <p>23 antibody has a higher or lower ADCC activity than</p> <p>24 Wei's Y104D antibody, either chimeric or humanized?</p> <p>25 A. Wei mentions that BA -- Liu mentions that</p>

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

Conducted on December 11, 2025

<p style="text-align: right;">113</p> <p>1 BA03 has higher ADCC activity compared to cetuximab.</p> <p>2 No comparisons were made to Wei's Y104D antibody.</p> <p>3 Q. So you do not know whether Liu's BA03</p> <p>4 antibody has a higher or lower ADCC activity than</p> <p>5 Wei's Y104D antibody; correct?</p> <p>6 A. Because such comparison was never done.</p> <p>7 Q. Have you analyzed whether Liu's BA03</p> <p>8 antibody has a higher or lower antitumor activity</p> <p>9 than Wei's Y104D antibody?</p> <p>10 A. Can you repeat the question?</p> <p>11 Q. Sure.</p> <p>12 Have you analyzed whether Liu's BA03</p> <p>13 antibody has a higher or lower antitumor activity</p> <p>14 than Wei's Y104D antibody, either chimeric or</p> <p>15 humanized?</p> <p>16 A. As an ADCC or as a naked antibody?</p> <p>17 Q. Either as ADCC or antibody.</p> <p>18 A. I don't believe Liu has any experiments</p> <p>19 done with BA03 as ADCC. And Wei has never included</p> <p>20 in their analysis BA03. So I cannot comment on</p> <p>21 nonexisting data.</p> <p>22 Q. Is it your opinion that as long as BA03 and</p> <p>23 Y104D have similar binding specificity and affinity,</p> <p>24 you don't need to review other data in order to</p> <p>25 arrive at the conclusion that they are substantially</p>	<p style="text-align: right;">115</p> <p>1 terms of properties like antigen binding and</p> <p>2 specificity for the antigen, they both recognize the</p> <p>3 same epitope.</p> <p>4 I cannot comment if one or the other has</p> <p>5 better activity in inhibiting phosphorylation in</p> <p>6 inducing ADCC unless an experiment is done to</p> <p>7 compare head-to-head these two antibodies.</p> <p>8 Q. Is Liu's BA03 antibody substantially the</p> <p>9 same as Leanna's Antibody 1?</p> <p>10 A. No.</p> <p>11 Q. How is Liu's BA03 antibody different from</p> <p>12 Leanna's Antibody 1?</p> <p>13 A. Liu's antibody is -- and Wei's -- come from</p> <p>14 the same parent, cetuximab, and they have the same</p> <p>15 properties. Leanna's Antibody 1 recognizes, I</p> <p>16 believe, a different epitope of EGFR, and that's the</p> <p>17 reason why it cannot bind on certain tumor types.</p> <p>18 So these are substantially different. But</p> <p>19 in a bigger context, they both recognize EGFR.</p> <p>20 Q. Have you analyzed how the properties of</p> <p>21 Liu's BA03 antibody differ from those of Leanna's</p> <p>22 Antibody 1?</p> <p>23 A. I haven't done any comparison between</p> <p>24 Leanna's Antibody 1 and BA03. All I know is that</p> <p>25 both are anti-EGFR antibodies.</p>
<p style="text-align: right;">114</p> <p>1 identical?</p> <p>2 MR. SUH: Objection to form.</p> <p>3 THE WITNESS: Can you please repeat the</p> <p>4 question?</p> <p>5 MR. QIU: Can the court reporter read back</p> <p>6 the question.</p> <p>7 THE STENOGRAPHER: Yes.</p> <p>8 (The question was read back by the court</p> <p>9 reporter.)</p> <p>10 MR. QIU: Sorry. Let me repeat the</p> <p>11 question.</p> <p>12 BY MR. QIU:</p> <p>13 Q. Is it your opinion that as long as BA03 and</p> <p>14 Y104D have similar binding specificity and the</p> <p>15 affinity, you don't need to review other data in</p> <p>16 order to arrive at the conclusion that they are</p> <p>17 substantially identical?</p> <p>18 MR. SUH: Objection to form.</p> <p>19 THE WITNESS: Substantially identical in</p> <p>20 which property?</p> <p>21 BY MR. QIU:</p> <p>22 Q. I mean, substantially identical in the</p> <p>23 sense in paragraph 187 of your declaration.</p> <p>24 A. Yes. So these are -- they are</p> <p>25 substantially identical in terms of sequence. In</p>	<p style="text-align: right;">116</p> <p>1 Q. Does Liu teach how its BA03 antibody can be</p> <p>2 used?</p> <p>3 A. I believe so.</p> <p>4 Q. What are the use cases of BA03 that Liu</p> <p>5 teaches?</p> <p>6 A. I believe these are described in</p> <p>7 paragraph 50 in Liu.</p> <p>8 Q. Liu does not teach using BA03 in ADC;</p> <p>9 correct?</p> <p>10 MR. SUH: Objection to form.</p> <p>11 THE WITNESS: Not as ADC.</p> <p>12 BY MR. QIU:</p> <p>13 Q. Does Liu teach using cetuximab in ADC?</p> <p>14 A. I don't believe so, but Wei does.</p> <p>15 Q. Does your -- does Ground 1 and Ground 2 in</p> <p>16 your declaration rely on Wei's teaching of using</p> <p>17 cetuximab in ADC?</p> <p>18 MR. SUH: Objection. Lacks foundation.</p> <p>19 THE WITNESS: I believe it's a combination</p> <p>20 of both Wei and Liu.</p> <p>21 BY MR. QIU:</p> <p>22 Q. Does your declaration rely on Wei's</p> <p>23 embodiment that uses the Y104D antibody or does it</p> <p>24 rely on using ADC -- using cetuximab in ADC?</p> <p>25 MR. SUH: Objection to form.</p>

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

<p>117</p> <p>1 THE WITNESS: Can you please repeat the 2 question? 3 BY MR. QIU: 4 Q. Does your declaration rely on Wei's 5 teaching of using the Y104D antibody in ADC or does 6 it rely of Wei's teaching of using cetuximab in ADC? 7 MR. SUH: Same objection. 8 THE WITNESS: So Wei discloses that an 9 anti-EGFR antibody drug conjugate include the 10 variant that I describe. Knowing that this variant 11 is a clonal variant of cetuximab, yes, my 12 declaration depends -- uses Wei as this example. 13 BY MR. QIU: 14 Q. Are you familiar with the Tikhomirov 15 reference that is Exhibit 1009? 16 A. 1009. Yes, I am. 17 Q. If we call it "Tikhomirov," would you 18 understand that it refers to that exhibit? 19 A. Yes, but we can call it 009, if you prefer, 20 20 1009. 21 Q. Okay. Thanks. 22 Does Tikhomirov teach an anti-EGFR ADC with 23 a cleavable linker? 24 A. Can you please repeat the question? 25 Q. Sure.</p>	<p>119</p> <p>1 affinity of its antibody, would that increase or 2 decrease the toxicity against normal cells? 3 A. How we will increase the affinity? 4 Q. By replacing the antibody with another 5 antibody that has a higher affinity. 6 A. If it's going to increase the toxicity? 7 Most likely not. 8 Q. What is your basis in saying that? 9 A. Because a change in affinity, to my 10 opinion, is not associated with toxicity. And I 11 haven't seen any literature that would support this 12 notion. 13 Q. Is the MMAE payload in Tikhomirov the same 14 as that taught in Wei? 15 A. The same as Wei? 16 Q. Yeah, so is the MMAE payload in Tikhomirov 17 the same as that taught in Wei? 18 A. It is the same as Wei, yes. 19 Q. Is the VC linker here also the same as that 20 used by Wei? 21 A. I believe so. 22 Q. Is it your opinion that Wei's ADC has 23 similar toxicity against normal cells as 24 Tikhomirov's ADC with a cleavable linker? 25 MR. SUH: Objection to form. Foundation.</p>
<p>118</p> <p>1 Does Tikhomirov teach an anti-EGFR ADC with 2 a cleavable linker? 3 A. Yes and no, because he teaches to use a 4 cleavable linker unless the conjugation -- unless 5 the drug is not an antimicrotubule agent. 6 Q. So it is your opinion that Tikhomirov does 7 not teach an anti-EGFR ADC with a cleavable linker? 8 A. The conclusion from Tikhomirov -- their 9 conclusion is that an anti-EGFR antibody or an 10 antibody that targets -- that has agonistic 11 activity -- antagonistic activity, it's better to 12 have them as noncleavable linker. 13 My opinion upon reviewing the data is that 14 the experiments do not support this notion. 15 Q. Is the Tikhomirov conclusion based on a 16 certain anti-EGFR ADC that it performed experiments 17 on? 18 A. They generated ADCs based on cetuximab. 19 Q. What is the linker and payload used? 20 A. So they used DM-1 as a noncleavable linker 21 and then MMAE with a cleavable linker. 22 Q. What is the cleavable linker that was used? 23 A. The VC. 24 Q. If we keep the VC linker and the MMAE 25 payload of Tikhomirov but increase the binding</p>	<p>120</p> <p>1 THE WITNESS: I cannot comment on Wei's 2 toxicity because he hasn't demonstrated toxicity 3 data. And the experiments done in Tikhomirov do not 4 allow me to draw any conclusions showing that -- 5 saying that their antibody with the same -- with a 6 vcMMAE linker has toxicity or not. 7 BY MR. QIU: 8 Q. Can you please go to page 31 of 9 Exhibit 1009. Please let me know when you're there. 10 A. Yes. 11 (Exhibit 1009 was previously marked by the 12 Certified Shorthand Reporter, and a copy is 13 attached hereto.) 14 BY MR. QIU: 15 Q. Actually, it's page 30 of the reference of 16 Tikhomirov and it's on page 31 of the stamp. 17 Actually, let's go to page 29 of Tikhomirov. It's 18 in the paragraph below Example 4. 19 Please let me know when you are there. 20 A. Yes, I'm there. 21 Q. At the end of this paragraph there's a 22 sentence saying that Figure 13 shows that 23 conjugation of cetuximab to MMAE by a cleavable 24 linker, parenthetical, the VC linker, potentiates 25 its toxicity against normal cells.</p>

<p style="text-align: right;">121</p> <p>1 Is that correct?</p> <p>2 A. I don't believe the data. And the reason</p> <p>3 for this is if you go to Figure 13, this is on</p> <p>4 page -- page 42 of the exhibit, you will see there</p> <p>5 that it contains a comparison between cetuximab --</p> <p>6 this is labeled as Cetux2C9-MMAE -- and then</p> <p>7 Cetux2C9-DM-1, along with cetuximab 2C9, which is</p> <p>8 the naked antibody, and then human Ig-DM-1, which I</p> <p>9 presume is an isotype control that has DM-1, and</p> <p>10 then human IgG, which is an irrelevant control.</p> <p>11 So to make the statement that a cleavable</p> <p>12 linker potentiates toxicity, first of all you need</p> <p>13 to have a head-to-head comparison having cetuximab</p> <p>14 MMAE with a cleavable linker versus cetuximab MMAE</p> <p>15 with a noncleavable linker because the sensitivity</p> <p>16 of the cells to different drugs is going to be</p> <p>17 different. It's comparing apples and oranges.</p> <p>18 So DM-1 would have different healing</p> <p>19 activity than MMAE.</p> <p>20 Then if you even want to be precise, we</p> <p>21 also need an isotype control and a relevant control</p> <p>22 with MMAE with or without cleavable linkers.</p> <p>23 So with the presented evidence, the lack of</p> <p>24 important controls, the lack of a payload-alone</p> <p>25 control, we cannot conclude that a cleavable linker</p>	<p style="text-align: right;">123</p> <p>1 linker used in Leanna are the same as the payload</p> <p>2 and linker in Tikhomirov?</p> <p>3 A. Yes. It's in a vcMMAE linker, and the same</p> <p>4 linker has used in Wei as well.</p> <p>5 Q. Is it fair to say that any property -- any</p> <p>6 differences between the properties of Wei and</p> <p>7 Tikhomirov's ADCs will be the result of their</p> <p>8 different antibodies?</p> <p>9 MR. SUH: Objection to form.</p> <p>10 THE WITNESS: I cannot comment on</p> <p>11 differences because, again, there is no head-to-head</p> <p>12 comparison on the activity of these two ADCs</p> <p>13 in vitro or in vivo.</p> <p>14 BY MR. QIU:</p> <p>15 Q. Do you use Tikhomirov as the basis of</p> <p>16 either ground of invalidity presented in your</p> <p>17 declaration?</p> <p>18 A. I believe the reason we reviewed</p> <p>19 Tikhomirov -- probably I'm mispronouncing the</p> <p>20 name -- was that it was brought up during the patent</p> <p>21 prosecution of the '370 patent. And I had to review</p> <p>22 the evidence that support whether or not cleavable</p> <p>23 or noncleavable linkers are better or worse for</p> <p>24 anti-EGFR antibodies.</p> <p>25 So upon reviewing the data, I concluded</p>
<p style="text-align: right;">122</p> <p>1 will have more toxicity than a noncleavable linker.</p> <p>2 Then in experiments in labs, what we do is</p> <p>3 we repeat the same experiment if we want to</p> <p>4 establish generality with different cleavable</p> <p>5 linkers.</p> <p>6 So here in this patent they only used one</p> <p>7 linker, VC, and one noncleavable linker, different</p> <p>8 chemistries. By making this conclusion that all</p> <p>9 cleavable linkers are bad, all noncleavable linkers</p> <p>10 are good, you need to show data. So you need</p> <p>11 different cytotoxic drugs in addition to MMAE,</p> <p>12 different linkers, cleavable, noncleavable, and,</p> <p>13 ideally, different antibodies.</p> <p>14 Q. Is the -- let me see.</p> <p>15 Is it correct to say that the only</p> <p>16 difference between the ADC of Tikhomirov and the ADC</p> <p>17 of Wei is the antibody used?</p> <p>18 A. If you are referring to cetuximab 2C9 MMAE,</p> <p>19 yes, the difference is the antibody; however, I'm</p> <p>20 not sure the purity of the antibody preparation, the</p> <p>21 drug-to-antibody ratio, and so on.</p> <p>22 So there are several different aspects that</p> <p>23 can be different between these two patents in</p> <p>24 addition to the antibody.</p> <p>25 Q. Is it your opinion that the payload and the</p>	<p style="text-align: right;">124</p> <p>1 that the experiments -- there is almost zero</p> <p>2 experimental evidence to suggest that. And on the</p> <p>3 contrary, everyone at the time of Tikhomirov or even</p> <p>4 before that -- Leanna, Wei, or even brentuximab</p> <p>5 vedotin, so that's Exhibit 1021, a critical product</p> <p>6 at the time -- was using a vcMMAE linker, a</p> <p>7 cleavable linker.</p> <p>8 Q. So to clarify, you do not use Tikhomirov</p> <p>9 for either ground in your declaration; correct?</p> <p>10 A. To determine obviousness of the claims, no.</p> <p>11 Only -- only because it was part of the patent</p> <p>12 prosecution.</p> <p>13 MR. QIU: Howard, we got to another good</p> <p>14 stopping point in my questions. Why don't you ask</p> <p>15 whether Dr. Bournazos would want a break or whether</p> <p>16 we should keep going.</p> <p>17 MR. SUH: Let's take a break.</p> <p>18 (Recess.)</p> <p>19 BY MR. QIU:</p> <p>20 Q. For Ground 1, you argue that the claims of</p> <p>21 the '370 patent are obvious in view of the</p> <p>22 combination of Wei and Liu; is that correct?</p> <p>23 MR. SUH: Objection to form.</p> <p>24 THE WITNESS: Can you refer me to the</p> <p>25 specific section in the declaration?</p>

Conducted on December 11, 2025

125	<p>1 BY MR. QIU: 2 Q. The section starting from page 86. 3 A. Got it. Yeah. 4 Q. Is it your opinion that the linker and 5 payload in Wei's ADC respectively satisfied the '370 6 patent's limitations regarding linker and payload? 7 A. The linker in Wei is identical to the 8 '370 patent. It's a vcMMAE linker. 9 Q. How about the payload? 10 A. Payload is the same, MMAE. 11 Q. Is it your opinion that the antibody in 12 Wei's ADC is not what the '370 patent claims? 13 A. It is a substantial identical antibody 14 compared to what patent '370 says. 15 Q. Is it your opinion that Liu teaches the 16 antibody that the '370 patent claims? 17 A. Correct. 18 Q. Is it your opinion that a POSA would have 19 found it obvious to replace the antibody of Wei's 20 ADC with Liu's antibody to arrive at the challenged 21 claims? 22 A. Yes, it's obvious. 23 Q. According to the Liu reference, the BA03 24 antibody has stronger activity than cetuximab in 25 inhibiting phosphorylation of EGFR; correct?</p>	127	<p>1 at higher dose than ADCs. But it really depends on 2 the tumor type. There's no one rule if it's 3 everything. 4 (Stenographer clarification.) 5 BY MR. QIU: 6 Q. Is it accurate to say that in the context 7 of an ADC the antibody's activity in inhibiting 8 phosphorylation is not the primary therapeutic 9 mechanism? 10 MR. SUH: Objection. Foundation. 11 THE WITNESS: Depends on the context. For 12 me, in the context of EGFR, I would consider it a 13 bonus. It's another antitumor function. 14 BY MR. QIU: 15 Q. When BA03 is incorporated into an ADC, does 16 its effect on EGFR phosphorylation decrease or 17 become clinically less significant compared to its 18 payload-mediated cytotoxicity? 19 A. It depends on the context. So if we see -- 20 for example, let's take Wei example. So in tumors 21 that are resistant to classical EGFR therapy, 22 cetuximab therapy, tumors that have KRAS or BRAF 23 mutations, an ADC, despite the fact that the 24 inhibition of EGFR signaling would be an added 25 bonus, it's still -- the mechanism of killing is</p>
126	<p>1 MR. SUH: Objection. Foundation. Form. 2 THE WITNESS: Correct. This is stated in 3 the Liu patent. 4 BY MR. QIU: 5 Q. Is that comparison made on the basis of 6 both antibodies being used as naked antibodies? 7 A. Correct. 8 Q. Would the benefit of stronger activity in 9 inhibiting phosphorylation by BA03 be of the same 10 magnitude when BA03 is used as part of ADC compared 11 to when BA03 is used as a naked antibody? 12 A. In principle it's going to be the same. So 13 the inhibition of EGFR phosphorylation will not be 14 substantially impacted by the presence or not of the 15 payload in the linker. 16 However, we need to consider two things: 17 One is that the addition of the payload might change 18 some of the properties of the antibody. And the 19 second is that the dose that an ADC will be used in 20 humans is going to be different than an antibody -- 21 a naked antibody. But in principle, they will -- 22 it's going to have comparable inhibitory activity 23 against phosphorylation of EGFR. 24 Q. How will the dose be different? 25 A. Normally naked antibodies are administered</p>	128	<p>1 going to be primarily by internalization of the 2 payload. 3 Now, in tumors that haven't mutated yet in 4 terms of KRAS or BRAF, having an inhibitory activity 5 against EGFR phosphorylation would still be one of 6 the mechanisms by which an anti-EGFR ADC would 7 mediate antitumor effects. 8 I don't really want to say what would be 9 the primary or the secondary mechanism because 10 everything depends on the tumor context, on the 11 tumor type and the mutations of the tumor. 12 Q. How would you describe the relative 13 clinical importance of EGFR phosphorylation 14 inhibition in the ADC versus naked or unconjugated 15 settings? 16 A. Can you please rephrase or repeat your 17 question, just to make sure that I understand 18 correctly? 19 Q. Sure. 20 I'm asking about the clinical importance of 21 EGFR phosphorylation inhibition and whether that is 22 more or less important between when the antibody is 23 used naked or when the antibody is used in ADC? 24 A. Oh, okay. I got it. I got it. Thanks for 25 clarifying.</p>

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

<p style="text-align: right;">129</p> <p>1 So again, it depends on the tumor type. So 2 it is an important function, and for certain tumors 3 that are still maintaining wild-type status KRAS or 4 BRAF, it is another antitumor activity. I cannot, 5 and I don't think anyone has done this comparison, 6 quantified the precise contribution of this activity 7 versus the cytotoxic activity of -- by the drug 8 itself in contributing to antitumor activity. 9 And I don't think it's a feasible 10 experiment, if you want to call it, to do. 11 (Stenographer clarification.) 12 BY MR. QIU: 13 Q. Would the activity inhibiting 14 phosphorylation by BA03 have any correlation to its 15 binding affinity? 16 A. Hard to tell. So Liu reports that BA03 has 17 better inhibitory activity against phosphorylated -- 18 phosphorylated EGFR and I believe higher affinity, 19 but one is not a requirement for the other. So a 20 higher affinity won't necessarily equate to better 21 inhibitor activity. 22 Q. Does the activity of inhibiting 23 phosphorylation affect both tumor and normal cells 24 expressing EGFR? 25 A. Partly true because the tumor is always in</p>	<p style="text-align: right;">131</p> <p>1 saying that expression matters, you isolate just one 2 component. What I see is that not all tumor 3 cells -- or not all cell types -- tumor cells, 4 malignant, or nonmalignant -- proliferate at the 5 same rate and are sensitive -- have the same 6 sensitivity to the drug payload. 7 And this is the basis of success for many 8 ADCs out there that are currently in the clinic. 9 (Stenographer clarification.) 10 BY MR. QIU: 11 Q. Earlier I believe you indicated that you 12 were not certain whether the expression level has an 13 impact on antibody binding. Are you changing that 14 opinion now? 15 MR. SUH: Objection. Mischaracterizes the 16 testimony. 17 THE WITNESS: I still stand with my opinion 18 because the question was very broad. So you asked 19 me in the context of any antibody, any expression of 20 any receptor, if this is true or not. I still 21 maintain this posi- -- this opinion. 22 BY MR. QIU: 23 Q. Let's -- let's keep it in the context of 24 the EGFR antigen and anti-EGFR antibody. 25 A. Okay.</p>
<p style="text-align: right;">130</p> <p>1 a more constant, in much higher level of 2 proliferation compared to normal tissues. And also 3 we need to consider that the level of expression of 4 EGFR is going to be substantially higher in the 5 tumor compared to normal tissues. 6 So yes, the effects can be seen also in 7 other cell types but are going to be -- expect to be 8 way more prominent on tumor cells. 9 Q. So now you are saying the expression level 10 of EGFR on the tissue would have a -- would be an 11 important factor in controlling whether the ADC will 12 impact the tissue; correct? 13 MR. SUH: Objection to form. 14 THE WITNESS: So if expressed -- 15 BY MR. QIU: 16 Q. Oh, I'm sorry. Please strike that 17 question. 18 Let me ask you: Is it your opinion that 19 the expression level of EGFR on the tissue is an 20 important factor in determining whether the antibody 21 will have activities on the tissue? 22 A. Tissue, you mean, normal tissue? 23 Q. I mean any tissue, normal or tumor. 24 A. It really depends on how sensitive the 25 tissue is to the drug, how much it's expressing. So</p>	<p style="text-align: right;">132</p> <p>1 Q. Is it your opinion that the expression 2 level does have an impact on antibody binding? 3 A. It is one of the determinants, certainly. 4 But again, it depends on which epitope the antibody 5 is recognizing. If we see Antibody 1, for example, 6 it doesn't bind EGFR that's expressing on some 7 glioma cells. But it's still -- an expression is 8 there on these tumor cells. 9 So everything needs to be taken in a 10 context and have specific examples for specific 11 antibodies. 12 Q. In the context of EGFR, what properties of 13 antibody determines the binding specificity to 14 target cells? 15 A. The binding specificity. So the binding 16 specificity is determined by the variable region of 17 the Fab. So this determines how specific the 18 antibody -- how specifically the antibody against 19 EGFR binds EGFR. So this is the primary 20 determinant. 21 Another determinant is how accessible the 22 epitope that is recognized by EGFR is. Is it 23 occluded? Is it mutated? Who knows. 24 Q. In the context of EGFR, the binding of an 25 antibody to cell services depend on the expression</p>

Conducted on December 11, 2025

<p style="text-align: right;">133</p> <p>1 level of antigen on the cell surfaces; correct?</p> <p>2 A. No. In the context of cetuximab or in the</p> <p>3 context of any anti-EGFR antibody?</p> <p>4 Q. In the context of EGFR. That's my</p> <p>5 question.</p> <p>6 A. No. Remember, Antibody 1 is an anti-EGFR</p> <p>7 antibody that binds -- that also some glioma cells,</p> <p>8 as we have seen in the other example, express EGFR,</p> <p>9 it cannot bond, it cannot bind and recognize this</p> <p>10 EGFR positive tumor cells.</p> <p>11 Q. So, Doctor, I'm a little confused.</p> <p>12 A. Sorry.</p> <p>13 Q. In the question of BA03, you said, you</p> <p>14 know, its effect on tissue would depend on the</p> <p>15 expression level of the EGFR antigen.</p> <p>16 A. Yes, correct, correct.</p> <p>17 Q. And here you are again saying it doesn't.</p> <p>18 A. Because your question, your previous</p> <p>19 question was generally for all anti-EGFR antibodies.</p> <p>20 When I asked you specifically if you were referring</p> <p>21 to cetuximab, your response was no, for all</p> <p>22 anti-EGFR.</p> <p>23 So for all anti-EGFR, what I can say is</p> <p>24 that it's not true. Expression does not equate with</p> <p>25 binding. And I gave you as a specific example</p>	<p style="text-align: right;">135</p> <p>1 been demonstrated by Liu.</p> <p>2 Q. For cetuximab, Wei's Y104D antibody, and</p> <p>3 Liu's BA03, would you expect there to be a threshold</p> <p>4 or minimum expression level of the EGFR antigen on</p> <p>5 cell surface for significant antibody binding?</p> <p>6 MR. SUH: Objection. Foundation. Form.</p> <p>7 THE WITNESS: A threshold is an arbitrary</p> <p>8 term because I'm not sure how we would define the</p> <p>9 threshold. So you mean how many molecules were</p> <p>10 going to be expressed? What I know is that you need</p> <p>11 expression for binding.</p> <p>12 BY MR. QIU:</p> <p>13 Q. How do you evaluate the level of expression</p> <p>14 of an antigen?</p> <p>15 A. There are several ways of doing this. You</p> <p>16 can do it by -- depends on the context. So you can</p> <p>17 assess by flow cytometry how much it is expressed.</p> <p>18 You can see it, for example, in tumor sections by</p> <p>19 immunohistochemistry. So this will tell you whether</p> <p>20 or not, for example, a tumor expresses EGFR or not.</p> <p>21 Q. What is the unit that you used to quantify</p> <p>22 this level of expression?</p> <p>23 A. I mean, in the clinic in biopsies, they do</p> <p>24 it based on a scoring system of plus, plus -- plus</p> <p>25 or minus. So it is the intensity of the staining.</p>
<p style="text-align: right;">134</p> <p>1 Antibody 1. We have expression, for example, of</p> <p>2 EGFR on glioma cells, some cell types. Antibody 1,</p> <p>3 according to the patent, doesn't bind.</p> <p>4 Is it clear now?</p> <p>5 Q. So in the context of cetuximab, does the</p> <p>6 binding of the antibody-to-cell surface depend on</p> <p>7 the expression level of antigen?</p> <p>8 A. Yes, unless as soon as the antigen is there</p> <p>9 and in a form that can be recognized by cetuximab.</p> <p>10 So if the epitope is preserved, yes.</p> <p>11 Q. And this does not apply to -- sorry.</p> <p>12 Strike that.</p> <p>13 And this also applies to variants of</p> <p>14 cetuximab; correct?</p> <p>15 A. Correct. And again, depends on the</p> <p>16 variants. If I generate a variant of cetuximab that</p> <p>17 can no longer bind or have mutated extensively, it</p> <p>18 doesn't apply. So that's why it's helpful if we</p> <p>19 talk on specific examples. So which variants are</p> <p>20 you referring to?</p> <p>21 Q. Does it apply to the Y104D variant and --</p> <p>22 A. Yeah.</p> <p>23 Q. -- it's either chimeric or humanized?</p> <p>24 A. Yeah. So 104D binds EGFR. This has been</p> <p>25 demonstrated in Wei. BA03 does bind EGFR. This has</p>	<p style="text-align: right;">136</p> <p>1 It's very arbitrary.</p> <p>2 In the lab, for example, in flow cytometry,</p> <p>3 you can measure the median fluorescence intensity.</p> <p>4 We don't really quantify, unless absolutely</p> <p>5 necessary, how many more -- the absolute numbers of</p> <p>6 molecules that are expressed on the cell surface.</p> <p>7 Q. So let's use whatever way to quantify the</p> <p>8 expression level that you are familiar with.</p> <p>9 Is there typically a threshold or minimum</p> <p>10 expression level of the antigen, like, would you</p> <p>11 expect there to be a threshold or minimum expression</p> <p>12 level of the antigen on cell surface for a</p> <p>13 significant binding by cetuximab BA03 or Y104D?</p> <p>14 MR. SUH: Objection to form.</p> <p>15 THE WITNESS: This is a very vague</p> <p>16 question. What do you mean by "significant</p> <p>17 binding"? How many molecules do you mean? Because</p> <p>18 the number of molecules that you would consider</p> <p>19 significant binding, I would say it needs to match,</p> <p>20 approximately, the numbers of receptors that need to</p> <p>21 be expressed.</p> <p>22 BY MR. QIU:</p> <p>23 Q. By "significant binding" I mean enough</p> <p>24 binding to reduce EGFR activity.</p> <p>25 A. To reduce EGFR activity?</p>

Conducted on December 11, 2025

<p style="text-align: right;">137</p> <p>1 Q. Mm-hmm.</p> <p>2 A. To reduce phosphorylation?</p> <p>3 Q. Sure. We can talk about phosphorylation,</p> <p>4 yeah.</p> <p>5 A. Yeah. So there is no arbitrary unit. So a</p> <p>6 cell line or a cell path needs to be paused before</p> <p>7 expression. I don't think that there is a right or</p> <p>8 wrong answer to this question. So whether I say</p> <p>9 1,000 units, let's say. It's not typically done.</p> <p>10 Q. In the context of the -- in the context of</p> <p>11 cetuximab BA03 and the Y104D, would you expect there</p> <p>12 to be a minimum density of surface antibody binding</p> <p>13 required to trigger internalization of the target</p> <p>14 cell?</p> <p>15 A. Internalization, you will need at least two</p> <p>16 receptors. This is for sure because antibodies are</p> <p>17 by valent molecules. So the internalization would</p> <p>18 happen once two receptors are cross-linked.</p> <p>19 Now, two molecules would be enough to</p> <p>20 internalize. My guess is yes. But in the context</p> <p>21 of an ADC, because I presume this is your -- your</p> <p>22 point, two receptors or one antibody, one drug, it</p> <p>23 might not be sufficient to kill a cell because</p> <p>24 everything depends on the dose of the drug and the</p> <p>25 express -- how much of the drug gets into the cell</p>	<p style="text-align: right;">139</p> <p>1 research in the area of Fc receptor-mediated</p> <p>2 effector functions and published some papers on it?</p> <p>3 A. Yes, that's my main area of research.</p> <p>4 MR. QIU: I'm introducing patent owner's</p> <p>5 Exhibit 2020. Let me upload it. This is a new</p> <p>6 exhibit. It's not in the paper files that we sent.</p> <p>7 MR. SUH: Oh.</p> <p>8 MR. QIU: Howard, do you have a way to</p> <p>9 either print it out or have Doctor look at it?</p> <p>10 THE WITNESS: Can we print it out?</p> <p>11 MR. SUH: We could try. Well, if you -- if</p> <p>12 you put it up on the screen, I don't know. Is there</p> <p>13 a way to print it out? We don't have it.</p> <p>14 REMOTE TECHNICIAN: I can share it</p> <p>15 electronically if we want to go that route.</p> <p>16 MR. QIU: That would be great.</p> <p>17 MR. SUH: Okay.</p> <p>18 REMOTE TECHNICIAN: Yeah, just let me know</p> <p>19 when it is uploaded.</p> <p>20 MR. QIU: Yeah, I have uploaded it.</p> <p>21 MR. DU: Is it in the Zoom?</p> <p>22 MR. SUH: They said they are going to</p> <p>23 upload it on the Zoom.</p> <p>24 REMOTE TECHNICIAN: Is it called</p> <p>25 Exhibit 2020? Is that what you said it was?</p>
<p style="text-align: right;">138</p> <p>1 along with the sensitivity of the cell.</p> <p>2 Q. So according to Liu, BA03 has a higher ADCC</p> <p>3 activity than cetuximab; correct?</p> <p>4 A. Yes.</p> <p>5 Q. Is that comparison made on the basis of</p> <p>6 both being used as naked antibodies?</p> <p>7 A. Yeah, I believe so. They are all both</p> <p>8 compared as naked antibodies, so Erbitux, cetuximab,</p> <p>9 versus BA03.</p> <p>10 Q. Would the benefit of stronger ADCC activity</p> <p>11 by BA03 be of the same magnitude when BA03 is used</p> <p>12 as part of ADC compared to when BA03 is used as</p> <p>13 naked antibody?</p> <p>14 A. Maybe, maybe not. It's hard to speculate</p> <p>15 on this because it depends on the chemistry. So it</p> <p>16 depends where the MMAE would be conjugated.</p> <p>17 If the conjugation happens to be near</p> <p>18 the Fc gamma receptor binding site, it might impact.</p> <p>19 But based on what we have seen before from what is</p> <p>20 typically used as a drug-antibody ratio, which is</p> <p>21 typically used for antibodies that are in the</p> <p>22 clinic, it does not impact any ADCC activity of</p> <p>23 cetuximab of any antibody when they are formulated</p> <p>24 as ADCs.</p> <p>25 Q. Is it right that you have done extensive</p>	<p style="text-align: right;">140</p> <p>1 MR. QIU: That's right. Exhibit 2020.</p> <p>2 REMOTE TECHNICIAN: Okay. And this one</p> <p>3 needs to be marked, right, or is it already marked?</p> <p>4 MR. QIU: We have already stamped it as</p> <p>5 Exhibit 2020.</p> <p>6 REMOTE TECHNICIAN: Okay.</p> <p>7 Okay, I just downloaded it.</p> <p>8 MR. SUH: I think they're going to e-mail</p> <p>9 it to us.</p> <p>10 REMOTE TECHNICIAN: I can -- I was just</p> <p>11 going to share it on my screen, but I can -- I can</p> <p>12 also share it in the chat and share it on the screen</p> <p>13 if that's also helpful.</p> <p>14 MR. SUH: If we wanted to print it, how do</p> <p>15 we print it?</p> <p>16 MR. QIU: Do you have the download link?</p> <p>17 REMOTE TECHNICIAN: I believe the download</p> <p>18 link is just for me to access the exhibits.</p> <p>19 MR. QIU: Oh, okay, sorry.</p> <p>20 REMOTE TECHNICIAN: No, you're good.</p> <p>21 Is it okay if I send it via chat now?</p> <p>22 MR. QIU: Or I can e-mail it to you.</p> <p>23 REMOTE TECHNICIAN: Is it all right if I</p> <p>24 send it in the chat here?</p> <p>25 MR. SUH: Yeah, why don't we do both.</p>

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

141	<p>1 REMOTE TECHNICIAN: Okay. And then I will 2 share it on my screen. 3 MR. SUH: And then, Fred, if you want to 4 e-mail it to us. 5 MR. QIU: Yes, I'm doing that. 6 THE WITNESS: I might have to stand. 7 MR. SUH: E-mail it to me and Erxin, 8 please. 9 MR. QIU: I'll just e-mail it to the entire 10 group. 11 THE WITNESS: No need to print it. 12 MR. SUH: We can proceed. Dr. Bournazos 13 says that he doesn't need a paper copy. 14 MR. QIU: Okay. 15 (Exhibit 2020 was marked for identification 16 by the Certified Shorthand Reporter, and a 17 copy is attached hereto.) 18 BY MR. QIU: 19 Q. Doctor, do you recognize this exhibit? 20 A. Of course. 21 Q. What is it? 22 (Interruption in proceedings.) 23 THE STENOGRAPHER: We'll go off the record 24 here, Counsel. 25 (Recess.)</p>	143	<p>1 induced upon Fc gamma receptor-IG interactions are 2 mediated through activating Type I" -- 3 Q. Doctor, you can feel free to review. 4 A. Oh, okay. Okay. 5 Q. You don't have to read it out loud. 6 A. Okay. 7 Yes. 8 Q. There you state that all cytotoxic effector 9 functions induced upon the Fc gamma receptor IGG 10 interactions are mediated through activating Type I 11 Fc gamma receptors; correct? 12 A. Correct. 13 Q. Can you explain what that means? 14 A. Is there a figure in here that I can 15 explain? No. Let me go back. 16 So antibodies when binding to cells that 17 express the antigen can mediate effector functions 18 through the Fc domain of the antibody. So there are 19 several leukocytes, monocytes, dendritic cells, 20 macrophages, NK cells, express activating and 21 inhibitory receptors. 22 So particularly for cytotoxicity against 23 antibody-coated targets, you need binding of the 24 Fc domain of the antibody to this activating, we'll 25 call them Type I, distinguish them from Type II,</p>
142	<p>1 BY MR. QIU: 2 Q. So let me repeat my last question. 3 MR. QIU: Drew, can you share the exhibit 4 on the screen again? 5 BY MR. QIU: 6 Q. Dr. Bournazos, what is Exhibit 2020? 7 A. It's a review that I wrote from 2017. 8 Q. Are you an author for this paper? 9 A. Yeah, I'm the first author. 10 Q. Can you please go to page 5 of this paper. 11 Can you read the first paragraph to yourself. 12 A. Give me a second. Let me print this 13 because it's too small. 14 Q. Sure. 15 THE WITNESS: Let's print it. 16 We're just trying to find a way to print 17 it. I can move closer to the screen and read it out 18 loud if you want. 19 MR. SUH: Why don't we do this. You can 20 read it off my computer. 21 THE WITNESS: Yeah, okay, good. 22 So paragraph 1, you said, on page 5? 23 BY MR. QIU: 24 Q. Yes. The first paragraph of page 5. 25 A. So: "All cytotoxic effector functions</p>	144	<p>1 Fc gamma receptors. 2 So these effector functions that are 3 mediated by the antibody are induced following the 4 engagement of these activating Type I Fc gamma 5 receptors. 6 Q. Does this mean that the antigen-binding 7 portion of the antibody is not directly involved in 8 the cytotoxic effector functions? 9 A. The cytotoxic function through the Fc 10 domain is mediated by the Fc-Fc gamma interaction. 11 However, our bodies have evolved. So we express 12 Fc gamma receptors, and we also have in our 13 circulations -- circulation about 10 mgs per mL 14 of IgG, of antibodies. 15 So these receptors have evolved in a way 16 that they will only bind with very low affinity to 17 antibodies. So at steady states, steady state, none 18 of the Fc gamma receptors are going to be 19 occupied -- are going to be sufficiently activated 20 by monomeric IgG. It is clear now. 21 Why do we have a virus or when we have an 22 infected cell or a malignant cell? The antibody 23 will bind to the antigens that are expressed by an 24 infected cell. Think about an infected bronchial 25 epithelial cell after flu infection. So this will</p>

Conducted on December 11, 2025

<p style="text-align: right;">145</p> <p>1 express antigens against influenza. 2 So the antibody will come, will bind. So 3 binding of the antibody is critical. So then the 4 Fc gamma receptors are going to -- on the effector 5 cells are going to recognize multiple antibodies 6 that are bound on the surface of the infected cell, 7 resulting in the clustering of the Fc gamma 8 receptors on the effector cell, on a leukocyte, that 9 will trigger cytotoxicity and killing of this 10 infected cell. 11 So in conclusion, the activities are 12 mediated through Fc-Fc gamma receptor interactions, 13 but they require multiple, low -- multiple 14 low-affinity hybrid interactions, and this results 15 only when the antibody is presented to the Fc gamma 16 receptor as an immune complex. In other words, 17 complex to an antigen. 18 Q. Your declaration noted that the BA03 19 antibody is a humanized version of the cetuximab. 20 A. Correct. 21 Q. Is it correct that the humanization did not 22 change the Fc portion of the antibody? 23 A. On the contrary. So cetuximab is chimeric. 24 So cetuximab has the NFc that is human. So what 25 humanization has done to BA03 is to keep it as</p>	<p style="text-align: right;">147</p> <p>1 scientifically it is one of the most important. 2 I wish we had the tools to solve this. 3 MR. QIU: Yeah, by the way, we can take off 4 the exhibit from the screen. 5 BY MR. QIU: 6 Q. Would it be reasonable to believe that the 7 increased ADCC arises from a higher amount of the 8 antibody bound to EGFR on the cell surface for BA03? 9 MR. SUH: Objection to form. 10 THE WITNESS: Higher amount, no, because I 11 don't think that they provide any data to explain 12 this. To my opinion, I don't -- I can only 13 speculate. The higher ADC activity might be because 14 of some minor changes that the BA03 was -- were 15 introduced in the way that it recognizes the 16 antigen. I wouldn't say higher binding, but 17 something is going on. 18 By the end of the day, BA03 seems to be a 19 better version of cetuximab. 20 BY MR. QIU: 21 Q. But I thought you said earlier that the 22 binding to a cell surface does impact ADCC activity, 23 earlier. 24 A. It really depends on -- 25 Q. Can you clarify this?</p>
<p style="text-align: right;">146</p> <p>1 human Z1 but also replace some of the residues that 2 are on the variable region. 3 If we go to the declaration -- it's helpful 4 if we go to the declaration on page 22 and you will 5 see what I mean. So all the blue is human. All the 6 red is mouse or other species. So chimeric, you 7 notice that the Fc is human. The Fabs are mouse. 8 In the humanized version, now, the vast majority of 9 the antibody is now human, including Fc, but the Fc 10 of cetuximab is human as well. The Fc domain of 11 BA03 is human as well. 12 Q. So just to confirm, it is your opinion that 13 the BA03 antibody and cetuximab, they have different 14 Fc portions? 15 A. No, no, on the contrary. They have 16 identical Fc portions. 17 Q. Oh, okay. 18 A. And they're both of human IgG 1. 19 Q. Since the BA03 antibody and cetuximab have 20 the same Fc portion, what is your view on why BA03 21 has increased ADCC activity? 22 A. Very good point. And that question keeps 23 bothering me almost every other night. Why by 24 changing the Fab you change the Fc activity? 25 It's -- it's not an easy question to answer. But</p>	<p style="text-align: right;">148</p> <p>1 A. It really depends on the context. So for 2 the -- in the case of EGFR, I cannot comment if -- 3 how ADCC is regulated. It's a line of 4 investigation, of active investigation. We know 5 from other antigen-antibody model systems that the 6 expression is not a -- not just from my group, just 7 several other groups have indicated this, that the 8 expression of an antigen is not really -- the level 9 of expression of an antigen is not -- cannot really 10 predict whether an antibody will induce ADC activity 11 or not. 12 Even if the antibody is expressed with the 13 identical Fc domain, identical subclass, identical 14 Fc glycan, this... 15 Q. Doctor, is that the end of your question 16 [verbatim]? I thought we paused in the middle of a 17 sentence. 18 A. No, no, no. I'm done. 19 Q. Does the ADCC activity affect both tumor 20 and normal cells in expressing EGFR? 21 A. Potentially, yes. 22 Q. Does the BA03 antibody have pH selectivity? 23 A. I don't believe that Liu has tested this. 24 Q. So you do not know whether BA03 antibody 25 has pH selectivity; correct?</p>

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

<p>149</p> <p>1 A. No. 2 MR. SUH: Objection to form. 3 THE WITNESS: I don't have data available 4 to comment on that. 5 BY MR. QIU: 6 Q. Does the BA03 antibody have higher binding 7 affinity for tumor cells than for normal cells? 8 A. It has equal activity to EGFR. Higher 9 binding affinity, again, it depends on the density. 10 But the absolute affinity, I don't expect to be 11 higher or lower as soon as EGFR is expressed. One 12 of the properties of BA02 [verbatim] and cetuximab 13 is that it can bind a mutated variant that is 14 predom- -- exclusively expressed by tumor cells. 15 So, yes, it has higher affinity for this 16 variant and no affinity because there is no 17 expression in normal cells. 18 Q. Is EGFR density a primary factor for 19 cetuximab to distinguish tumor cells from normal 20 cells? 21 A. Yes, I believe that's correct. 22 Q. How about the BA03 antibody? Is EGFR 23 density a primary factor for BA03 to distinguish 24 tumor cells from normal cells? 25 A. Given the fact that BA03 is substantially</p>	<p>151</p> <p>1 need to do this experiment in vivo to see whether or 2 not it can bind normal tissues or not. But these 3 studies are not presented in Wei. 4 Q. Are you aware of petitioners' SYS6010 or 5 CPO301 ADC candidate? 6 A. Which exhibit is this? 7 Q. No, that's a general question. I'm not 8 showing an exhibit. 9 A. Can you please repeat the question, then? 10 MR. QIU: Can the court reporter repeat the 11 question. 12 THE STENOGRAPHER: Yes. 13 (The previous question was read back by the 14 court reporter as follows: 15 "QUESTION: Are you aware of 16 petitioners' SYS6010 or CPO301 ADC 17 candidate?") 18 MR. SUH: Objection. Lacks foundation. 19 THE WITNESS: I don't recall reviewing any 20 of this. But again, it's a number, so I may have 21 reviewed it but... 22 BY MR. QIU: 23 Q. Can you please open Paper 7 in this case, 24 which is Petitioners' Response to Patent Owner's 25 Request For Discretionary Denial of Institution.</p>
<p>150</p> <p>1 identical to cetuximab, I would assume so, yes. The 2 level of receptor expression is going to determine 3 whether cetuximab -- whether cetuximab or BA03 would 4 bind to malignant or nonmalignant cells. 5 Q. Is EGFR density a primary factor for Wei's 6 Y104D antibody or the humanized version to 7 distinguish tumor cells from normal cells? 8 A. Given the fact that Wei's antibodies are 9 variants of cetuximab, I would assume so. But 10 neither Wei nor Liu have demonstrated that their 11 antibody does or does not bind to normal cells. 12 My assumption is yes. 13 Q. So I understand that you don't believe 14 Wei's Y104D antibody has pH selectivity. 15 Would Y104D still have some advantage over 16 cetuximab in distinguishing tumor cells from normal 17 cells? 18 A. Y104D, no, because there are no data to 19 support this, that this particular mutation had 20 changed from Y to D, but that position will make 21 this antibody more selective for tumors compared to 22 cetuximab. 23 Q. How about the humanized version of Y104D? 24 A. Again, no data presented for selectivity of 25 tumor cells versus nontumor cells. Ideally you will</p>	<p>152</p> <p>1 That is -- I believe that is included in the box. 2 MR. SUH: It's actually not in the box. 3 Your POPR is not in the box, but we may have an 4 extra copy. 5 MR. QIU: Oh, it's not the POPR. It's the 6 Petitioners' Response to Patent Owner's Request For 7 Discretionary Denial of Institution. 8 MR. SUH: Oh, okay. 9 MR. QIU: Is that in there? 10 MR. SUH: Hold on. Petitioners' response. 11 Okay. Yes. 12 Here you go. 13 (Exhibit 7 was previously marked by the 14 Certified Shorthand Reporter, and a copy is 15 attached hereto.) 16 BY MR. QIU: 17 Q. Doctor, can you please go to page 45 of the 18 Paper 7. 19 A. 45, yes. 20 Q. At the bottom of that page there's a 21 paragraph starting with "Moreover"; correct? 22 A. Is there a specific section that you want 23 me to review? 24 Q. Yeah. So I'm asking whether you see a 25 paragraph starting with the term "Moreover," at the</p>

Transcript of Stylianos Bournazos, Ph.D.
Conducted on December 11, 2025

39 (153 to 156)

153	1 bottom of page 45? 2 A. I see it. I see it, yes. 3 Q. Can you please review that paragraph and 4 the next paragraph that starts with "Notably" to 5 yourself. 6 A. Yes. 7 Can we also review Exhibit 1103 and 2? 8 Because there is a reference. 9 Q. Sure. I think it should be in the -- 10 A. 1102 and 3. 11 Q. Yes. Yes, you can read those. 12 MR. SUH: 1102. 13 THE WITNESS: Oh, it's the same. 14 1101 here. 15 MR. SUH: Here's 1101. 16 THE WITNESS: Okay. Thank you. 17 (Exhibit 1101, Exhibit 1102, and 18 Exhibit 1103 were previously marked by the 19 Certified Shorthand Reporter, and copies 20 are attached hereto.) 21 THE WITNESS: Yes, I have reviewed the 22 paragraph. 23 And the next paragraph, you said, 24 "Notably"? 25 ///	155	1 these will be applied or tested in patients who have 2 already progressed. So these patients are in need. 3 BY MR. QIU: 4 Q. So I take that a "yes." 5 MR. SUH: Objection. 6 BY MR. QIU: 7 Q. Correct? 8 MR. SUH: Objection to the question. 9 THE WITNESS: Yes, sure, you can take it as 10 a yes, but, again, it depends on the definition of 11 "unmet need." 12 BY MR. QIU: 13 Q. Would you consider petitioners' development 14 of the SYS6010 ADC to be a success? 15 MR. SUH: Objection. Form. 16 THE WITNESS: For me, my personal opinion, 17 a success is any drug that saves even a single life. 18 But I don't think my opinion matters to companies 19 that develop drugs. So other companies have other 20 standards. So -- or clinicians have other 21 standards. 22 So a success for me is even one life saved 23 is a success. 24 BY MR. QIU: 25 Q. Do you know what antibody is used in the
154	1 BY MR. QIU: 2 Q. Yes, the next paragraph starting with 3 "Notably." 4 A. Can I have Exhibit 1100, please. 5 Q. It should be in the box as well. 6 A. Yes. 7 Q. Have you finished reviewing the two 8 paragraphs? 9 A. I did, yes. 10 Q. Okay. In your opinion -- let me reframe my 11 question. 12 Are you aware of any other anti-EGFR ADC 13 that is further along in the regulatory approval 14 process than petitioners' SYS6010 or CPO301 ADC? 15 A. I have -- I haven't reviewed this, so I'm 16 not fully aware if there are any. 17 Q. In your opinion, does petitioners' SYS6010 18 or CPO301 ADC address a previously unmet need to 19 develop a clinical -- clinically applicable 20 anti-EGFR ADC? 21 MR. SUH: Objective. Lacks foundation. 22 Objection. Lacks foundation. 23 THE WITNESS: Depending on how you define 24 "clinically" and "medically," every drug helps. And 25 you can see that, for example, from the trials,	156	1 SYS6010 ADC? 2 A. I'm not entirely sure. I believe it's the 3 BA03. 4 Q. Do you think the BA0 -- 5 A. I haven't reviewed any of this data. These 6 are new to me. 7 Q. Do you think the BA03 antibody is a good 8 antibody to use in ADCs because the SYS6010 ADC is 9 advanced in the regulatory approval process? 10 MR. SUH: Objection to form. 11 THE WITNESS: If I believe that BA03 as an 12 ADC is a good antibody, given the FDA, they have 13 given the Phase III. 14 So what -- can you please rephrase or 15 clarify your question? 16 BY MR. QIU: 17 Q. Given that petitioners' development of a -- 18 the SYS6010 ADC has been advanced in the regulatory 19 approval process, does that inform you that the BA03 20 antibody is a good antibody or suitable antibody to 21 use in ADC? 22 A. It depends on the clinical data. I would 23 assume that since it has received clearance for FDA 24 Phase III, this is a very good indicator that it has 25 shown -- I haven't reviewed the clinical data, so I

PLANET DEPOS

888.433.3767 | WWW.PLANETDEPOS.COM

Transcript of Stylianos Bournazos, Ph.D.
Conducted on December 11, 2025

157	<p>1 cannot comment on that, but given the fact that they 2 have been initiated Phase III trials, I would assume 3 that the signals from Phase I and II trials were 4 positive. 5 Q. Are you aware of the -- sorry. Strike that 6 question. 7 Are you aware of the patent owner's ADC 8 candidate MRG003? 9 A. No, I am not. 10 Q. Do you have any comment on the fact that 11 after so many years where cetuximab has been 12 available, petitioners' SYS6010 ADC has been so 13 advanced ahead of many other candidates? 14 MR. SUH: Objection to form. Foundation. 15 THE WITNESS: If I am -- 16 Sorry. What was the question? 17 BY MR. QIU: 18 Q. Do you have any comment on the fact that 19 after so many years of the industry trying to 20 develop anti-EGFR ADCs, the SYS6010 ADC that uses 21 the BA03 antibody is one of the earlier ones to be 22 so advanced in the clinical regulatory approval 23 process? 24 MR. SUH: Objection. Lacks foundation. 25 THE WITNESS: No substantive comment. I</p>	159	<p>1 DECLARATION UNDER PENALTY OF PERJURY 2 3 I hereby declare under penalty of perjury 4 that the foregoing is my deposition under oath; that 5 I have read same; and that I have made the 6 corrections, additions, or changes to my answers 7 that I deem necessary. 8 9 In witness thereof, I hereby subscribe my 10 name this day of , 2025. 11 12 13 14 15 _____ 16 STYLIANOS BOURNAZOS, Ph.D. 17 18 19 20 21 22 23 24 25</p>
158	<p>1 don't know what to say here. Fine. 2 MR. QIU: Can we take a break here? We 3 just want to make sure that we are finished with all 4 the questions. 5 MR. SUH: Okay. That would be great. 6 Yeah. We will note that it is 5:26 here, well past 7 close of business. 8 MR. QIU: Let's take a ten-minute break. 9 (Recess.) 10 MR. QIU: Patent owner has no further 11 questions. We will pass the witness. 12 MR. SUH: Petitioner has no questions, but 13 the witness reserves the right to review and sign. 14 All right. All done. 15 THE WITNESS: All done. 16 MR. SUH: Off the record. 17 THE STENOGRAPHER: Mr. Suh, I don't have 18 your firm's standing order. Would you require a 19 rough draft also? 20 MR. SUH: Yeah. If you could send us a 21 rough, that would be great, through an e-mail. That 22 would be terrific. 23 (Deposition concluded at 2:35 p.m.) 24 -o0o- 25</p>	160	<p>1 DEPONENT'S CHANGES OR CORRECTIONS 2 3 Note: If adding to your testimony, print 4 the words you want to add. If deleting from your 5 testimony, print the words you want to delete. 6 Specify with "Add" or "Delete" and sign this form. 7 8 DEPOSITION OF: STYLIANOS BOURNAZOS, Ph.D. 9 DATE OF DEPOSITION: DECEMBER 11, 2025 10 11 PAGE LINE CHANGE/ADD/DELETE 12 _____ 13 _____ 14 _____ 15 _____ 16 _____ 17 _____ 18 _____ 19 _____ 20 _____ 21 _____ 22 _____ 23 _____ 24 _____ 25 Deponent's Signature _____ Date _____</p>

Transcript of Stylianos Bournazos, Ph.D.
Conducted on December 11, 2025

1 COUNTY OF LOS ANGELES,)

)

2 STATE OF CALIFORNIA,)

3

4 I, Cody Knacke, Registered Diplome
5 Reporter, Certified Shorthand Reporter in and for
6 the State of California, License No. 13691, hereby
7 certify that the deponent was by me first duly sworn
8 and the foregoing testimony was stenographically
9 reported by me and was thereafter transcribed with
10 computer-aided transcription; that the foregoing is
11 a full, complete, and true record of said
12 proceedings.

13 I further certify that I am not of counsel
14 or attorney for either or any of the parties in the
15 foregoing proceedings and caption named or in any
16 way interested in the outcome of the cause in said
17 caption.

18 The dismantling, unsealing, or unbinding of
19 the original transcript will render the reporter's
20 certificate null and void.

21 In witness whereof, I have hereunto set my
22 hand this day: December 18, 2025.

23

24

Cody Knacke

25 CODY KNACKE, RDR, CSR No. 13691

A			
al	according	83:16, 83:18,	32:14, 35:18,
3:27, 4:13	14:13, 29:1,	89:13, 89:23,	38:4, 38:9,
ability	81:18, 90:17,	90:2, 91:7,	38:14, 38:18,
60:11, 81:8	105:18, 125:23,	91:9, 93:21,	39:6, 39:12,
able	134:3, 138:2	97:25, 99:13,	39:13, 52:16,
8:3, 41:22,	account	110:16, 111:20,	52:18, 52:23,
43:3, 48:13,	37:23	112:13, 112:15,	52:24, 53:4,
60:7, 81:25,	accurate	112:23, 113:1,	54:3, 63:25,
85:23, 93:22	8:4, 26:14,	113:4, 113:8,	64:4, 64:8,
about	43:5, 127:6	113:13, 115:5,	64:10, 64:15,
8:24, 14:9,	acid	118:11, 121:19,	64:21, 65:2,
17:6, 17:15,	75:25, 77:25,	123:12, 125:24,	65:4, 65:15,
17:22, 20:12,	78:1, 78:9,	126:8, 126:22,	65:16, 65:21,
22:22, 27:23,	79:22, 80:1,	127:7, 128:4,	65:24, 66:3,
33:7, 45:25,	88:7, 88:16,	129:4, 129:6,	66:6, 66:7,
46:3, 47:16,	101:5, 104:25	129:7, 129:8,	68:1, 68:7,
48:20, 52:8,	acidic	129:13, 129:17,	68:8, 70:1,
52:10, 60:22,	77:16, 80:24,	129:21, 129:22,	71:1, 71:11,
61:22, 66:9,	87:3, 87:5	136:24, 136:25,	71:17, 118:18,
71:14, 73:11,	acids	138:3, 138:10,	123:7, 123:12,
79:6, 92:13,	88:10, 104:23,	138:22, 146:21,	127:1, 131:8,
97:5, 125:9,	105:24, 106:20	146:24, 147:13,	138:24, 156:8,
128:20, 137:3,	acronym	147:22, 148:10,	157:20
144:13, 144:24,	9:6	148:19, 149:8	add
149:22, 150:23	across	actual	160:4, 160:6,
above	112:8	16:1	160:11
18:16	act	actually	added
absolute	32:9	16:1, 18:8,	127:24
47:22, 89:8,	action	22:11, 23:3,	adding
136:5, 149:10	38:11	71:16, 76:8,	160:3
absolutely	activated	76:17, 89:16,	addition
64:2, 136:4	144:19	91:19, 95:1,	33:23, 34:17,
abstain	activating	120:15, 120:17,	122:11, 122:24,
29:3	143:2, 143:10,	152:2	126:17
abstracts	143:20, 143:24,	adc-targeted	additional
10:3, 27:13	144:4	67:7	71:8
abundantly	active	adcc	additionally
67:19, 67:20	148:4	112:15, 112:23,	97:12
acceptable	activities	113:1, 113:4,	additions
92:9	38:15, 130:21,	113:16, 113:17,	159:6
access	145:11	113:19, 115:6,	address
3:9, 72:11,	activity	138:2, 138:10,	154:18
140:18	17:17, 20:19,	138:22, 146:21,	adequate
accessibility	32:15, 34:16,	147:7, 147:22,	14:5
42:10	34:19, 39:9,	148:3, 148:19	adjusting
accessible	57:4, 57:10,	adcs	50:9, 50:16
132:21	77:2, 77:16,	20:13, 20:15,	administer
	80:23, 81:5,	20:20, 31:9,	33:4, 81:9

<p>administered 32:6, 126:25</p> <p>administration 3:29, 4:7</p> <p>adult 4:31</p> <p>advance 5:15</p> <p>advanced 4:27, 4:32, 156:9, 156:18, 157:13, 157:22</p> <p>advances 60:22</p> <p>advantage 150:15</p> <p>advise 29:3</p> <p>affect 55:24, 56:24, 68:24, 73:6, 129:23, 148:19</p> <p>affinity 41:7, 43:15, 50:9, 50:16, 50:22, 51:5, 51:19, 52:3, 52:11, 52:19, 53:1, 53:6, 53:13, 53:21, 54:2, 54:5, 80:24, 88:9, 107:15, 108:3, 108:14, 110:22, 113:23, 114:15, 119:1, 119:3, 119:5, 119:9, 129:15, 129:18, 129:20, 144:16, 149:7, 149:9, 149:10, 149:15, 149:16</p> <p>after 87:8, 97:23, 99:23, 144:25, 157:11, 157:19</p> <p>afternoon 3:4</p>	<p>again 20:14, 25:25, 37:15, 50:20, 61:22, 63:22, 66:8, 83:25, 85:14, 105:1, 110:7, 123:11, 129:1, 132:4, 133:17, 134:15, 142:4, 149:9, 150:24, 151:20, 155:10</p> <p>against 23:1, 26:17, 42:22, 55:23, 61:16, 71:1, 92:16, 93:18, 93:21, 99:3, 99:13, 119:2, 119:23, 120:25, 126:23, 128:5, 129:17, 132:18, 143:22, 145:1</p> <p>agent 31:25, 118:5</p> <p>agents 32:3</p> <p>ago 17:25</p> <p>agonistic 118:10</p> <p>agree 40:2, 51:18, 51:24, 52:24, 53:4, 72:23, 73:2, 73:6, 85:3, 85:4, 98:16</p> <p>agreed 82:2</p> <p>agreements 17:1</p> <p>ah 25:18, 70:16</p> <p>ahead 34:4, 38:22, 43:11, 46:10, 50:15, 104:22,</p>	<p>105:23, 157:13</p> <p>aim 101:13, 106:17</p> <p>aiming 35:9</p> <p>al 3:24, 4:18, 4:36</p> <p>alex 2:12</p> <p>alignments 75:3</p> <p>all 2:7, 8:12, 15:14, 16:13, 16:15, 23:6, 23:7, 23:12, 23:13, 26:18, 39:7, 39:11, 43:25, 47:4, 61:14, 63:3, 63:6, 63:18, 73:8, 75:12, 78:23, 79:8, 79:21, 80:11, 84:22, 91:25, 92:1, 104:5, 104:7, 104:16, 104:23, 105:15, 105:16, 105:22, 106:7, 106:13, 115:24, 121:12, 122:8, 122:9, 131:2, 131:3, 133:19, 133:21, 133:23, 138:7, 140:23, 142:25, 143:8, 146:5, 158:3, 158:14, 158:15</p> <p>allow 95:2, 108:13, 110:19, 111:24, 120:4</p> <p>allowed 7:12, 28:14, 29:2, 29:8, 29:17</p>	<p>almost 11:5, 124:1, 146:23</p> <p>along 41:1, 67:1, 121:7, 138:1, 154:13</p> <p>already 12:10, 15:13, 15:17, 39:21, 39:25, 40:3, 43:23, 44:24, 45:11, 46:18, 46:23, 54:6, 61:20, 65:22, 108:10, 140:3, 140:4, 155:2</p> <p>also 2:29, 14:19, 20:18, 22:23, 25:5, 26:20, 32:2, 34:9, 34:18, 36:4, 38:7, 38:15, 41:4, 52:22, 58:11, 70:18, 70:25, 71:12, 75:5, 76:7, 76:11, 76:18, 79:13, 82:10, 83:13, 90:21, 100:20, 104:20, 119:19, 121:21, 130:2, 130:6, 133:7, 134:13, 140:12, 140:13, 144:12, 146:1, 153:7, 158:19</p> <p>alter 50:9, 50:16</p> <p>altering 54:16</p> <p>always 22:19, 25:13, 28:4, 33:21, 37:21, 37:24, 39:14, 43:20, 44:21, 88:24,</p>
---	--	--	--

<p>89:7, 129:25 amino 77:25, 78:1, 78:9, 79:22, 80:1, 88:7, 88:10, 88:16, 101:5, 104:23, 104:25, 105:24, 106:20 among 35:7, 36:3, 76:6, 76:10 amount 47:25, 48:5, 48:13, 58:8, 147:7, 147:10 amounts 97:15 analysis 60:15, 61:17, 62:15, 72:7, 75:18, 93:10, 111:7, 111:16, 113:20 analyze 75:17, 92:22 analyzed 62:2, 62:11, 102:13, 102:19, 110:4, 110:21, 111:2, 111:18, 112:22, 113:7, 113:12, 115:20 analyzing 62:16, 62:20, 93:12 angeles 161:1 anie@sheppardmul- lin 2:17 another 5:7, 21:20, 22:18, 28:15, 45:1, 52:14, 59:12, 71:3, 83:13, 88:1, 89:8, 119:4,</p>	<p>124:13, 127:13, 129:4, 132:21 answer 7:22, 10:16, 12:16, 13:19, 22:16, 26:10, 39:24, 41:19, 43:12, 45:25, 62:7, 72:9, 79:1, 85:20, 112:4, 112:5, 137:8, 146:25 answered 11:3, 34:3, 46:17, 61:19, 61:21, 65:22, 105:8, 108:10 answers 159:6 antagonistic 118:11 anti-egfr 16:18, 17:7, 26:6, 26:23, 27:8, 61:2, 61:8, 64:4, 64:10, 64:12, 64:15, 64:21, 65:2, 65:20, 65:24, 66:3, 66:7, 66:21, 68:1, 68:7, 77:1, 81:5, 99:1, 115:25, 117:9, 117:22, 118:1, 118:7, 118:9, 118:16, 123:24, 128:6, 131:24, 133:3, 133:6, 133:19, 133:22, 133:23, 154:12, 154:20, 157:20 antibodies 3:11, 14:18, 17:7, 20:10, 23:6, 23:7, 23:12, 23:14,</p>	<p>24:8, 25:17, 25:19, 25:23, 25:24, 26:5, 26:7, 26:16, 26:23, 27:8, 27:14, 28:20, 38:10, 38:14, 38:17, 38:25, 39:4, 39:7, 39:12, 39:14, 40:9, 42:21, 43:6, 43:13, 43:19, 49:23, 50:21, 54:2, 61:23, 62:16, 62:17, 63:3, 63:18, 66:21, 76:19, 77:1, 79:15, 80:7, 81:5, 88:12, 90:22, 96:17, 97:9, 97:13, 97:18, 98:8, 98:11, 103:2, 103:3, 103:5, 103:12, 105:16, 106:8, 107:7, 107:20, 107:23, 108:16, 110:8, 110:11, 112:18, 115:7, 115:25, 122:13, 123:8, 123:24, 126:6, 126:25, 132:11, 133:19, 137:16, 138:6, 138:8, 138:21, 143:16, 144:14, 144:17, 145:5, 150:8 antibody's 40:25, 50:9, 50:16, 53:13, 127:7 antibody-coated 143:23 antibody-drug 19:25 antibody-to-cell 134:6</p>	<p>anticipate 5:5 antigen 25:4, 25:6, 25:9, 25:24, 26:1, 26:2, 32:17, 40:14, 40:19, 41:7, 41:16, 42:15, 42:19, 42:23, 43:4, 43:18, 44:5, 44:11, 44:12, 44:21, 45:2, 45:6, 45:8, 45:10, 45:14, 45:16, 45:22, 45:24, 46:5, 46:6, 46:15, 46:16, 46:24, 47:1, 47:8, 47:24, 48:5, 48:9, 48:12, 49:17, 50:3, 50:18, 50:21, 50:25, 51:8, 51:20, 52:4, 52:21, 58:5, 59:3, 59:5, 60:1, 60:2, 63:2, 63:14, 67:6, 67:15, 67:16, 69:16, 69:18, 69:20, 69:21, 71:20, 88:9, 88:18, 88:22, 89:6, 107:16, 108:8, 115:1, 115:2, 131:24, 133:1, 133:15, 134:7, 134:8, 135:4, 135:14, 136:10, 136:12, 143:17, 145:17, 147:16, 148:8, 148:9 antigen-antibody 148:5</p>
--	---	--	--

<p>antigen-binding 144:6</p> <p>antigens 25:22, 33:11, 71:12, 144:23, 145:1</p> <p>antimicrotubule 118:5</p> <p>antitumor 32:12, 32:15, 39:9, 57:4, 57:10, 65:25, 89:13, 89:23, 90:1, 91:6, 91:9, 113:8, 113:13, 127:13, 128:7, 129:4, 129:8</p> <p>any 5:8, 5:15, 8:1, 8:3, 9:9, 10:5, 10:25, 11:4, 12:8, 14:19, 16:18, 17:6, 20:12, 23:16, 23:20, 24:3, 24:14, 28:3, 28:10, 28:13, 38:15, 39:6, 44:10, 45:22, 46:15, 47:7, 49:13, 53:18, 53:25, 58:18, 64:12, 67:5, 67:14, 68:8, 68:13, 68:14, 71:8, 77:21, 78:4, 78:7, 78:17, 79:4, 81:12, 82:18, 83:22, 87:7, 88:14, 88:20, 88:21, 90:19, 91:23, 93:10, 101:1, 101:9, 102:17, 102:19, 102:25, 103:7, 106:17, 107:18,</p>	<p>108:12, 108:25, 109:3, 109:21, 110:10, 110:14, 110:19, 111:7, 111:15, 111:24, 112:17, 113:18, 115:23, 119:11, 120:4, 123:5, 129:14, 130:23, 131:19, 131:20, 133:3, 138:22, 138:23, 147:11, 151:19, 154:12, 154:16, 155:17, 156:5, 157:10, 157:18, 161:15, 161:16</p> <p>anyone 100:3, 129:5</p> <p>anything 9:10, 14:8, 26:20, 92:13, 95:6</p> <p>apologize 5:15</p> <p>appeal 1:2</p> <p>appear 84:6, 100:18</p> <p>appearances 2:7, 2:8</p> <p>appeared 83:17</p> <p>appears 83:15, 85:1, 86:7, 98:5, 98:6, 98:11</p> <p>apples 121:17</p> <p>applicable 154:19</p> <p>application 3:23, 3:30, 4:8, 4:35, 77:5</p> <p>applied 55:22, 155:1</p> <p>applies 44:2, 88:11,</p>	<p>88:13, 134:13</p> <p>apply 134:11, 134:18, 134:21</p> <p>approach 20:16, 30:4, 30:14, 30:18, 33:8, 65:7, 65:14, 65:18, 66:23, 67:4</p> <p>approaches 20:7</p> <p>appropriate 76:11</p> <p>approval 64:13, 154:13, 156:9, 156:19, 157:22</p> <p>approved 27:5, 31:14, 64:16, 68:1, 68:7, 68:9, 71:16</p> <p>approximately 27:7, 136:20</p> <p>arbitrary 135:7, 136:1, 137:5</p> <p>area 139:1, 139:3</p> <p>areas 26:2, 66:11, 88:17</p> <p>argue 124:20</p> <p>arguments 10:24</p> <p>arises 147:7</p> <p>arm 49:18</p> <p>arms 43:13</p> <p>arrive 76:21, 113:25, 114:16, 125:20</p> <p>art 8:25, 9:5,</p>	<p>14:15, 60:10</p> <p>article 4:14, 4:21, 4:25, 4:30, 19:9, 19:20, 19:22, 21:1</p> <p>articles 18:13, 18:14, 18:17, 18:25, 19:6, 19:7, 60:18</p> <p>articulate 29:6</p> <p>asked 11:3, 34:3, 46:17, 61:19, 105:8, 131:18, 133:20</p> <p>asking 24:2, 46:3, 46:19, 46:20, 62:9, 79:2, 101:17, 111:6, 111:7, 128:20, 152:24</p> <p>aspartic 75:25</p> <p>aspect 102:17, 106:25, 112:7</p> <p>aspects 112:17, 112:21, 122:22</p> <p>assess 17:17, 135:17</p> <p>assessed 54:1, 84:8</p> <p>assessing 20:9, 20:19</p> <p>associated 119:10</p> <p>assume 7:18, 85:10, 150:1, 150:9, 156:23, 157:2</p> <p>assumption 48:20, 150:12</p> <p>assumptions 26:3</p>
---	--	---	---

<p>atom 40:13, 40:18</p> <p>attached 15:23, 69:11, 74:15, 91:17, 95:14, 100:11, 120:13, 141:17, 152:15, 153:20</p> <p>attending 5:4, 60:19</p> <p>attorney 7:23, 161:15</p> <p>attractive 66:4</p> <p>author 3:9, 142:8, 142:9</p> <p>available 26:24, 149:3, 157:12</p> <p>avenue 2:24</p> <p>avidity 43:15</p> <p>avoid 36:17, 37:7</p> <p>aware 5:7, 44:10, 44:14, 53:8, 53:18, 53:25, 68:8, 102:5, 103:7, 151:4, 151:15, 154:12, 154:16, 157:5, 157:7</p> <p>away 5:9</p> <hr/> <p style="text-align: center;">B</p> <hr/> <p>ba 100:14, 100:15, 100:22, 101:6, 101:7, 101:11, 101:19, 101:25, 102:2, 102:7, 102:14, 102:20, 103:4, 103:8, 103:14, 103:24,</p>	<p>104:4, 104:8, 104:13, 104:15, 105:5, 105:11, 106:2, 106:23, 107:1, 108:2, 108:6, 108:7, 108:11, 109:6, 109:14, 109:21, 109:25, 110:5, 110:13, 110:21, 110:25, 111:2, 111:11, 111:18, 111:24, 112:1, 112:6, 112:10, 112:13, 112:22, 112:25, 113:1, 113:3, 113:7, 113:12, 113:19, 113:20, 113:22, 114:13, 115:8, 115:11, 115:21, 115:24, 116:1, 116:4, 116:8, 125:23, 126:9, 126:10, 126:11, 127:15, 129:14, 129:16, 133:13, 134:25, 135:3, 136:13, 137:11, 138:2, 138:9, 138:11, 138:12, 145:18, 145:25, 146:11, 146:13, 146:19, 146:20, 147:8, 147:14, 147:18, 148:22, 148:24, 149:6, 149:12, 149:22, 149:23, 149:25, 150:3, 156:3, 156:7, 156:11, 156:19, 157:21</p> <p>ba0 156:4</p> <p>back 11:6, 29:24, 48:24, 57:17, 57:20, 59:19,</p>	<p>73:17, 83:25, 99:23, 109:12, 112:12, 114:5, 114:8, 143:15, 151:13</p> <p>backbone 88:17</p> <p>background 72:16, 76:25</p> <p>backup 5:8</p> <p>bad 122:9</p> <p>ballpark 9:16, 27:11</p> <p>based 50:11, 50:18, 60:10, 65:16, 66:21, 67:2, 76:19, 81:11, 89:22, 97:16, 101:11, 106:1, 118:15, 118:18, 135:24, 138:19</p> <p>basically 20:6, 32:13</p> <p>basis 65:6, 84:9, 91:2, 105:4, 119:8, 123:15, 126:5, 131:7, 138:5</p> <p>because 6:14, 7:5, 12:3, 18:22, 21:25, 22:20, 25:21, 26:4, 36:1, 36:18, 37:10, 42:9, 43:7, 43:9, 45:12, 45:18, 47:2, 47:3, 53:15, 57:4, 63:6, 64:25, 66:9, 66:23, 70:16, 70:21, 71:14, 74:25, 75:11, 75:13,</p>	<p>78:7, 80:9, 88:15, 90:1, 96:2, 97:22, 98:19, 103:2, 103:10, 105:9, 107:3, 107:18, 108:22, 110:17, 111:15, 112:18, 113:6, 118:3, 119:9, 120:2, 121:15, 123:11, 124:11, 128:9, 129:25, 131:18, 133:18, 135:8, 136:17, 137:16, 137:21, 137:23, 138:15, 142:13, 147:10, 147:13, 149:16, 150:18, 153:8, 156:8</p> <p>become 26:23, 127:17</p> <p>becomes 32:18, 63:8, 72:19</p> <p>been 5:22, 6:6, 11:5, 12:3, 15:19, 21:14, 22:1, 27:8, 29:13, 31:24, 48:13, 60:7, 64:3, 64:6, 64:16, 65:1, 66:7, 66:24, 67:25, 68:6, 68:9, 71:6, 71:16, 71:17, 74:4, 90:13, 106:2, 134:24, 135:1, 156:18, 157:2, 157:11, 157:12</p> <p>before 1:2, 2:2, 6:6, 14:1, 18:16, 19:4, 19:6, 19:7, 31:5,</p>
--	--	--	---

<p>40:5, 41:12, 60:21, 89:16, 91:19, 98:4, 112:4, 124:4, 137:6, 138:19</p> <p>begin 109:24</p> <p>behave 112:19</p> <p>being 5:19, 6:14, 47:24, 50:24, 51:7, 52:20, 53:8, 53:11, 81:25, 85:23, 126:6, 138:6</p> <p>believe 10:8, 14:5, 14:21, 14:24, 15:4, 15:13, 27:3, 29:10, 29:11, 29:13, 58:21, 61:10, 61:20, 62:16, 63:21, 63:25, 64:7, 66:4, 66:18, 69:24, 71:1, 71:4, 71:25, 74:21, 75:11, 75:20, 76:10, 78:16, 79:23, 82:20, 83:11, 85:25, 89:21, 89:24, 89:25, 90:18, 91:11, 92:19, 92:25, 93:7, 93:12, 94:11, 97:24, 99:11, 99:12, 100:20, 100:24, 107:2, 108:5, 108:10, 109:17, 113:18, 115:16, 116:3, 116:6, 116:14, 116:19, 119:21, 121:2, 123:18, 129:18, 131:11,</p>	<p>138:7, 140:17, 147:6, 148:23, 149:21, 150:13, 152:1, 156:2, 156:11</p> <p>below 120:18</p> <p>benefit 23:8, 23:13, 39:7, 56:9, 57:3, 67:1, 126:8, 138:10</p> <p>benefits 22:14, 22:17, 23:2, 23:7, 23:9, 23:20, 23:23, 24:3, 24:8, 24:9, 66:5</p> <p>best 5:6, 7:2, 66:15</p> <p>better 7:5, 28:4, 28:5, 39:9, 39:14, 83:16, 85:2, 86:3, 87:22, 88:1, 98:16, 115:5, 118:11, 123:23, 129:17, 129:20, 147:19</p> <p>between 21:3, 21:12, 35:18, 38:17, 40:13, 69:22, 70:4, 70:7, 70:22, 71:23, 72:5, 77:22, 78:1, 78:3, 78:4, 78:14, 82:18, 83:20, 84:3, 84:17, 98:20, 101:25, 103:3, 103:8, 103:11, 103:14, 108:11, 109:21, 110:8, 110:25, 111:20, 111:23, 112:6, 115:23,</p>	<p>121:5, 122:16, 122:23, 123:6, 128:22</p> <p>beyond 66:19</p> <p>bibliography 18:13</p> <p>big 83:5, 84:1, 95:10</p> <p>bigger 115:19</p> <p>bind 33:10, 33:16, 40:9, 40:10, 41:22, 42:2, 42:15, 42:22, 43:3, 43:6, 43:20, 44:12, 44:21, 45:1, 45:2, 45:5, 45:10, 45:16, 45:23, 46:6, 46:22, 97:20, 98:12, 99:5, 115:17, 132:6, 133:9, 134:3, 134:17, 134:25, 144:16, 144:23, 145:2, 149:13, 150:4, 150:11, 151:2</p> <p>binding 26:2, 40:4, 40:8, 40:24, 41:7, 41:15, 41:23, 42:17, 44:6, 44:24, 45:12, 45:17, 46:1, 46:14, 47:7, 47:20, 48:14, 48:23, 48:24, 49:7, 49:9, 49:13, 49:18, 50:3, 50:22, 50:24, 51:5, 51:7, 51:13, 52:3,</p>	<p>52:19, 53:13, 53:21, 63:9, 63:14, 77:2, 80:24, 84:7, 84:23, 86:25, 87:5, 87:11, 97:19, 106:19, 107:4, 107:14, 108:3, 108:14, 110:22, 113:23, 114:14, 115:1, 118:25, 129:15, 131:13, 132:2, 132:13, 132:15, 132:24, 133:25, 134:6, 135:5, 135:11, 136:13, 136:17, 136:19, 136:23, 136:24, 137:12, 138:18, 143:16, 143:23, 145:3, 147:16, 147:22, 149:6, 149:9</p> <p>binds 25:6, 34:16, 42:9, 42:25, 46:25, 47:3, 49:17, 50:2, 62:22, 62:23, 62:25, 63:4, 63:11, 63:19, 85:12, 106:4, 132:19, 133:7, 134:24</p> <p>biochemistry 14:16</p> <p>biological 78:17</p> <p>biologically 78:11, 78:14, 85:24, 90:4</p> <p>biology 14:16, 47:10</p> <p>biopharmaceutical 1:5</p> <p>biopsies 135:23</p>
---	---	---	--

<p>bit 31:18, 70:22, 87:13 bladder 71:5 blank 37:9 block 34:18 blocking 34:17, 111:20 blocks 34:16 blue 146:5 board 1:2, 29:7 board's 29:1 bodies 144:11 body 22:20 bond 133:9 bonus 127:13, 127:25 both 51:20, 52:5, 53:11, 101:21, 102:23, 105:7, 109:17, 115:2, 115:19, 115:25, 116:20, 126:6, 129:23, 138:6, 138:7, 140:25, 146:18, 148:19 bothering 146:23 bottom 152:20, 153:1 bound 145:6, 147:8 bournazos 1:21, 2:1, 3:21, 5:21, 6:3, 18:20, 21:11, 24:2, 74:3,</p>	<p>74:7, 91:21, 96:11, 124:15, 141:12, 142:6, 159:16, 160:8 bournazos's 15:19 box 8:18, 152:1, 152:2, 152:3, 154:5 braf 127:22, 128:4, 129:4 break 7:9, 47:13, 47:14, 73:12, 91:22, 91:23, 99:19, 99:22, 100:4, 124:15, 124:17, 158:2, 158:8 breaks 7:8, 7:14, 91:21 breast 4:27, 70:24 brentuximab 4:17, 124:4 briefly 16:20, 20:4, 27:23, 31:20 bring 38:15 brings 33:6 broad 17:13, 131:18 bronchial 144:24 brought 123:20 business 158:7</p> <hr/> <p style="text-align: center;">C</p> <hr/> <p>california 2:4, 2:14, 161:3, 161:7</p>	<p>call 24:9, 117:17, 117:19, 129:10, 143:25 called 5:22, 22:24, 91:24, 139:24 camino 2:13 cancer 4:28, 21:4, 50:10, 50:17, 66:13, 66:14, 68:14, 69:22, 71:6, 71:7, 71:24 cancers 70:1 candidate 38:4, 151:5, 151:17, 157:8 candidates 64:7, 157:13 cannot 6:18, 11:5, 16:22, 25:18, 26:3, 26:12, 31:8, 31:19, 33:4, 37:16, 39:12, 39:13, 45:2, 45:12, 48:20, 49:10, 50:20, 51:16, 64:19, 64:25, 72:8, 75:13, 84:16, 87:20, 98:19, 102:10, 108:6, 110:16, 110:24, 111:16, 112:17, 113:20, 115:4, 115:17, 120:1, 121:25, 123:10, 129:4, 133:9, 148:2, 148:9, 157:1 capacity 20:10 caption 161:16, 161:18</p>	<p>carefully 80:10 cartoon 22:11 case 1:7, 10:23, 15:20, 16:14, 21:22, 28:5, 34:15, 47:7, 47:9, 53:18, 61:14, 74:8, 92:13, 94:20, 100:7, 148:2, 151:23 cases 35:15, 52:16, 52:18, 66:14, 116:4 category 36:18 cause 161:17 cd 69:16, 69:18, 69:21, 69:25, 70:1, 70:3, 70:8, 70:9, 70:16, 70:23, 71:10, 71:19, 71:20, 71:22, 71:25, 72:4 cell 8:22, 20:11, 32:6, 32:16, 32:19, 35:18, 36:22, 40:20, 41:15, 41:17, 42:16, 42:18, 42:19, 44:5, 44:6, 46:16, 47:1, 47:21, 48:1, 48:7, 50:2, 97:14, 98:9, 106:19, 130:7, 131:3, 132:25, 133:1, 134:2, 135:5, 136:6, 136:12,</p>
---	---	---	--

<p>137:6, 137:14, 137:23, 137:25, 138:1, 144:22, 144:24, 144:25, 145:6, 145:8, 145:10, 147:8, 147:22 cells 32:10, 33:11, 33:17, 37:15, 39:20, 40:8, 40:10, 40:11, 42:8, 44:12, 45:5, 45:10, 45:16, 45:23, 46:6, 46:14, 50:10, 50:17, 50:24, 50:25, 51:1, 51:7, 51:8, 51:9, 51:21, 52:5, 53:12, 58:9, 58:13, 69:22, 69:23, 70:4, 70:7, 70:18, 70:24, 70:25, 71:5, 71:13, 71:24, 72:1, 72:2, 72:5, 77:8, 93:21, 97:22, 97:25, 98:10, 98:17, 119:2, 119:23, 120:25, 121:16, 129:23, 130:8, 131:3, 132:7, 132:8, 132:14, 133:7, 133:10, 134:2, 143:16, 143:19, 143:20, 145:5, 148:20, 149:7, 149:14, 149:17, 149:19, 149:20, 149:24, 150:4, 150:7, 150:11, 150:16, 150:17, 150:25 certain 42:17, 98:14,</p>	<p>115:17, 118:16, 129:2, 131:12 certainly 132:3 certificate 161:21 certified 2:3, 15:22, 69:10, 74:14, 91:16, 95:13, 120:12, 141:16, 152:14, 153:19, 161:6 certify 161:8, 161:14 cetux2c9-dm-1 121:7 cetux2c9-mmae 121:6 cetuximab-based 67:24 chain 74:24, 75:7, 100:16, 100:17 chains 75:4 challenged 125:20 challenges 64:20, 64:22, 64:24, 64:25, 65:3, 65:19, 66:2 challenging 70:12 change 9:10, 24:7, 24:9, 24:16, 79:25, 80:2, 81:12, 87:7, 88:14, 89:5, 89:9, 97:4, 105:24, 112:20, 119:9, 126:17, 145:22, 146:24, 160:11 changed 24:25, 101:16,</p>	<p>106:3, 150:20 changes 24:19, 25:2, 25:4, 78:9, 83:5, 88:7, 88:8, 88:16, 88:20, 101:3, 101:5, 101:12, 101:14, 102:25, 105:2, 106:2, 107:23, 147:14, 159:6, 160:1 changing 108:25, 131:13, 146:24 characteristics 62:3, 62:12, 67:5, 67:14, 106:3 chat 140:12, 140:21, 140:24 check 60:21, 72:8, 75:9, 80:12, 82:22, 82:24, 83:25 chemical 36:16, 88:10 chemistries 122:8 chemistry 20:16, 138:15 chemoenzymatic 20:1 chemotherapy 4:23, 4:27, 31:25, 32:3, 33:8 chimeric 21:12, 21:17, 21:19, 21:23, 23:7, 23:13, 25:12, 27:24, 79:17, 79:18, 83:17, 88:12, 89:20, 109:7, 109:16, 110:1,</p>	<p>110:6, 110:13, 110:23, 111:4, 111:13, 111:21, 112:24, 113:14, 134:23, 145:23, 146:6 china 3:28, 4:6 chinese 3:32 circulation 58:11, 144:13 circulations 144:13 citing 98:7 claims 13:5, 13:7, 13:22, 14:1, 81:20, 124:10, 124:20, 125:12, 125:16, 125:21 clarification 24:18, 25:7, 40:16, 65:8, 79:2, 106:11, 109:2, 127:4, 129:11, 131:9 clarify 45:18, 124:8, 147:25, 156:15 clarifying 48:16, 128:25 class 76:19 classical 127:21 classify 97:10, 97:21 clean 95:5 clear 23:4, 29:7, 40:20, 47:5, 134:4, 144:20 clearance 156:23 clearer 13:10</p>
---	--	---	---

<p>clearly 29:6 cleavable 35:18, 36:3, 36:5, 36:8, 36:13, 36:18, 36:24, 37:8, 37:9, 117:23, 118:2, 118:4, 118:7, 118:21, 118:22, 119:24, 120:23, 121:11, 121:14, 121:22, 121:25, 122:4, 122:9, 122:12, 123:22, 124:7 cleaved 36:5, 36:19, 37:11 clinic 55:22, 131:8, 135:23, 138:22 clinical 4:25, 26:7, 26:24, 38:5, 54:1, 57:3, 57:6, 65:3, 65:16, 65:17, 65:25, 66:3, 66:24, 66:25, 68:1, 68:7, 71:18, 83:9, 128:13, 128:20, 154:19, 156:22, 156:25, 157:22 clinically 127:17, 154:19, 154:24 clinicians 155:20 clonal 102:24, 117:11 clone 74:18, 101:22, 104:2, 107:18, 108:22, 109:18 clones 26:1, 108:24</p>	<p>close 158:7 closer 7:4, 7:6, 23:17, 142:17 clustering 145:7 cn 3:31, 4:9 cody 1:30, 2:2, 5:18, 161:5, 161:27 collaboration 17:25 com 2:16, 2:17, 2:27, 2:28 combination 37:24, 116:19, 124:22 combinations 107:20 combining 66:25 come 38:15, 73:17, 99:22, 104:2, 107:3, 107:8, 115:13, 145:2 comes 86:4 commencing 2:4 comment 26:12, 31:8, 37:16, 44:9, 51:16, 65:6, 66:19, 72:9, 75:13, 85:23, 87:20, 98:19, 102:10, 108:6, 110:24, 111:16, 112:17, 113:20, 115:4, 120:1, 123:10, 148:2, 149:4, 157:1, 157:10, 157:18,</p>	<p>157:25 commercial 56:12 common 28:18, 30:4, 30:10, 30:18, 31:1, 31:7, 38:3 commonly 32:1, 32:16, 38:8 commotion 67:10 communicate 91:23, 92:2, 92:7, 92:13, 100:3 community 66:15 companies 64:3, 66:9, 155:18, 155:19 company 28:16, 56:12, 66:10 comparable 107:15, 126:22 comparably 83:18 compare 25:11, 69:20, 71:19, 71:22, 109:25, 110:12, 110:16, 115:7 compared 38:24, 39:3, 53:22, 68:3, 77:3, 78:18, 79:16, 106:22, 107:18, 108:8, 112:11, 112:16, 112:18, 113:1, 125:14, 126:10, 127:17, 130:2, 130:5, 138:8, 138:12, 150:21 comparing 54:2, 83:14, 110:8, 110:14,</p>	<p>121:17 comparison 25:19, 98:20, 103:3, 103:11, 108:11, 110:7, 110:25, 111:23, 112:6, 113:6, 115:23, 121:5, 121:13, 123:12, 126:5, 129:5, 138:5 comparisons 113:2 compensate 43:15 complete 161:12 complex 47:11, 72:17, 145:16, 145:17 complicated 32:22 complimentary 5:13 component 31:21, 33:3, 59:8, 62:14, 63:17, 131:2 components 32:11, 38:10, 42:5, 60:6 compound 35:16 computer 5:9, 8:20, 142:20 computer-aided 161:11 concept 8:24 concern 71:14 concerned 69:15 conclude 121:25 concluded 123:25, 158:23</p>
---	---	--	--

<p>conclusion 39:13, 84:19, 93:23, 113:25, 114:16, 118:8, 118:9, 118:15, 122:8, 145:11</p> <p>conclusions 110:10, 110:19, 111:25, 120:4</p> <p>condition 36:20</p> <p>conditions 36:5, 36:20, 77:16, 77:17, 80:24, 81:1, 87:3, 87:4, 89:6</p> <p>conference 10:3, 61:24</p> <p>conferences 60:19</p> <p>conferring 39:6</p> <p>confidence 103:4</p> <p>confidentiality 17:1</p> <p>confirm 89:18, 146:12</p> <p>conflicting 87:24</p> <p>confused 133:11</p> <p>conjugate 67:2, 72:18, 117:9</p> <p>conjugated 31:24, 38:13, 138:16</p> <p>conjugates 17:20, 17:23, 19:25, 31:23, 38:12</p> <p>conjugation 20:7, 20:8, 118:4, 120:23, 138:17</p> <p>consider 56:10, 56:12,</p>	<p>57:13, 58:1, 61:15, 87:12, 104:24, 107:17, 107:24, 126:16, 127:12, 130:3, 136:18, 155:13</p> <p>consideration 39:10</p> <p>considerations 34:20, 35:4, 35:7, 37:19, 37:22</p> <p>considered 54:10, 58:19, 58:23, 71:9</p> <p>constant 130:1</p> <p>constructed 101:11</p> <p>constructing 34:23</p> <p>contact 42:12</p> <p>contains 121:5</p> <p>content 13:25</p> <p>context 13:4, 22:22, 24:10, 33:1, 33:18, 34:5, 39:1, 39:8, 41:12, 41:20, 43:16, 43:25, 47:4, 49:20, 52:24, 53:4, 54:23, 56:5, 56:14, 57:2, 57:7, 57:9, 63:23, 70:22, 108:20, 115:19, 127:6, 127:11, 127:12, 127:19, 128:10, 131:19, 131:23, 132:10, 132:12, 132:24, 133:2, 133:3, 133:4, 134:5,</p>	<p>135:16, 137:10, 137:20, 148:1</p> <p>continue 43:12, 85:20</p> <p>continued 4:2, 99:16</p> <p>continuing 83:8</p> <p>contrary 98:3, 124:3, 145:23, 146:15</p> <p>contrast 86:24</p> <p>contribute 32:12</p> <p>contributing 129:8</p> <p>contribution 129:6</p> <p>control 68:24, 86:25, 121:9, 121:10, 121:21, 121:25</p> <p>controlling 130:11</p> <p>controls 121:24</p> <p>convenient 16:4</p> <p>conversations 5:10</p> <p>conversion 18:6, 19:12, 19:23</p> <p>copies 100:11, 153:19</p> <p>copy 15:7, 15:22, 16:9, 18:2, 69:10, 74:14, 75:14, 91:13, 91:16, 95:6, 95:13, 120:12, 141:13, 141:17, 152:4, 152:14</p> <p>correct 8:13, 22:5, 23:10, 30:11,</p>	<p>31:14, 33:9, 33:15, 37:5, 39:15, 39:17, 40:2, 41:1, 49:2, 52:6, 53:24, 63:5, 63:15, 63:20, 68:12, 68:25, 69:3, 69:16, 70:4, 70:5, 70:9, 70:19, 70:20, 72:5, 72:21, 73:4, 75:8, 76:15, 76:23, 79:19, 79:20, 82:6, 82:8, 82:11, 82:13, 82:16, 82:17, 89:3, 90:5, 90:6, 90:22, 90:23, 92:23, 94:7, 94:8, 96:18, 96:19, 103:9, 104:14, 104:18, 105:19, 107:10, 111:14, 111:15, 113:5, 116:9, 121:1, 122:15, 124:9, 124:22, 125:17, 125:25, 126:2, 126:7, 130:12, 133:1, 133:16, 134:14, 134:15, 138:3, 143:11, 143:12, 145:20, 145:21, 148:25, 149:21, 152:21, 155:7</p> <p>corrections 159:6, 160:1</p> <p>correctly 52:10, 128:18</p> <p>correlation 129:14</p> <p>could 47:15, 73:14, 139:11, 158:20</p>
---	---	--	--

<p>counsel 2:8, 7:13, 12:6, 21:7, 28:23, 92:3, 92:5, 141:24, 161:14 county 161:1 course 17:24, 58:20, 141:20 court 6:15, 6:17, 19:16, 57:17, 57:21, 59:16, 59:20, 74:12, 109:9, 109:13, 114:5, 114:8, 151:10, 151:14 covalently 35:15 cpo 4:31, 151:5, 151:16, 154:14, 154:18 create 27:15, 27:18, 27:25, 28:11, 28:18, 30:5, 30:10, 70:8 created 90:12, 90:19, 90:21, 101:8, 104:9, 104:14, 104:17 creating 30:14, 57:8, 59:14, 59:23, 70:15, 71:9, 71:10, 73:7, 75:18, 89:12, 89:19, 90:25, 98:23, 99:3 creation 56:4 critical 62:14, 62:18, 124:5, 145:3</p>	<p>cross-linked 137:18 cross-linking 50:5 cspc 1:4 csr 1:30, 2:2, 5:19, 161:27 currently 17:2, 131:8 cv 18:2, 18:12 cytometry 135:17, 136:2 cytotoxic 35:16, 38:15, 38:16, 39:19, 58:7, 58:12, 122:11, 129:7, 142:25, 143:8, 144:8, 144:9 cytotoxicity 127:18, 143:22, 145:9 cytotoxin 35:16, 35:21, 35:22, 35:25, 36:7, 36:22, 37:3</p> <hr/> <p style="text-align: center;">D</p> <hr/> <p>d 84:4 d-h 85:21 d-mmad 83:15 dai 18:19 data 67:3, 77:10, 78:16, 80:10, 82:1, 83:19, 84:14, 90:17, 103:10, 110:8, 110:14, 113:21, 113:24, 114:15,</p>	<p>118:13, 120:3, 121:2, 122:10, 123:25, 147:11, 149:3, 150:18, 150:24, 156:5, 156:22, 156:25 database 72:8 datasets 110:16 date 160:9, 160:25 dated 4:18 day 147:18, 159:10, 161:23 dde2-7 99:9 death 20:11 december 1:22, 2:5, 5:1, 74:1, 160:9, 161:23 decide 63:11, 80:7 decided 10:22 declaration 3:20, 9:9, 9:13, 9:20, 9:25, 10:7, 11:1, 11:2, 11:8, 11:11, 11:16, 11:21, 12:11, 12:12, 15:3, 15:5, 15:7, 15:8, 15:9, 15:12, 15:18, 15:19, 16:9, 18:4, 22:10, 56:17, 68:17, 72:12, 72:14, 75:19, 80:14, 93:6, 93:11, 94:1, 103:18, 114:23,</p>	<p>116:16, 116:22, 117:4, 117:12, 123:17, 124:9, 124:25, 145:18, 146:3, 146:4, 159:1 declare 159:3 decrease 53:13, 119:2, 127:16 deem 159:7 define 44:7, 44:8, 54:19, 56:1, 56:14, 57:5, 62:5, 102:16, 135:8, 154:23 defined 44:14 definition 14:22, 108:19, 108:21, 155:10 definitively 84:16 degree 102:1, 105:1 delete 160:5, 160:6, 160:11 deleting 160:4 deletion 99:7 deliver 32:9 delivered 52:20, 53:11 demonstrated 90:1, 120:2, 134:25, 135:1, 150:10 dendritic 143:19 denial 3:17, 151:25, 152:7</p>
--	--	--	---

<p>density 47:19, 47:25, 48:5, 48:14, 48:21, 49:7, 63:23, 137:12, 149:9, 149:18, 149:23, 150:5</p> <p>depend 37:6, 41:16, 42:18, 132:25, 133:14, 134:6</p> <p>dependency 88:5</p> <p>dependent 43:25</p> <p>depending 24:6, 72:19, 154:23</p> <p>depends 24:10, 24:16, 34:1, 34:5, 35:20, 36:16, 37:10, 37:15, 39:1, 39:5, 39:7, 39:11, 41:20, 42:23, 42:24, 43:24, 44:7, 46:24, 47:4, 48:17, 49:15, 49:20, 50:7, 50:20, 51:14, 53:16, 54:8, 63:22, 104:21, 106:10, 106:16, 108:19, 117:12, 127:1, 127:11, 127:19, 128:10, 129:1, 130:24, 132:4, 134:15, 135:16, 137:24, 138:15, 138:16, 147:24, 148:1, 149:9, 155:10, 156:22</p> <p>depicted 75:5</p> <p>deponent 161:8</p>	<p>deponent's 160:1, 160:25</p> <p>deposed 6:6</p> <p>deposition 1:20, 2:1, 5:14, 5:19, 6:5, 6:14, 12:1, 12:6, 12:9, 12:19, 15:3, 87:8, 99:16, 158:23, 159:4, 160:8, 160:9</p> <p>depositions 29:3, 29:8</p> <p>describe 16:21, 16:23, 17:12, 17:14, 17:22, 20:4, 26:6, 98:24, 117:10, 128:12</p> <p>described 27:9, 83:11, 84:14, 93:6, 94:6, 112:9, 116:6</p> <p>describes 78:25, 79:4, 79:7</p> <p>description 3:8, 3:14, 4:5, 75:2</p> <p>design 54:16</p> <p>designation 37:9</p> <p>designing 61:16</p> <p>desirable 30:7, 30:16</p> <p>desired 28:20</p> <p>despite 45:2, 127:23</p> <p>detailed 26:13</p> <p>determinant 132:20, 132:21</p>	<p>determinants 41:9, 42:14, 53:17, 132:3</p> <p>determine 42:14, 47:24, 48:5, 48:13, 60:11, 60:16, 62:3, 62:12, 62:24, 63:12, 103:13, 124:10, 150:2</p> <p>determined 132:16</p> <p>determiner 40:17</p> <p>determines 40:7, 41:6, 132:13, 132:17</p> <p>determining 16:16, 57:11, 57:22, 130:20</p> <p>develop 64:4, 64:9, 65:15, 66:20, 67:7, 67:16, 154:19, 155:19, 157:20</p> <p>developed 27:8, 66:7, 71:6, 71:16</p> <p>development 52:2, 64:21, 65:4, 65:16, 65:20, 66:3, 71:18, 155:13, 156:17</p> <p>dictate 49:11</p> <p>dictated 40:24</p> <p>differ 35:18, 38:9, 79:21, 102:8, 102:14, 102:20, 110:5, 115:21</p> <p>difference 38:17, 70:3, 70:7, 72:4,</p>	<p>77:21, 78:3, 78:4, 78:8, 78:14, 82:18, 83:9, 83:13, 83:20, 84:7, 84:17, 85:1, 85:24, 85:25, 86:6, 87:12, 87:13, 90:4, 103:7, 109:21, 122:16, 122:19</p> <p>differences 21:12, 50:11, 50:18, 69:24, 69:25, 77:24, 78:1, 78:6, 78:10, 78:11, 78:18, 79:10, 79:13, 82:20, 82:21, 83:1, 83:6, 86:7, 103:1, 103:14, 106:18, 109:23, 110:10, 110:18, 123:6, 123:11</p> <p>different 10:8, 20:7, 20:16, 21:21, 24:21, 25:17, 25:18, 25:19, 25:22, 25:24, 26:1, 26:2, 26:4, 26:5, 36:20, 42:5, 57:5, 61:23, 75:21, 79:5, 79:12, 88:9, 89:6, 91:9, 97:9, 100:23, 102:2, 102:6, 102:10, 108:16, 108:18, 108:20, 109:1, 110:20, 112:9, 112:19, 115:11, 115:16, 115:18, 121:16, 121:17, 121:18, 122:4, 122:7,</p>
--	---	---	--

<p>122:11, 122:12, 122:13, 122:22, 122:23, 123:8, 126:20, 126:24, 146:13 differentials 69:21, 71:23 differently 36:9, 36:14, 79:12 differs 103:5, 103:6 difficulty 70:15 diplomate 161:5 direct 20:19, 108:11, 110:7, 110:25, 112:6 directly 20:15, 40:9, 88:18, 144:7 discipline 14:17 disclose 17:2 disclosed 82:10, 104:7 discloses 117:8 discovery 4:15 discretionary 3:17, 151:25, 152:7 discuss 7:13, 29:18, 29:21, 43:17 discussed 27:23, 39:25, 40:3 discussion 26:21 discussions 5:8 disease 55:23</p>	<p>diseases 32:4 dismantling 161:19 display 93:16, 93:20 distinguish 143:25, 149:19, 149:23, 150:7 distinguishing 98:17, 150:16 diverse 107:22 diversity 107:19 dm-1 38:6, 118:20, 121:9, 121:18 doc 10:16 doctor 16:25, 26:10, 46:10, 99:15, 100:3, 133:11, 139:9, 141:19, 143:3, 148:15, 152:17 document 10:5, 10:25 documents 8:14, 10:1, 10:2, 10:9, 12:8 doing 31:6, 135:15, 141:5 domain 17:18, 75:7, 143:18, 143:24, 144:10, 146:10, 148:13 domains 42:6 done 24:7, 54:1, 60:21, 93:10, 110:18, 111:5, 112:8, 113:6, 113:19, 115:6,</p>	<p>115:23, 120:3, 129:5, 137:9, 138:25, 145:25, 148:18, 158:14, 158:15 dose 53:17, 83:15, 126:19, 126:24, 127:1, 137:24 doses 54:14, 81:9 double 82:22 double-check 82:23 doubt 78:12 download 94:23, 140:16, 140:17 downloaded 140:7 downstream 34:7 dr 6:3, 15:19, 21:11, 24:2, 74:7, 91:21, 96:11, 124:15, 141:12, 142:6 draft 11:8, 11:11, 11:13, 11:14, 11:15, 11:16, 11:21, 158:19 draw 39:13, 110:19, 111:24, 120:4 drew 2:30, 142:3 drug 4:15, 17:19, 17:23, 20:9, 20:15, 31:23, 31:24, 31:25, 32:10, 32:18, 33:2, 33:6, 37:16, 37:17,</p>	<p>38:12, 52:20, 55:22, 56:9, 58:7, 58:12, 59:4, 60:2, 60:13, 67:1, 68:13, 68:14, 72:18, 72:19, 99:4, 117:9, 118:5, 129:7, 130:25, 131:6, 137:22, 137:24, 137:25, 154:24, 155:17 drug-antibody 138:20 drug-to-antibody 122:21 drugs 32:3, 33:2, 33:4, 37:17, 52:23, 66:17, 121:16, 122:11, 155:19 du 2:23, 139:21 due 53:10, 53:11, 54:14 duly 5:22, 74:4, 161:8 during 7:13, 10:10, 24:17, 24:20, 91:21, 100:4, 123:20 dying 68:13</p> <hr/> <p style="text-align: center;">E</p> <hr/> <p>e-mail 140:8, 140:22, 141:4, 141:7, 141:9, 158:21 each 19:16, 24:21, 31:20, 36:20, 59:8, 66:9,</p>
---	--	---	---

<p>87:4, 104:6, 104:18, 105:18, 106:9, 108:18 earlier 45:25, 62:7, 90:3, 91:22, 131:11, 147:21, 147:23, 157:21 early 31:18 easier 96:3 eastern 73:18, 99:23 easy 31:22, 75:10, 146:25 ec 84:22, 85:10, 85:13, 85:17, 85:22, 86:24, 87:2 edited 11:23 edu@foxrothschild 2:28 effect 88:11, 127:16, 133:14 effective 72:19 effector 139:2, 142:25, 143:8, 143:17, 144:2, 144:8, 145:4, 145:8 effects 34:10, 43:15, 128:7, 130:6 efficacy 38:23, 39:3, 54:1, 65:1, 65:25, 81:7, 83:10 efficient 19:24, 46:25, 58:11, 60:2, 63:22</p>	<p>efficiently 43:6, 43:20, 45:5, 45:9, 45:15, 45:23, 46:5, 46:21 effort 59:14, 59:23 efforts 27:15, 27:25, 32:2, 64:6 egf 111:21 egfr 26:16, 26:17, 26:18, 34:16, 61:14, 61:16, 64:7, 65:4, 65:15, 65:16, 66:23, 67:5, 67:14, 67:18, 68:8, 69:20, 70:1, 70:4, 70:6, 70:8, 70:17, 70:21, 70:23, 71:9, 71:19, 71:22, 72:1, 72:5, 77:2, 84:8, 85:12, 89:22, 92:16, 93:18, 97:13, 97:15, 98:8, 99:3, 99:5, 99:13, 106:4, 107:5, 108:15, 111:20, 112:3, 112:14, 115:16, 115:19, 125:25, 126:13, 126:23, 127:12, 127:16, 127:21, 127:24, 128:5, 128:13, 128:21, 129:18, 129:24, 130:4, 130:10, 130:19, 131:24, 132:6, 132:12, 132:19, 132:22, 132:24, 133:4,</p>	<p>133:8, 133:10, 133:15, 134:2, 134:24, 134:25, 135:4, 135:20, 136:24, 136:25, 147:8, 148:2, 148:20, 149:8, 149:11, 149:18, 149:22, 150:5 egfr-mutated 4:24 either 36:24, 110:23, 111:4, 111:13, 111:21, 112:24, 113:14, 113:17, 123:16, 124:9, 134:23, 139:9, 161:15 el 2:13 elaborate 27:21 electronically 94:21, 139:15 elegant 65:9 eleventh 18:24, 19:2, 19:3 elisa 18:23, 84:8 else 23:1 embodiment 116:23 embodiments 105:15 enable 103:4 enabled 5:11 end 10:22, 18:16, 18:24, 19:3, 120:21, 147:18, 148:15 endless 108:23</p>	<p>endothelial 71:5, 72:2 engagement 144:4 engineered 21:4 english 4:10 enhance 88:4 enough 43:14, 77:12, 81:19, 136:23, 137:19 enter 66:17, 66:18 entire 12:25, 141:9 entirely 22:8, 55:12, 64:11, 85:15, 156:2 entirety 13:13 entitled 3:10, 4:15, 4:21, 4:25, 4:30 environment 77:4 enzyme 40:5, 49:16 epithelial 72:3, 144:25 epitope 40:14, 40:19, 42:10, 43:17, 45:13, 47:4, 51:15, 102:24, 115:3, 115:16, 132:4, 132:22, 134:10 epitopes 26:3 equal 149:8 equally 90:20 equate 48:25, 49:10,</p>
---	--	--	--

<p>51:13, 129:20, 133:24 eradication 38:24, 39:3 erbitux 138:8 errors 9:9 erxin 2:23, 141:7 esq 2:11, 2:12, 2:22, 2:23 establish 122:4 established 53:1, 53:6, 53:9 estimate 9:16, 12:23, 27:11 et 3:24, 4:18, 4:36 evaluate 135:13 even 18:4, 25:25, 36:18, 43:5, 43:13, 68:14, 107:23, 121:20, 124:3, 124:4, 148:12, 155:17, 155:22 ever 12:25, 103:13, 111:2 every 11:5, 28:6, 45:12, 45:13, 47:9, 47:10, 89:9, 146:23, 154:24 everyone 5:3, 124:3 everything 38:2, 51:14, 53:16, 54:9,</p>	<p>105:24, 112:12, 127:3, 128:10, 132:9, 137:24 evidence 31:6, 77:12, 77:19, 81:18, 81:20, 83:24, 97:17, 121:23, 123:22, 124:2 evidenced 87:2 evolved 47:11, 144:11, 144:15 exact 9:14, 10:18, 26:25, 31:12, 32:10, 37:3, 84:15 exactly 10:18, 19:11, 28:22, 69:17 examination 3:2, 6:1 examined 74:5 example 22:13, 24:24, 27:22, 34:12, 34:14, 42:4, 42:21, 44:1, 48:9, 58:25, 59:2, 61:12, 71:3, 75:6, 76:25, 83:2, 86:4, 99:1, 117:12, 120:18, 127:20, 132:5, 133:8, 133:25, 134:1, 135:18, 135:20, 136:2, 154:25 examples 33:20, 39:6, 60:23, 132:10, 134:19 exceptions 33:21, 33:22</p>	<p>exclude 54:8 exclusively 149:14 excuse 21:7 exemplary 75:3 exert 57:10 exhibit 3:9, 3:15, 3:20, 3:22, 3:25, 3:28, 4:6, 4:11, 4:14, 4:21, 4:25, 4:30, 4:34, 10:13, 15:11, 15:13, 15:17, 15:20, 15:21, 15:25, 23:6, 23:13, 56:17, 56:19, 68:19, 69:2, 69:4, 69:6, 69:9, 69:13, 69:15, 72:11, 74:8, 74:13, 75:14, 77:2, 77:15, 80:14, 80:23, 81:7, 84:22, 87:5, 89:15, 91:13, 91:15, 94:1, 94:9, 94:21, 95:12, 95:16, 95:17, 96:1, 96:21, 100:9, 100:15, 100:18, 103:18, 117:15, 117:18, 120:9, 120:11, 121:4, 124:5, 139:5, 139:6, 139:25, 140:1, 140:5, 141:15, 141:19, 142:3, 142:6, 147:4, 151:6, 151:8,</p>	<p>152:13, 153:7, 153:17, 153:18, 154:4 exhibited 86:23 exhibits 3:13, 4:4, 8:15, 8:17, 8:19, 10:6, 140:18 existing 65:17 exists 81:1 expect 78:8, 78:9, 79:11, 79:14, 130:7, 135:3, 136:11, 137:11, 149:10 expectation 57:12, 57:24 expected 23:17, 39:9, 78:7, 79:5 expecting 54:5 experience 14:17, 14:20, 16:21, 17:14 experiences 14:25, 15:2, 15:5 experiment 111:5, 115:6, 122:3, 129:10, 151:1 experimental 84:15, 86:8, 124:2 experimentation 103:16 experiments 98:6, 110:18, 110:25, 112:9, 113:18, 118:14, 118:16, 120:3, 122:2, 124:1</p>
---	---	--	--

<p>expert 3:20, 11:8</p> <p>explain 21:11, 31:20, 55:13, 56:7, 64:15, 143:13, 143:15, 147:11</p> <p>explained 23:9, 43:23, 45:11, 46:18, 46:23, 49:9, 49:15</p> <p>explicitly 29:16</p> <p>exploring 21:2</p> <p>express 76:3, 79:12, 133:8, 137:25, 143:17, 143:20, 144:11, 145:1</p> <p>expressed 40:11, 40:20, 42:8, 42:16, 43:4, 43:19, 51:20, 52:5, 59:5, 59:6, 63:1, 67:19, 67:20, 70:17, 70:23, 70:25, 71:4, 71:12, 71:25, 72:1, 97:14, 98:8, 130:14, 135:10, 135:17, 136:6, 136:21, 144:23, 148:12, 149:11, 149:14</p> <p>expresses 135:20</p> <p>expressing 52:21, 97:15, 129:24, 130:25, 132:6, 148:20</p> <p>expression 41:16, 41:21, 41:23, 42:3, 42:18, 43:1,</p>	<p>43:14, 44:5, 44:11, 44:16, 44:19, 44:24, 45:1, 45:4, 45:8, 45:12, 45:14, 45:21, 46:2, 46:4, 46:15, 46:21, 46:24, 47:2, 47:8, 50:18, 50:25, 51:1, 51:8, 51:9, 53:16, 63:23, 69:22, 70:3, 70:6, 71:14, 71:23, 72:4, 72:8, 130:3, 130:9, 130:19, 131:1, 131:12, 131:19, 132:1, 132:7, 132:25, 133:15, 133:24, 134:1, 134:7, 135:4, 135:11, 135:13, 135:22, 136:8, 136:10, 136:11, 137:7, 148:6, 148:8, 148:9, 149:17, 150:2</p> <p>extend 55:8, 69:25</p> <p>extends 68:14</p> <p>extensive 31:7, 58:24, 138:25</p> <p>extensively 134:17</p> <p>extent 16:25</p> <p>external 83:19</p> <p>extra 152:4</p> <p>extracellular 32:16</p> <hr/> <p style="text-align: center;">F</p> <hr/> <p>f-a-b 40:18</p>	<p>fab 34:9, 40:13, 40:18, 50:3, 132:17, 146:24</p> <p>fabs 146:7</p> <p>fact 86:4, 105:6, 127:23, 149:25, 150:8, 157:1, 157:10, 157:18</p> <p>factor 58:25, 130:11, 130:20, 149:18, 149:23, 150:5</p> <p>factors 46:12, 55:24, 56:23, 57:13, 57:25, 58:3, 58:14, 58:18, 58:21, 58:23, 59:9, 60:3, 61:14, 64:19, 66:8, 68:24, 69:2, 72:20, 73:4, 73:6</p> <p>fair 7:10, 7:20, 79:25, 123:5</p> <p>familiar 9:1, 27:15, 55:15, 64:5, 69:13, 69:18, 71:20, 74:7, 93:22, 95:19, 100:6, 117:14, 136:8</p> <p>family 105:12</p> <p>fangzhou 2:11</p> <p>far 111:9</p> <p>fc 17:18, 21:3, 34:9, 138:18, 139:1, 143:1, 143:9, 143:11,</p>	<p>143:18, 143:24, 144:1, 144:4, 144:9, 144:12, 144:18, 145:4, 145:7, 145:15, 145:22, 146:7, 146:9, 146:10, 146:14, 146:16, 146:20, 146:24, 148:13, 148:14</p> <p>fc-fc 144:10, 145:12</p> <p>fd 31:14, 71:16, 156:12, 156:23</p> <p>fd 38:4</p> <p>fdp-h3 86:25</p> <p>feasible 129:9</p> <p>february 14:23, 15:1</p> <p>feel 143:3</p> <p>few 6:8, 10:4, 12:7, 60:23, 64:7, 68:15, 76:6</p> <p>fewer 81:6</p> <p>field 14:18, 14:19, 53:18, 56:3, 64:5</p> <p>figure 74:22, 74:23, 74:24, 75:2, 75:5, 83:11, 96:17, 120:22, 121:3, 143:14</p> <p>figures 96:10, 96:14</p> <p>filed 15:19</p> <p>files 139:6</p>
--	---	---	---

<p>filing 16:1 find 25:13, 96:3, 142:16 fine 12:17, 16:6, 158:1 finished 154:7, 158:3 firm's 158:18 first 5:22, 6:7, 11:21, 25:12, 25:13, 25:15, 26:18, 26:23, 31:15, 32:9, 51:3, 56:21, 58:5, 89:15, 121:12, 142:9, 142:11, 142:24, 161:8 fits 38:1 five 14:17, 73:3 floor 2:24 flow 135:17, 136:2 flu 144:25 fluorescence 136:3 follow 91:4 following 58:12, 144:3 follows 5:23, 57:21, 59:20, 74:5, 109:13, 151:14 foregoing 159:4, 161:9, 161:11, 161:16 foreign 22:21, 22:23</p>	<p>form 10:15, 11:18, 13:8, 13:18, 33:12, 43:22, 44:22, 46:8, 51:23, 52:7, 70:10, 77:9, 80:3, 82:12, 92:24, 101:10, 104:20, 114:2, 114:18, 116:10, 116:25, 119:25, 123:9, 124:23, 126:1, 130:13, 134:9, 135:6, 136:14, 147:9, 149:2, 155:15, 156:10, 157:14, 160:6 former 34:25 formulate 76:3 formulated 138:23 forwarding 22:18 found 53:10, 125:19 foundation 12:15, 26:9, 30:20, 39:23, 41:18, 49:19, 50:6, 51:10, 54:17, 57:14, 70:10, 116:18, 119:25, 126:1, 127:10, 135:6, 151:18, 154:21, 154:22, 157:14, 157:24 fox 2:21 fqi@sheppardmul- lin 2:16 frame 27:2, 30:21,</p>	<p>30:25, 31:4, 31:17 francis 18:19 fred 2:11, 15:10, 15:16, 47:12, 73:9, 94:14, 94:24, 141:3 free 18:6, 19:12, 19:23, 143:3 fresh 4:16 front 7:2, 8:20, 26:20, 74:10 fulfill 15:4 full 161:12 fully 154:16 function 33:24, 36:9, 36:14, 37:12, 37:14, 40:6, 47:2, 47:8, 88:21, 109:1, 127:13, 129:2, 144:9 functionalized 18:6, 19:13, 19:24 functions 33:24, 33:25, 34:13, 139:2, 142:25, 143:9, 143:17, 144:2, 144:8 further 81:4, 154:13, 158:10, 161:14</p> <hr/> <p style="text-align: center;">G</p> <hr/> <p>gamma 21:3, 138:18, 143:1, 143:9,</p>	<p>143:11, 144:1, 144:4, 144:10, 144:12, 144:18, 145:4, 145:7, 145:12, 145:15 gastric 70:24 gave 133:25 general 55:20, 151:7 generality 122:4 generalization 51:12 generally 31:1, 31:2, 36:25, 39:8, 50:5, 79:4, 88:11, 88:13, 133:19 generate 67:24, 86:3, 101:4, 104:22, 134:16 generated 89:21, 105:16, 106:8, 108:13, 110:17, 118:18 generating 20:7, 98:25, 107:19, 108:23 genetically 21:4 getting 73:13 give 8:6, 9:16, 12:23, 24:24, 26:12, 26:15, 26:17, 34:12, 34:14, 42:4, 67:8, 72:25, 74:25, 75:11, 83:24, 96:2, 97:7, 102:9, 142:12 given 22:19, 70:6,</p>
--	---	--	--

<p>71:11, 81:12, 149:25, 150:8, 156:12, 156:13, 156:17, 157:1 glioma 97:14, 97:22, 98:9, 132:7, 133:7, 134:2 gliomas 97:16 global 36:17 glycan 18:7, 19:24, 20:1, 148:14 glycans 41:4, 41:13 glycoproteins 41:4 glycosylation 42:13 go 6:8, 18:12, 21:8, 22:12, 27:12, 29:20, 34:4, 37:21, 38:22, 43:11, 46:10, 47:15, 50:15, 56:16, 56:19, 67:9, 69:7, 72:12, 75:1, 80:13, 80:16, 83:2, 83:25, 84:10, 86:9, 93:25, 95:16, 96:1, 96:14, 96:20, 103:17, 104:22, 105:23, 120:8, 120:17, 121:3, 139:15, 141:23, 142:10, 143:15, 146:3, 146:4, 152:12, 152:17 goal 54:15, 101:4, 101:17 goes 13:25</p>	<p>going 8:24, 10:19, 22:19, 22:20, 60:19, 65:23, 67:10, 94:14, 105:25, 119:6, 121:16, 124:16, 126:12, 126:20, 126:22, 128:1, 130:4, 130:7, 135:10, 139:22, 140:8, 140:11, 144:18, 144:19, 145:4, 145:5, 147:17, 150:2 gone 47:12 good 6:3, 6:4, 12:3, 16:8, 16:12, 47:13, 66:5, 66:18, 73:16, 90:20, 122:10, 124:13, 140:20, 142:21, 146:22, 156:7, 156:12, 156:20, 156:24 great 6:20, 94:23, 95:4, 139:16, 158:5, 158:21 greater 77:16, 80:23, 87:5 ground 6:8, 116:15, 123:16, 124:9, 124:20 group 17:25, 141:10, 148:6 groups 31:8, 148:7 growth 83:10 guarantee 45:12 guaranteeing 45:17, 46:1</p>	<p>guess 137:20 guide 29:12, 29:15</p> <hr/> <p style="text-align: center;">H</p> <hr/> <p>hand 95:2, 161:23 happen 48:15, 137:18 happens 138:17 hard 53:15, 80:4, 102:9, 129:16, 138:14 harder 70:8, 70:11, 70:14 head 72:10 head-to-head 98:20, 103:3, 103:11, 108:5, 111:23, 115:7, 121:13, 123:11 healing 121:18 hear 6:21, 6:23 heard 55:16 heavy 74:24, 75:3, 75:7, 100:16 help 5:11, 63:12, 109:9 helpful 22:12, 112:12, 134:18, 140:13, 146:3 helps 154:24 hematopoietic 72:1 hence 84:22</p>	<p>her2 70:23, 71:2 herceptin 71:15 here 8:6, 61:5, 68:21, 69:7, 73:10, 80:19, 83:6, 96:24, 119:19, 122:6, 133:17, 140:24, 141:24, 143:14, 152:12, 153:14, 158:1, 158:2, 158:6 here's 153:15 hereby 159:3, 159:9, 161:7 herein 77:1 hereto 15:23, 69:11, 74:15, 91:17, 95:14, 100:11, 120:13, 141:17, 152:15, 153:20 hereunto 161:22 hhs 3:9 high 22:8, 41:21, 42:3 high-affinity 43:6 higher 50:25, 51:8, 51:21, 52:6, 52:16, 52:19, 53:21, 54:2, 54:5, 70:3, 72:4, 81:9, 82:5, 84:22, 85:5, 86:24, 87:2, 93:20, 97:24, 108:2,</p>
--	--	--	--

<p>108:7, 110:22, 111:3, 111:12, 111:19, 112:14, 112:23, 113:1, 113:4, 113:8, 113:13, 119:5, 127:1, 129:18, 129:20, 130:1, 130:4, 138:2, 147:7, 147:10, 147:13, 147:16, 149:6, 149:8, 149:11, 149:15 highly 52:18, 52:25, 53:5, 58:7, 72:17 hindrance 42:13 history 26:6, 26:12, 26:17 hold 152:10 homogenous 19:25 hope 7:5 hour 47:13, 99:17 hours 9:14, 9:15, 9:17, 12:7, 12:18, 12:21, 12:24, 26:21 howard 2:22, 99:15, 124:13, 139:8 however 122:19, 126:16, 144:11 hsuh@foxrothschi- ld 2:27 hu 96:10, 96:17 human 21:24, 22:2,</p>	<p>22:7, 22:8, 22:19, 83:8, 83:15, 83:21, 121:8, 121:10, 145:24, 146:1, 146:5, 146:7, 146:9, 146:10, 146:11, 146:18 humanization 22:14, 23:2, 23:10, 23:21, 24:4, 24:6, 24:12, 24:15, 24:17, 24:20, 25:1, 25:2, 76:9, 83:22, 84:6, 85:2, 85:21, 87:13, 87:25, 88:4, 88:6, 88:12, 88:16, 88:23, 89:4, 101:2, 101:3, 101:15, 101:17, 106:10, 106:16, 106:17, 106:22, 106:25, 107:9, 145:21, 145:25 humanize 76:8, 89:9, 101:13 humanized 21:13, 22:4, 22:6, 23:6, 23:12, 25:11, 28:1, 76:15, 76:19, 79:13, 79:15, 82:10, 83:16, 84:4, 84:18, 89:8, 90:21, 98:25, 100:24, 101:4, 101:20, 102:3, 102:8, 102:15, 102:20, 103:9, 103:15, 103:24, 105:6, 105:11, 106:7, 106:13,</p>	<p>107:7, 108:3, 108:9, 108:12, 110:23, 111:4, 111:13, 111:22, 112:24, 113:15, 134:23, 145:19, 146:8, 150:6, 150:23 humanizing 101:8 humans 22:9, 23:17, 33:4, 33:5, 79:16, 126:20 hundreds 27:12, 27:14 huyd 82:15, 82:19 huyd-mmae 83:8 hybrid 145:14</p> <hr/> <p style="text-align: center;">I</p> <hr/> <p>id 75:6, 100:16, 100:17, 100:20 ideally 122:13, 150:25 identical 26:4, 102:11, 103:25, 104:6, 104:18, 104:24, 105:1, 105:5, 105:13, 105:18, 105:25, 106:9, 106:14, 107:2, 107:10, 107:17, 107:25, 108:22, 108:24, 112:20, 114:1, 114:17, 114:19, 114:22, 114:25, 125:7, 125:13, 146:16, 148:13, 150:1 identification 141:15 identify 5:12, 30:6,</p>	<p>30:15 ig-dm-1 121:8 igg 121:10, 143:9, 144:14, 144:20, 146:18 ii 143:25, 157:3 iii 156:13, 156:24, 157:2 illustrates 22:11 immune 22:25, 145:16 immunogenic 22:24 immunogenicity 22:25, 23:3, 23:11, 23:18, 24:12, 24:25, 25:14, 27:24, 28:2, 59:12, 76:10, 76:13, 79:16, 111:3, 111:9, 111:12, 111:16, 112:16 immunohistochemi- stry 135:19 immunology 14:15 immunostimulator 38:16 impact 20:9, 45:4, 45:9, 45:15, 45:22, 46:2, 83:23, 88:20, 130:12, 131:13, 132:2, 138:18, 138:22, 147:22 impacted 126:14 impacts 46:4, 46:12 importance 128:13, 128:20</p>
--	---	--	---

<p>important 34:20, 35:4, 37:19, 39:10, 58:21, 62:21, 63:17, 121:24, 128:22, 129:2, 130:11, 130:20, 147:1 improve 28:8 improved 53:20, 68:2, 68:3, 77:1, 81:7 inc 1:11 include 10:9, 35:7, 117:9 included 12:11, 14:21, 113:19, 152:1 including 10:2, 88:21, 91:22, 110:14, 146:9 incorporated 127:15 incorrect 81:17, 81:23 increase 28:8, 52:19, 53:13, 58:15, 60:14, 60:25, 118:25, 119:1, 119:3, 119:6 increased 38:23, 39:3, 77:2, 112:10, 146:21, 147:7 increases 88:24 increasing 53:12 index 55:11, 55:14, 55:19 indicated 131:11, 148:7</p>	<p>indicates 96:16 indicator 156:24 indirectly 88:18 induce 20:10, 50:4, 148:10 induced 143:1, 143:9, 144:3 inducing 115:6 industry 157:19 infected 42:8, 144:22, 144:24, 145:6, 145:10 infection 144:25 infinite 107:20 influence 25:5, 35:22, 35:24, 36:1, 36:4, 36:6, 36:21, 42:9, 46:21, 48:22, 49:6, 59:9, 87:17, 112:21 influenced 46:15, 47:3 influenza 44:2, 145:1 inform 156:19 information 48:18, 61:24 informed 60:22, 61:25 inhibiting 112:2, 112:14, 115:5, 125:25, 126:9, 127:7, 129:13, 129:22 inhibition 126:13, 127:24,</p>	<p>128:14, 128:21 inhibitor 129:21 inhibitory 111:19, 126:22, 128:4, 129:17, 143:21 initial 11:16, 53:20 initially 27:4, 31:9, 67:18 initiated 157:2 instead 32:3 institution 3:18, 151:25, 152:7 instructs 7:23 intellectual 3:25, 3:28, 4:6, 4:11 intensity 135:25, 136:3 intentionally 51:19, 52:4 inter 8:7 interaction 41:11, 144:10 interactions 40:13, 111:20, 143:1, 143:10, 145:12, 145:14 interested 102:18, 161:17 interface 41:14 internalization 47:20, 48:1, 48:6, 48:15, 48:23, 48:25, 49:8, 49:10, 49:14, 50:4, 51:13, 58:12, 63:16, 63:19,</p>	<p>63:21, 128:1, 137:13, 137:15, 137:17 internalize 137:20 internalized 32:18, 49:12, 50:24, 51:7, 59:3, 60:1, 63:8, 67:22 internalizing 34:18 interplay 21:2 interpret 81:25 interpretation 32:14, 32:23 interruption 141:22 interruptions 5:16 intra-experiment- al 85:16 intracellularly 32:19 introduce 25:4, 25:5, 88:14 introduced 24:16, 24:20, 101:3, 101:12, 106:2, 147:15 introduces 88:7 introducing 139:4 introduction 86:2, 87:16 invalidity 123:16 invented 31:9 invention 3:30, 4:8 investigation 148:4</p>
--	--	---	--

<p>invokes 25:2</p> <p>involved 20:19, 41:5, 144:7</p> <p>involves 88:16</p> <p>involving 8:7</p> <p>ipr 1:8</p> <p>iprs 29:9</p> <p>irrelevant 121:10</p> <p>isolate 131:1</p> <p>isolation 55:16</p> <p>isotype 121:9, 121:21</p> <p>issue 71:8</p> <p>issues 43:17, 59:13, 59:22</p> <p>itself 59:4, 63:2, 129:8</p> <hr/> <p style="text-align: center;">J</p> <hr/> <p>january 4:19</p> <p>job 1:31</p> <hr/> <p style="text-align: center;">K</p> <hr/> <p>keep 9:18, 43:7, 52:22, 118:24, 124:16, 131:23, 145:25</p> <p>keeps 146:22</p> <p>key 51:18</p> <p>kill 37:14, 137:23</p>	<p>killing 32:5, 33:5, 35:17, 35:20, 39:19, 127:25, 145:9</p> <p>kind 73:13</p> <p>knacke 1:30, 2:2, 5:18, 161:5, 161:27</p> <p>know 6:19, 6:25, 7:17, 13:3, 13:16, 14:1, 32:11, 32:21, 37:17, 42:6, 44:15, 55:10, 62:21, 64:3, 66:23, 68:20, 72:13, 80:8, 80:18, 85:14, 88:13, 88:14, 102:22, 103:2, 111:11, 112:1, 112:18, 113:3, 115:24, 120:9, 120:19, 133:14, 135:10, 139:12, 139:18, 148:4, 148:24, 155:25, 158:1</p> <p>knowing 48:19, 117:10</p> <p>knowledge 27:7, 110:15</p> <p>known 38:7, 64:17</p> <p>knows 48:11, 48:17, 60:6, 132:23</p> <p>kras 127:22, 128:4, 129:3</p> <hr/> <p style="text-align: center;">L</p> <hr/> <p>lab 136:2</p>	<p>label 37:8</p> <p>labeled 121:6</p> <p>labs 122:2</p> <p>lack 41:18, 57:14, 121:23, 121:24</p> <p>lacks 12:15, 26:8, 30:19, 39:23, 49:19, 50:6, 51:10, 116:18, 151:18, 154:21, 154:22, 157:24</p> <p>large 79:18, 80:6</p> <p>last 18:15, 18:25, 19:9, 20:14, 20:24, 22:3, 36:11, 142:2</p> <p>late 73:14</p> <p>later-on 32:2</p> <p>latter 34:25</p> <p>lead 24:8, 107:19, 110:10</p> <p>leads 76:9</p> <p>leanna 89:14, 89:16, 91:12, 91:19, 93:4, 98:22, 123:1, 124:4</p> <p>leanna's 91:12, 92:15, 92:20, 92:22, 93:16, 93:20, 97:5, 97:24, 98:24, 115:9, 115:12, 115:15, 115:21, 115:24</p> <p>least 14:17, 71:1,</p>	<p>106:18, 137:15</p> <p>left 8:16</p> <p>less 54:7, 127:17, 128:22</p> <p>lesser 81:6</p> <p>let's 6:5, 6:8, 29:20, 44:25, 48:24, 79:6, 91:12, 94:20, 94:21, 120:17, 124:17, 127:20, 131:23, 136:7, 137:9, 142:15, 158:8</p> <p>leukocyte 145:8</p> <p>leukocytes 143:19</p> <p>level 41:16, 42:18, 43:5, 43:19, 44:5, 44:11, 44:19, 45:4, 45:8, 45:14, 45:22, 46:2, 46:4, 46:16, 46:21, 46:23, 46:24, 47:2, 47:8, 53:16, 69:22, 71:23, 86:8, 111:19, 130:1, 130:3, 130:9, 130:19, 131:12, 132:2, 133:1, 133:15, 134:7, 135:4, 135:13, 135:22, 136:8, 136:10, 136:12, 148:8, 150:2</p> <p>levels 50:19, 51:21, 52:6, 52:21</p> <p>li 18:19</p>
---	---	---	--

<p>license 161:7</p> <p>life 68:15, 155:17, 155:22</p> <p>light 75:4, 100:17</p> <p>likelihood 55:25, 56:24, 58:15, 59:10, 60:14, 60:25, 68:25, 73:7</p> <p>likely 60:8, 60:16, 119:7</p> <p>limit 53:1, 53:6</p> <p>limitations 125:6</p> <p>line 97:14, 98:9, 137:6, 148:3, 160:11</p> <p>link 94:22, 140:16, 140:18</p> <p>linker 35:12, 35:14, 35:21, 35:24, 36:2, 36:8, 36:9, 36:13, 36:14, 36:17, 36:18, 36:24, 37:7, 37:8, 37:11, 37:25, 58:9, 60:13, 61:12, 117:23, 118:2, 118:4, 118:7, 118:12, 118:19, 118:20, 118:21, 118:22, 118:24, 119:19, 119:24, 120:6, 120:24, 121:12, 121:14, 121:15, 121:25, 122:1, 122:7, 123:1, 123:2, 123:3,</p>	<p>123:4, 124:6, 124:7, 125:4, 125:6, 125:7, 125:8, 126:15</p> <p>linkers 35:19, 36:2, 36:4, 36:19, 60:23, 121:22, 122:5, 122:9, 122:12, 123:23</p> <p>links 35:14</p> <p>liquid 70:1</p> <p>list 10:6, 10:13, 20:24, 58:22, 58:24, 59:1, 64:23, 64:25</p> <p>listed 10:6, 10:12, 11:2, 15:5, 16:13, 18:5, 68:24, 73:3</p> <p>listing 75:15</p> <p>lists 79:23</p> <p>literature 26:19, 27:9, 27:13, 60:20, 65:17, 65:23, 119:11</p> <p>little 6:24, 70:22, 75:12, 87:13, 133:11</p> <p>liu 100:6, 102:23, 104:15, 108:5, 110:17, 112:8, 112:9, 112:25, 113:18, 116:1, 116:4, 116:7, 116:8, 116:13, 116:20, 124:22, 125:15, 125:23, 126:3, 129:16,</p>	<p>135:1, 138:2, 148:23, 150:10</p> <p>liu's 100:13, 100:22, 101:19, 102:2, 102:7, 102:14, 102:19, 103:5, 103:8, 103:14, 108:7, 109:6, 109:14, 109:21, 109:25, 110:5, 110:12, 110:21, 111:2, 111:11, 111:18, 112:1, 112:7, 112:22, 113:3, 113:7, 113:12, 115:8, 115:11, 115:13, 115:21, 125:20, 135:3</p> <p>localization 58:13</p> <p>long 12:5, 44:19, 67:25, 68:6, 107:6, 107:7, 113:22, 114:13</p> <p>longer 134:17</p> <p>look 82:25, 90:16, 94:14, 139:9</p> <p>looking 15:14, 74:25</p> <p>looks 95:19</p> <p>los 161:1</p> <p>lost 75:12</p> <p>lot 67:23</p> <p>lots 10:2, 10:8</p> <p>loud 94:2, 97:1, 103:21, 142:18, 143:5</p>	<p>low 41:22, 43:4, 43:5, 43:14, 43:19, 44:25, 51:1, 52:21, 63:22, 97:19, 144:16, 145:13</p> <p>low-affinity 145:14</p> <p>lower 23:18, 25:14, 51:9, 52:11, 54:2, 108:3, 108:8, 110:22, 111:3, 111:12, 111:19, 112:15, 112:23, 113:4, 113:8, 113:13, 149:11</p> <p>lowered 51:19, 52:4</p> <p>lowering 50:22, 51:5, 52:25, 53:5</p> <p>lunch 73:14, 73:15, 91:22, 92:8</p> <p>luncheon 73:20</p> <hr/> <p style="text-align: center;">M</p> <hr/> <p>macrophages 143:20</p> <p>made 72:25, 76:6, 76:7, 76:16, 76:17, 76:18, 79:13, 87:25, 88:1, 107:1, 113:2, 126:5, 138:5, 159:5</p> <p>magnets 49:21</p> <p>magnitude 126:10, 138:11</p> <p>mailed 8:18</p> <p>main 24:11, 32:24,</p>
--	--	--	---

<p>35:12, 37:12, 37:14, 38:17, 40:18, 58:20, 59:11, 76:22, 139:3 mainly 34:8, 39:18, 39:19 maintain 87:15, 106:18, 107:14, 107:16, 131:21 maintained 107:4 maintaining 97:19, 129:3 major 66:1 majority 21:24, 146:8 make 6:15, 13:10, 19:15, 25:18, 26:3, 28:4, 28:16, 48:20, 51:12, 52:14, 54:6, 59:14, 59:22, 76:11, 78:8, 92:11, 92:12, 93:23, 108:17, 109:1, 109:4, 121:11, 128:17, 150:20, 158:3 makes 67:23, 70:8, 79:18, 81:14, 105:12, 109:18 making 28:24, 29:13, 37:8, 57:12, 57:24, 122:8 malignant 37:15, 131:4, 144:22, 150:4 management 71:7 manufacturing 70:12</p>	<p>manuscript 3:10 many 9:14, 10:11, 12:24, 27:7, 27:10, 27:22, 28:19, 31:7, 34:22, 42:13, 42:14, 53:17, 66:24, 79:23, 106:20, 131:7, 135:9, 136:5, 136:17, 157:11, 157:13, 157:19 mark 15:10 marked 3:8, 3:13, 3:14, 4:4, 4:5, 15:13, 15:16, 15:21, 18:22, 69:9, 74:13, 91:15, 95:12, 100:10, 120:11, 140:3, 141:15, 152:13, 153:18 market 66:17, 66:19 maryland 18:1 match 136:19 matches 95:25 materials 10:4, 10:18, 10:19, 12:2 matters 43:17, 87:22, 131:1, 155:18 maybe 9:17, 73:14, 82:25, 83:4, 83:5, 83:18, 138:14 md 14:20 mean 9:6, 13:2,</p>	<p>13:21, 13:22, 13:25, 23:8, 28:5, 28:22, 28:25, 32:7, 34:22, 37:2, 41:8, 43:2, 44:2, 46:7, 46:11, 48:8, 54:18, 55:7, 55:12, 56:8, 56:25, 57:7, 68:2, 70:11, 70:18, 76:2, 76:22, 77:6, 99:7, 99:9, 102:16, 114:22, 130:22, 130:23, 135:9, 135:23, 136:16, 136:17, 136:23, 144:6, 146:5 meaning 13:3, 54:21, 54:25, 55:10, 55:18, 55:21 meaningful 66:20, 78:12, 78:14, 90:4 means 21:23, 55:5, 56:3, 143:13 meant 84:3 measure 136:3 measuring 84:25 mechanism 32:7, 32:8, 32:10, 36:10, 36:15, 37:16, 38:14, 127:9, 127:25, 128:9 mechanisms 38:11, 128:6 median 136:3 mediate 32:14, 128:7,</p>	<p>143:17 mediated 143:2, 143:10, 144:3, 144:10, 145:12 medical 27:5 medically 154:24 medication 8:1 megalith 1:4 membrane 42:12 membrane-express- ed 32:17 memory 12:3 menlo 2:14 mention 20:23, 90:15 mentioned 12:10, 23:11, 37:7, 39:10, 40:5, 40:11, 41:12, 42:20, 44:1, 44:23, 51:12, 62:6, 62:25, 63:6, 72:16, 76:8, 93:5, 94:5, 95:24, 97:10, 98:4, 98:5, 105:23 mentions 112:25 merely 40:4 mess 106:19 metastatic 4:33 method 98:25 mgs 144:13</p>
---	--	--	---

mic 5:10	104:19, 105:20, 107:13, 131:15	monomeric 144:20	much 9:12, 12:13, 22:7, 32:21, 51:21, 52:5, 130:1, 130:25, 135:17, 137:25
mice 101:15	mispronouncing 123:19	months 68:15	mullin 2:10
microenvironment 77:3, 80:25	misrepresents 46:8	more 6:18, 29:6, 32:22, 33:8, 36:25, 47:12, 52:15, 61:22, 76:11, 77:7, 80:9, 87:14, 89:17, 99:16, 122:1, 128:22, 130:1, 130:8, 136:5, 150:21	multiple 37:22, 67:20, 145:5, 145:13
microphone 6:25	missing 96:2	moreover 152:25	mutant 99:5, 99:9
middle 18:21, 148:16	ml 144:13	moreover" 152:21	mutants 86:25, 87:4, 87:11
might 28:12, 31:18, 41:21, 42:22, 79:11, 80:12, 84:1, 88:8, 88:20, 89:4, 96:3, 99:11, 112:21, 126:17, 137:23, 138:18, 141:6, 147:13	mm-hmm 83:4, 84:5, 103:20, 137:1	morning 6:3, 6:4	mutated 128:3, 132:23, 134:17, 149:13
million 66:8	mnae 38:7, 91:8, 118:21, 118:24, 119:13, 119:16, 120:23, 121:14, 121:19, 121:22, 122:11, 122:18, 125:10, 138:16	most 10:10, 10:23, 33:1, 33:2, 33:20, 35:15, 38:8, 62:21, 119:7, 147:1	mutation 87:16, 150:19
millions 64:18, 78:21	model 83:10, 83:11, 87:25, 88:1, 148:5	mostly 57:3, 103:2	mutations 76:18, 127:23, 128:11
mind 23:24, 33:22, 33:25, 43:8, 52:22, 54:10, 64:24	models 21:4, 66:1, 91:9	motivated 67:6, 67:15	mute 5:10
minimum 44:4, 44:10, 47:19, 47:22, 135:4, 136:9, 136:11, 137:12	modifications 24:20, 41:2, 76:6, 76:7	motives 76:11	myself 111:5
minor 147:14	modify 76:1, 76:2, 76:4, 76:5, 76:20, 78:19, 78:22	mouse 21:4, 21:12, 21:14, 21:15, 21:16, 21:20, 21:23, 21:25, 22:1, 146:6, 146:7	<hr/> N <hr/>
minus 135:25	molecular 14:16	move 7:4, 91:12, 142:17	naked 39:7, 113:16, 121:8, 126:6, 126:11, 126:21, 126:25, 128:14, 128:23, 138:6, 138:8, 138:13
minute 67:11	molecule 31:21, 35:8, 43:25, 63:1, 91:6, 91:8	moved 7:6	name 14:14, 20:21, 21:19, 31:22, 35:14, 92:17, 123:20, 159:10
minutes 73:15, 73:16, 99:23	molecules 40:10, 135:9, 136:6, 136:17, 136:18, 137:17, 137:19	moving 89:16, 91:19	named 82:15, 161:16
miracogen 1:11	monocytes 143:19	mrq 157:8	national 3:28, 4:6
mischaracter 107:11			naturally 67:23
mischaracterizes 85:7, 98:1,			

<p>nature 4:14, 34:7, 35:11, 36:1, 36:16, 37:6, 54:10, 54:11, 60:21 near 6:25, 138:17 neat 65:6, 65:9, 65:13 necessarily 42:20, 43:2, 47:1, 52:22, 70:21, 129:20 necessary 51:25, 136:5, 159:7 nectin4 71:3, 71:17 need 6:13, 6:15, 7:8, 14:12, 26:19, 37:23, 44:15, 58:15, 63:7, 67:25, 68:6, 68:10, 80:9, 82:22, 94:2, 97:1, 98:5, 103:21, 113:24, 114:15, 121:12, 121:21, 122:10, 126:16, 130:3, 135:10, 136:20, 137:15, 141:11, 141:13, 143:23, 151:1, 154:18, 155:2, 155:11 needed 44:11, 58:10 needs 54:9, 132:9, 136:19, 137:6, 140:3 negative 87:21 negligent 87:12</p>	<p>neither 150:10 neoplastic 32:4 neutral 77:17, 81:1, 87:3, 87:20 never 108:5, 113:6, 113:19 new 2:25, 66:17, 87:22, 139:5, 156:6 next 21:17, 153:4, 153:23, 154:2 nfc 145:24 nice 22:11, 66:23, 67:3 nie 2:12 night 146:23 night's 12:4 nk 143:20 noise 61:5 non-tumor 81:2 noncleavable 35:19, 36:3, 36:9, 36:14, 36:24, 37:10, 118:12, 118:20, 121:15, 122:1, 122:7, 122:9, 122:12, 123:23 none 144:17 nonexisting 113:21 nonmalignant 131:4, 150:4</p>	<p>nontumor 77:3, 150:25 normal 50:10, 50:17, 51:1, 51:9, 51:21, 52:5, 52:20, 53:12, 54:7, 69:22, 70:4, 70:7, 70:18, 70:25, 71:12, 71:24, 72:5, 77:8, 93:21, 97:15, 97:19, 97:20, 97:25, 98:17, 119:2, 119:23, 120:25, 129:23, 130:2, 130:5, 130:22, 130:23, 148:20, 149:7, 149:17, 149:19, 149:24, 150:7, 150:11, 150:16, 151:2 normally 126:25 notably 153:4, 153:24, 154:3 note 16:24, 158:6, 160:3 noted 145:18 notes 95:6 nothing 8:15 notice 146:7 notion 118:14, 119:12 nsclc 4:24 ntd 42:6 null 161:21</p>	<p>number 8:8, 9:15, 12:18, 12:21, 30:5, 30:14, 59:9, 79:18, 80:6, 95:25, 100:16, 100:17, 106:18, 107:20, 136:18, 151:20 numbers 15:25, 136:5, 136:20</p> <hr/> <p style="text-align: center;">o</p> <hr/> <p>o0o 158:24 oath 6:10, 159:4 object 22:21, 104:20 objection 10:14, 11:3, 11:18, 11:19, 12:15, 13:8, 13:18, 22:15, 23:15, 23:22, 24:5, 26:8, 28:21, 28:24, 29:1, 29:2, 29:4, 29:16, 30:8, 30:19, 33:12, 34:2, 34:3, 37:1, 39:22, 39:23, 41:18, 43:22, 44:13, 44:22, 46:8, 46:17, 49:19, 50:6, 51:10, 51:23, 52:7, 54:17, 57:14, 58:2, 61:19, 70:10, 77:9, 80:3, 82:12, 85:7, 88:25, 92:24, 98:1, 101:10, 104:19, 105:8, 105:20, 107:11,</p>
--	--	--	--

<p>107:13, 114:2, 114:18, 116:10, 116:18, 116:25, 117:7, 119:25, 123:9, 124:23, 126:1, 127:10, 130:13, 131:15, 135:6, 136:14, 147:9, 149:2, 151:18, 154:22, 155:5, 155:8, 155:15, 156:10, 157:14, 157:24</p> <p>objections 29:8, 29:14</p> <p>objective 77:4, 98:24, 154:21</p> <p>objects 76:25</p> <p>observed 54:13</p> <p>obstacles 59:13, 59:22</p> <p>obtain 93:4</p> <p>obvious 77:24, 124:21, 125:19, 125:22</p> <p>obviousness 124:10</p> <p>occluded 132:23</p> <p>occupied 144:19</p> <p>occur 49:8</p> <p>occurs 52:3</p> <p>off-the-record 5:8</p> <p>off-tumor 53:2, 53:7, 54:14</p> <p>offer 99:19</p> <p>office 1:1</p>	<p>often 52:2</p> <p>oh 14:2, 19:2, 20:23, 31:4, 48:16, 62:8, 94:20, 95:7, 95:10, 96:6, 96:13, 128:24, 130:16, 139:7, 140:19, 143:4, 146:17, 152:5, 152:8, 153:13</p> <p>okay 7:3, 7:5, 7:7, 8:20, 8:23, 10:17, 10:25, 13:24, 15:15, 15:24, 16:7, 16:8, 16:12, 18:18, 19:2, 23:12, 29:18, 29:20, 48:16, 62:8, 73:16, 84:11, 92:2, 92:10, 92:11, 94:4, 94:15, 94:20, 95:8, 96:6, 96:13, 97:2, 99:15, 99:18, 99:25, 117:21, 128:24, 131:25, 139:17, 140:2, 140:6, 140:7, 140:19, 140:21, 141:1, 141:14, 142:21, 143:4, 143:6, 146:17, 152:8, 152:11, 153:16, 154:10, 158:5</p> <p>old 4:36</p> <p>once 32:6, 137:18</p> <p>one 5:6, 8:23, 17:24, 18:7,</p>	<p>19:14, 20:14, 20:23, 20:24, 23:2, 27:22, 27:25, 38:1, 38:6, 38:20, 40:5, 45:1, 45:19, 46:1, 51:18, 52:2, 63:17, 76:6, 76:10, 79:22, 79:25, 83:17, 85:9, 87:25, 90:15, 91:8, 95:21, 95:23, 99:20, 108:13, 110:9, 110:20, 112:21, 115:4, 122:6, 122:7, 126:17, 127:2, 128:5, 129:19, 131:1, 132:3, 137:22, 140:2, 147:1, 149:11, 155:22, 157:21</p> <p>one-pot 18:5, 19:12, 19:23</p> <p>ones 10:10, 30:6, 30:15, 157:21</p> <p>ongoing 16:22, 16:23, 17:17, 20:18</p> <p>only 8:15, 28:14, 38:20, 58:7, 70:17, 78:19, 88:6, 98:12, 112:11, 122:6, 122:15, 124:11, 144:16, 145:15, 147:12</p> <p>open 15:9, 56:16, 94:9, 151:23</p> <p>opinion 14:11, 14:13, 24:9, 43:18,</p>	<p>44:20, 56:11, 63:3, 63:18, 66:22, 67:2, 76:14, 77:12, 77:18, 77:21, 78:13, 81:16, 81:21, 82:3, 87:15, 88:23, 89:18, 90:7, 90:13, 90:18, 91:2, 91:6, 92:21, 93:14, 97:5, 97:11, 101:7, 104:5, 104:8, 104:13, 104:16, 105:18, 106:7, 106:13, 107:6, 113:22, 114:13, 118:6, 118:13, 119:10, 119:22, 122:25, 125:4, 125:11, 125:15, 125:18, 130:18, 131:14, 131:17, 131:21, 132:1, 146:12, 147:12, 154:10, 154:17, 155:16, 155:18</p> <p>opportunity 55:3</p> <p>options 92:7</p> <p>oranges 121:17</p> <p>order 113:24, 114:16, 158:18</p> <p>ordinary 8:25, 9:5, 14:14</p> <p>organization 3:26, 4:12</p> <p>organize 25:22</p> <p>organized 42:11</p> <p>origin 72:2, 72:3</p>
---	--	--	---

Transcript of Stylianos Bournazos, Ph.D.
 Conducted on December 11, 2025

<p>original 161:20 originate 101:22, 105:9, 109:18 originated 22:1 other 4:28, 6:25, 16:4, 19:16, 20:12, 23:20, 23:23, 24:3, 24:14, 24:25, 28:3, 28:7, 28:10, 28:12, 32:3, 33:24, 33:25, 34:12, 38:7, 38:13, 42:12, 45:16, 46:4, 46:11, 46:12, 49:23, 58:18, 58:22, 60:20, 63:10, 63:14, 66:6, 71:11, 76:18, 78:3, 82:25, 83:1, 83:5, 83:6, 85:4, 90:12, 94:14, 97:18, 101:2, 101:9, 102:25, 104:6, 104:18, 105:6, 105:18, 106:9, 107:18, 108:15, 108:18, 108:25, 109:3, 110:9, 110:14, 110:20, 113:24, 114:15, 115:4, 129:19, 130:7, 133:8, 145:16, 146:6, 146:23, 148:5, 148:7, 154:12, 155:19, 155:20, 157:13 others 38:8, 49:22, 59:11, 60:4,</p>	<p>71:17 otherwise 7:18, 7:23 ou 18:19 out 27:14, 28:7, 66:15, 70:22, 77:19, 80:13, 94:2, 97:1, 103:21, 105:24, 131:8, 139:9, 139:10, 139:13, 142:17, 143:5 outcome 161:17 outlined 15:2, 58:4 outside 67:11 over 5:6, 6:8, 19:16, 23:7, 23:13, 27:12, 39:7, 50:10, 50:17, 60:20, 65:23, 95:2, 108:14, 150:15 overexpressed 71:5 overexpression 43:1 overview 26:13 own 66:10 owned 28:15 owner 1:13, 2:19, 158:10 owner's 3:16, 139:4, 151:24, 152:6, 157:7 oxazolines 18:7, 19:24</p> <hr/> <p style="text-align: center;">P</p> <hr/> <p>p-o-s-a 9:4</p>	<p>pacific 2:5 package 94:11 page 3:2, 3:8, 3:14, 4:5, 18:5, 18:11, 18:16, 18:21, 19:1, 19:10, 22:13, 83:8, 86:9, 96:3, 96:5, 96:7, 96:23, 100:19, 100:20, 100:21, 120:8, 120:15, 120:16, 120:17, 121:4, 125:2, 142:10, 142:22, 142:24, 146:4, 152:17, 152:20, 153:1, 160:11 pages 1:32, 96:3 paper 11:6, 75:10, 139:6, 141:13, 142:8, 142:10, 151:23, 152:18 papers 10:9, 16:2, 27:13, 139:2 paragraph 56:19, 56:22, 57:9, 58:4, 68:16, 68:23, 72:12, 73:3, 75:1, 80:16, 80:20, 80:22, 81:10, 81:11, 83:12, 84:20, 86:13, 87:9, 93:5, 93:25, 95:24, 96:1, 96:6, 96:7, 96:9, 96:16, 96:20, 96:22, 96:23, 96:25,</p>	<p>97:4, 97:12, 97:23, 98:4, 98:7, 103:17, 108:21, 114:23, 116:7, 120:18, 120:21, 142:11, 142:22, 142:24, 152:21, 152:25, 153:3, 153:4, 153:22, 153:23, 154:2 paragraphs 14:1, 16:13, 154:8 parent 101:23, 104:3, 105:10, 105:12, 105:17, 106:8, 107:3, 107:8, 107:16, 107:24, 115:14 parental 53:22 parenthetical 120:24 park 2:14, 2:24 part 21:23, 36:11, 51:3, 75:18, 124:11, 126:10, 138:12 partes 8:7 participate 41:13, 88:18 particular 41:7, 75:23, 150:19 particularly 143:22 parties 161:15 partly 129:25 pass 158:11 past 100:4, 158:6</p>
---	---	---	--

<p>patent 1:1, 1:2, 1:10, 1:13, 2:19, 3:16, 3:22, 3:30, 4:8, 4:34, 8:8, 8:10, 8:11, 12:14, 13:1, 13:4, 13:7, 13:14, 13:17, 13:25, 14:6, 14:9, 60:20, 72:17, 72:24, 73:4, 76:17, 77:11, 80:11, 81:19, 82:2, 83:5, 84:1, 87:23, 110:9, 112:10, 122:6, 123:20, 123:21, 124:11, 124:21, 125:8, 125:12, 125:14, 125:16, 126:3, 134:3, 139:4, 151:24, 152:6, 157:7, 158:10 patent's 125:6 patents 10:2, 10:9, 27:13, 61:24, 102:23, 122:23 path 137:6 patient 32:6, 33:5, 55:3, 55:9, 56:10, 68:15 patients 4:23, 4:32, 66:5, 155:1, 155:2 pattern 28:23 paused 137:6, 148:16 payload 36:23, 37:13,</p>	<p>37:20, 37:24, 37:25, 38:1, 38:16, 39:19, 53:11, 61:13, 118:19, 118:25, 119:13, 119:16, 122:25, 123:1, 125:5, 125:6, 125:9, 125:10, 126:15, 126:17, 128:2, 131:6 payload-alone 121:24 payload-mediated 127:18 payloads 38:3, 52:19, 52:25, 53:5, 60:23 penalty 159:1, 159:3 pending 7:10 people 31:6, 60:20, 68:13 percent 21:15, 26:14, 31:19, 64:5, 72:6, 75:9, 75:15, 93:1, 102:11 perfect 40:22, 95:7 perform 33:24 performed 60:15, 61:17, 111:8, 118:16 performs 39:19 perhaps 101:17 perjury 159:1, 159:3 permitting 58:11 person 8:25, 9:5,</p>	<p>14:12, 14:14, 91:23 personal 56:11, 66:22, 91:5, 155:16 personally 56:10, 107:24 petition 14:21 petitioner 1:7, 2:9, 158:12 petitioners 3:15, 151:4, 151:16, 151:24, 152:6, 152:10, 154:14, 154:17, 155:13, 156:17, 157:12 ph 1:21, 2:2, 3:21, 5:21, 14:15, 74:3, 77:16, 77:17, 80:24, 81:1, 82:5, 83:23, 84:3, 84:7, 84:17, 84:23, 85:1, 85:5, 85:11, 86:3, 86:22, 86:24, 87:1, 87:2, 87:3, 87:5, 87:6, 87:10, 87:18, 88:4, 88:21, 88:24, 89:6, 89:10, 108:16, 108:25, 148:22, 148:25, 150:14, 159:16, 160:8 ph-selective 81:5 phase 4:30, 156:13, 156:24, 157:2, 157:3 phone 8:22</p>	<p>phonetic 49:21, 53:22 phosphorylated 129:17, 129:18 phosphorylation 112:3, 112:14, 115:5, 125:25, 126:9, 126:13, 126:23, 127:8, 127:16, 128:5, 128:13, 128:21, 129:14, 129:23, 137:2, 137:3 phrase 9:1, 56:2 phs 88:10 physiological 71:13 piece 75:10 pile 94:13, 94:14 pipeline 4:16, 66:10 platinum-based 4:22 please 5:5, 5:7, 5:9, 5:11, 11:10, 17:14, 17:22, 20:25, 21:8, 21:11, 29:25, 43:12, 48:2, 51:25, 53:3, 54:19, 55:13, 56:1, 56:7, 56:16, 56:21, 57:15, 58:22, 58:25, 59:15, 61:4, 64:23, 68:20, 69:5, 72:11, 72:12, 77:20, 80:13, 80:18, 80:20, 82:24, 85:20, 86:9, 86:12, 93:25, 94:9,</p>
--	--	---	---

<p>95:16, 96:1, 96:9, 96:20, 96:25, 102:16, 103:17, 104:11, 109:8, 112:5, 114:3, 117:1, 117:24, 120:8, 120:9, 120:19, 128:16, 130:16, 141:8, 142:10, 151:9, 151:23, 152:17, 153:3, 154:4, 156:14 plus 135:24 point 6:17, 26:15, 28:13, 70:16, 74:19, 77:19, 92:18, 100:13, 124:14, 137:22, 146:22 poor 60:1 popr 152:3, 152:5 portion 32:25, 34:9, 144:7, 145:22, 146:20 portions 146:14, 146:16 posa 9:3, 14:12, 14:13, 14:22, 14:23, 15:1, 15:4, 15:6, 16:16, 47:24, 48:5, 48:11, 48:13, 48:17, 57:13, 57:25, 58:15, 58:18, 58:23, 60:6, 60:7, 60:11, 60:15, 60:24, 61:1, 61:7, 61:10, 61:15, 61:17, 62:2,</p>	<p>62:11, 62:19, 63:12, 71:8, 71:13, 81:21, 81:24, 82:3, 82:9, 125:18 posi 131:21 position 75:24, 150:20 positive 87:18, 87:21, 133:10, 157:4 possibility 108:23 possible 22:7, 22:9, 37:22, 61:25, 110:9 post-market 57:6 post-translation 41:2 potency 28:8 potent 36:25, 37:21, 58:7, 89:13 potential 23:3, 28:2 potentially 148:21 potentiates 120:24, 121:12 practice 29:12, 29:15, 31:1 precise 121:20, 129:6 preclinical 57:5, 66:1, 67:2 predict 60:8, 80:4, 148:10 predom 149:14 prefer 117:19</p>	<p>preferentially 50:23, 51:6 preparation 12:19, 93:11, 122:20 prepare 11:25 prepared 11:21 preparing 9:12, 9:19, 9:24, 11:1, 12:5, 12:8 presence 126:14 present 2:29, 80:25, 92:5 presented 80:11, 81:18, 82:1, 121:23, 123:16, 145:15, 150:24, 151:3 preserved 134:10 presume 102:4, 121:9, 137:21 prevent 65:20 prevented 65:3, 66:2 preventing 64:21 previous 18:25, 19:9, 45:19, 57:20, 59:19, 65:17, 83:17, 109:12, 133:18, 151:13 previously 3:13, 4:4, 12:12, 15:21, 37:7, 69:9, 74:4, 74:13, 76:9, 91:15, 93:6, 95:12, 100:10, 104:1,</p>	<p>120:11, 152:13, 153:18, 154:18 primarily 33:7, 35:10, 41:11, 42:10, 58:4, 70:2, 71:4, 71:25, 72:2, 128:1 primary 33:9, 33:15, 40:17, 54:15, 127:8, 128:9, 132:19, 149:18, 149:23, 150:5 principle 23:16, 24:11, 44:2, 106:17, 126:12, 126:21 print 139:9, 139:10, 139:13, 140:14, 140:15, 141:11, 142:12, 142:15, 142:16, 160:3, 160:5 prior 10:3, 14:25, 60:10 prioritize 66:11 probably 8:24, 123:19 procedures 84:16 proceed 141:12 proceeding 5:4, 11:9, 11:12 proceedings 8:7, 61:25, 141:22, 161:13, 161:16 process 10:10, 22:24, 24:15, 24:21, 25:1, 32:5, 32:7, 32:12,</p>
---	---	---	---

<p>32:21, 35:17, 35:20, 36:6, 41:5, 81:25, 106:22, 106:25, 107:9, 107:18, 154:14, 156:9, 156:19, 157:23 produce 81:6 produced 21:15 product 124:5 profile 28:9 progress 3:11, 65:24 progressed 155:2 project 16:22, 17:16 projects 16:23, 20:18 proliferate 131:4 proliferation 130:2 prominent 130:8 prop 89:5 properties 24:7, 28:20, 30:7, 30:16, 40:7, 40:12, 41:6, 41:8, 48:22, 49:6, 49:11, 54:12, 62:2, 62:11, 62:15, 62:17, 62:20, 63:10, 77:22, 78:5, 78:7, 78:24, 79:5, 79:8, 79:10, 80:2, 82:19, 90:16, 101:16, 102:13, 103:1, 103:8,</p>	<p>103:14, 107:15, 109:3, 110:4, 110:11, 110:12, 115:1, 115:15, 115:20, 123:6, 126:18, 132:12, 149:12 property 3:25, 3:29, 4:7, 4:11, 24:10, 24:14, 24:24, 87:19, 88:10, 102:17, 102:19, 114:20, 123:5 proposal 16:5 prosecution 123:21, 124:12 protein 42:5, 42:7, 42:22 protein-protein 40:12, 41:3, 41:12 provide 5:12, 8:4, 38:23, 39:2, 55:23, 58:5, 58:22, 58:25, 64:23, 77:1, 90:18, 103:11, 111:15, 112:5, 147:11 provided 74:21, 81:6, 87:8, 92:20, 93:3 provides 39:18, 40:4, 56:9, 90:17 public 3:9 publication 3:23, 3:26, 3:31, 4:9, 4:12, 4:35, 17:24, 18:5, 18:8,</p>	<p>18:11, 18:16, 18:24, 20:22 publications 10:3, 17:6, 20:12, 60:19, 61:24 published 4:14, 139:2 purchase 5:14 purity 122:20 purpose 16:23, 32:24, 35:12 purposes 5:8, 19:17 put 139:12</p> <hr/> <p style="text-align: center;">Q</p> <hr/> <p>qualifications 14:11, 16:14, 16:15 qualified 15:1 qualifies 15:6 qualify 14:23, 16:16 quality 35:11 quantified 129:6 quantify 135:21, 136:4, 136:7 question 7:10, 7:16, 7:19, 9:21, 9:23, 9:24, 11:10, 13:10, 13:20, 21:17, 22:3, 24:2, 24:3, 26:11, 30:1, 30:9, 30:13, 30:17, 30:19, 31:3,</p>	<p>33:13, 35:2, 36:12, 40:4, 45:7, 45:18, 48:2, 48:11, 49:3, 49:4, 51:2, 52:9, 52:12, 52:14, 53:3, 54:24, 56:6, 56:15, 57:16, 57:18, 57:20, 57:22, 59:15, 59:17, 59:19, 59:21, 61:4, 62:7, 62:10, 65:22, 68:4, 68:10, 79:1, 91:20, 104:11, 108:10, 109:8, 109:10, 109:12, 109:14, 113:10, 114:4, 114:6, 114:8, 114:11, 117:2, 117:24, 128:17, 130:17, 131:18, 133:5, 133:13, 133:18, 133:19, 136:16, 137:8, 142:2, 146:22, 146:25, 148:15, 151:7, 151:9, 151:11, 151:13, 151:15, 154:11, 155:8, 156:15, 157:6, 157:16 questions 7:22, 29:6, 89:17, 124:14, 158:4, 158:11, 158:12 quick 73:15, 82:25 quite 9:14, 10:4, 27:10</p> <hr/> <p style="text-align: center;">R</p> <hr/> <p>radioimmunoconju- gates 21:3</p>
--	---	---	---

<p>radioisotopes 20:16</p> <p>rate 131:5</p> <p>rather 77:8</p> <p>ratio 87:5, 122:21, 138:20</p> <p>rationale 54:4, 76:22</p> <p>ravetch 18:20</p> <p>rbd 42:6</p> <p>rdr 1:30, 2:2, 161:27</p> <p>reach 58:8</p> <p>reaction 22:20, 22:25</p> <p>read 56:21, 57:17, 57:20, 59:19, 76:17, 80:9, 80:20, 86:12, 86:14, 86:15, 86:18, 94:2, 96:25, 97:1, 97:11, 97:17, 103:21, 109:9, 109:12, 114:5, 114:8, 142:11, 142:17, 142:20, 143:5, 151:13, 153:11, 159:5</p> <p>reading 12:14, 60:18, 81:11, 81:21, 82:3, 87:8, 97:4, 97:23, 98:3</p> <p>real 2:13, 65:2</p> <p>really 9:18, 16:23, 24:10, 26:12,</p>	<p>37:6, 39:13, 41:23, 66:1, 69:25, 71:14, 84:16, 87:16, 87:22, 93:15, 127:1, 128:8, 130:24, 136:4, 147:24, 148:1, 148:8, 148:9</p> <p>reason 8:3, 24:11, 28:3, 28:10, 67:17, 88:4, 97:11, 115:17, 121:2, 123:18</p> <p>reasonable 57:11, 57:23, 73:8, 147:6</p> <p>reasons 27:20, 27:21, 27:22, 28:12</p> <p>recall 9:14, 10:17, 11:4, 12:22, 26:25, 31:12, 93:9, 151:19</p> <p>received 64:12, 156:23</p> <p>recent 3:11, 18:25</p> <p>receptor 32:15, 32:18, 34:6, 34:7, 34:8, 34:17, 34:18, 34:19, 67:21, 131:20, 138:18, 143:9, 145:12, 145:16, 150:2</p> <p>receptor-ig 143:1</p> <p>receptor-mediated 139:1</p> <p>receptors 21:3, 42:12, 136:20, 137:16, 137:18, 137:22, 143:11, 143:21,</p>	<p>144:1, 144:5, 144:12, 144:15, 144:18, 145:4, 145:8</p> <p>recess 21:9, 29:23, 47:17, 67:12, 73:20, 100:1, 124:18, 141:25, 158:9</p> <p>recognition 44:17, 88:8, 88:19, 88:21</p> <p>recognize 32:15, 32:17, 33:10, 33:16, 40:14, 40:15, 40:19, 88:17, 89:6, 95:18, 97:13, 97:18, 98:8, 115:2, 115:19, 133:9, 141:19, 145:5</p> <p>recognized 132:22, 134:9</p> <p>recognizes 25:3, 25:8, 72:17, 115:15, 147:15</p> <p>recognizing 35:10, 45:2, 51:15, 132:5</p> <p>record 16:25, 20:22, 21:8, 29:19, 29:21, 29:22, 29:24, 47:16, 67:10, 80:21, 86:16, 95:5, 141:23, 158:16, 161:12</p> <p>recorded 5:19</p> <p>recording 5:7, 5:13</p> <p>red 146:6</p> <p>reduce 23:3, 24:12,</p>	<p>28:1, 28:8, 136:24, 136:25, 137:2</p> <p>reduced 76:9, 79:16</p> <p>reducing 76:12</p> <p>refer 8:10, 21:22, 38:6, 79:3, 112:12, 124:24</p> <p>reference 74:9, 74:11, 81:3, 89:14, 92:20, 93:4, 95:18, 100:6, 117:15, 120:15, 125:23, 153:8</p> <p>references 95:23</p> <p>referring 8:17, 30:22, 30:25, 37:18, 55:9, 57:3, 65:13, 70:14, 122:18, 133:20, 134:20</p> <p>refers 9:4, 13:17, 57:3, 105:1, 108:22, 117:18</p> <p>reframe 154:10</p> <p>refreshed 12:2</p> <p>regarding 125:6</p> <p>regardless 104:17, 107:8</p> <p>region 40:25, 88:15, 132:16, 146:2</p> <p>registered 161:5</p> <p>regulated 148:3</p> <p>regulatory 64:12, 154:13,</p>
---	--	--	---

<p>156:9, 156:18, 157:22 related 14:16, 14:19, 49:13, 74:18, 101:23, 104:3, 105:11, 106:5 relative 128:12 release 58:11 released 32:19, 35:23, 35:25, 36:7, 36:22 relevant 10:10, 10:23, 16:14, 16:15, 93:13, 121:21 rely 116:16, 116:22, 116:24, 117:4, 117:6 remember 5:5, 5:10, 10:25, 11:5, 11:20, 72:9, 88:15, 111:10, 133:6 remodeling 20:2 remote 1:20, 2:1, 2:30, 5:3, 139:14, 139:18, 139:24, 140:2, 140:6, 140:10, 140:17, 140:20, 140:23, 141:1 remotely 5:4 render 92:21, 161:20 rendering 93:13 repeat 9:21, 9:22, 9:23, 11:10,</p>	<p>29:25, 33:13, 35:2, 36:11, 45:7, 48:2, 51:2, 51:25, 53:3, 57:15, 59:15, 59:16, 61:4, 68:4, 104:10, 109:8, 113:10, 114:3, 114:10, 117:1, 117:24, 122:3, 128:16, 142:2, 151:9, 151:10 rephrase 7:17, 13:9, 49:4, 51:25, 104:10, 128:16, 156:14 replace 90:11, 125:19, 146:1 replaced 90:7, 104:23 replacement 75:24, 86:2 replacing 119:4 report 111:9 reported 1:29, 161:10 reporter 2:3, 5:12, 6:15, 6:18, 15:22, 57:17, 57:21, 59:16, 59:20, 69:10, 74:12, 74:14, 91:16, 95:13, 100:10, 109:9, 109:13, 114:5, 114:9, 120:12, 141:16, 151:10, 151:14, 152:14, 153:19, 161:6 reporter's 19:17, 161:20 reports 78:6, 129:16</p>	<p>represent 78:19 reproducible 85:15 request 3:16, 151:25, 152:6 require 103:16, 145:13, 158:18 required 47:20, 47:25, 48:6, 48:15, 48:23, 49:7, 50:5, 137:13 requirement 63:7, 129:19 requirements 15:4 research 14:18, 14:20, 16:19, 17:10, 17:20, 17:22, 18:13, 18:14, 19:8, 20:5, 30:13, 56:23, 139:1, 139:3 researchers 27:18, 28:10, 28:18, 30:4, 64:9, 67:6, 67:15 researching 17:15 reserves 158:13 residues 146:1 resistant 127:21 respect 17:1, 99:2, 112:7 respectively 125:5 response 3:15, 133:21, 151:24, 152:6,</p>	<p>152:10 responses 6:13, 6:16 rest 21:24, 22:1 restricted 98:13 result 50:23, 51:6, 58:10, 88:8, 90:8, 123:7 resulted 24:15, 84:7, 101:14 resulting 90:13, 145:7 results 84:21, 85:15, 86:22, 87:23, 145:14 revealed 56:23 review 8:7, 9:19, 9:25, 10:1, 12:8, 18:17, 19:6, 19:7, 26:15, 26:19, 78:16, 86:18, 96:9, 96:12, 96:13, 98:5, 113:24, 114:15, 123:21, 142:7, 143:3, 152:23, 153:3, 153:7, 158:13 reviewed 10:5, 10:8, 10:11, 11:1, 11:6, 11:13, 11:14, 12:2, 12:10, 12:25, 13:2, 13:13, 77:11, 93:23, 95:20, 123:18, 151:21, 153:21, 154:15, 156:5, 156:25</p>
---	--	---	---

<p>reviewing 12:14, 65:23, 102:22, 118:13, 123:25, 151:19, 154:7</p> <p>reviews 4:15</p> <p>right 7:3, 8:12, 10:13, 10:21, 15:14, 18:2, 19:6, 27:1, 27:4, 31:17, 31:18, 55:15, 61:12, 61:13, 61:18, 62:4, 62:5, 62:6, 62:13, 62:17, 62:24, 84:4, 92:9, 137:7, 138:25, 140:1, 140:3, 140:23, 158:13, 158:14</p> <p>risk 52:20, 53:14</p> <p>rodriguez 20:23</p> <p>role 31:20, 33:10, 33:15</p> <p>room 92:5</p> <p>rothschild 2:21</p> <p>rough 158:19, 158:21</p> <p>route 139:15</p> <p>rule 33:21, 127:2</p> <p>rules 6:8, 29:1, 29:7</p> <p>run 5:5</p> <hr/> <p style="text-align: center;">S</p> <hr/> <p>s2 42:6</p>	<p>safe 72:19</p> <p>safety 28:9, 54:1</p> <p>said 26:5, 68:21, 86:20, 94:10, 103:19, 104:1, 133:13, 139:22, 139:25, 142:22, 147:21, 153:23, 161:12, 161:17</p> <p>same 11:19, 15:25, 20:16, 23:7, 23:13, 24:5, 25:23, 25:25, 36:23, 37:3, 44:2, 45:2, 45:19, 58:2, 73:3, 78:24, 79:8, 83:15, 99:11, 101:20, 101:21, 101:22, 102:23, 104:2, 105:10, 105:11, 105:12, 105:17, 106:8, 107:3, 107:8, 107:15, 109:7, 109:15, 109:18, 112:4, 115:3, 115:9, 115:14, 117:7, 119:13, 119:15, 119:17, 119:18, 119:19, 120:5, 122:3, 123:1, 123:3, 125:10, 126:9, 126:12, 131:5, 138:11, 146:20, 153:13, 159:5</p> <p>same-cell 49:21</p> <p>sars-cov-2 42:4, 42:8, 42:21, 44:1</p> <p>satisfied 125:5</p>	<p>saved 155:22</p> <p>saves 155:17</p> <p>say 7:17, 9:17, 12:24, 15:16, 27:12, 28:15, 33:9, 33:15, 39:13, 39:15, 39:17, 44:25, 66:22, 79:25, 84:16, 89:1, 89:4, 89:11, 90:24, 98:13, 98:22, 102:12, 103:4, 108:13, 122:15, 123:5, 127:6, 128:8, 133:23, 136:19, 137:8, 137:9, 147:16, 158:1</p> <p>saying 84:9, 91:5, 105:4, 119:8, 120:5, 120:22, 130:9, 131:1, 133:17</p> <p>says 84:21, 97:12, 125:14, 141:13</p> <p>scenario 51:18, 52:2, 52:9, 52:10, 54:9</p> <p>schueler 2:30</p> <p>scientific 27:9, 54:4, 64:22, 64:24, 65:6, 65:19, 66:2, 66:14, 81:25</p> <p>scientifically 26:14, 65:5, 147:1</p> <p>scoring 135:24</p>	<p>screen 28:19, 30:6, 80:6, 139:12, 140:11, 140:12, 141:2, 142:4, 142:17, 147:4</p> <p>screening 30:15</p> <p>scroll 18:15, 68:16</p> <p>searching 75:10</p> <p>second 25:12, 25:14, 25:16, 58:6, 67:8, 73:1, 74:25, 75:11, 83:25, 96:2, 97:8, 102:9, 126:19, 142:12</p> <p>secondary 42:10, 128:9</p> <p>section 16:12, 19:3, 58:4, 124:25, 125:2, 152:22</p> <p>sections 135:18</p> <p>see 8:15, 18:12, 20:3, 22:13, 22:20, 34:16, 60:20, 66:1, 67:1, 70:16, 71:14, 72:7, 75:6, 76:24, 77:11, 83:1, 83:6, 83:13, 83:20, 85:9, 85:13, 85:17, 85:18, 87:10, 91:7, 121:4, 122:14, 127:19, 131:2, 132:5, 135:18, 146:5, 151:1, 152:24, 153:2, 154:25</p> <p>seeing 60:18, 65:24,</p>
--	--	--	---

<p>86:4 seeking 61:23 seems 65:18, 67:3, 147:18 seen 28:23, 67:3, 83:24, 89:7, 98:20, 106:1, 119:11, 130:6, 133:8, 138:19 select 61:18 selected 58:5, 62:19, 67:18 selecting 34:21, 34:22, 34:25, 35:5, 35:6, 37:20, 37:23, 61:12, 61:15, 62:17 selection 59:4, 60:1 selective 97:6, 97:10, 97:22, 98:14, 150:21 selectivity 50:10, 50:17, 58:6, 77:7, 82:5, 83:23, 84:3, 84:17, 85:2, 85:6, 85:11, 86:3, 87:17, 87:18, 88:24, 93:17, 108:17, 148:22, 148:25, 150:14, 150:24 send 140:21, 140:24, 158:20 sense 52:15, 62:9, 67:23, 114:23 sensitive 130:24, 131:5</p>	<p>sensitivity 88:21, 89:10, 121:15, 131:6, 138:1 sent 94:12, 139:6 sentence 56:21, 57:1, 120:22, 148:17 separately 110:18 seq 75:6, 75:8 sequence 21:15, 21:20, 22:7, 22:8, 22:18, 74:19, 74:21, 75:14, 75:16, 75:17, 76:2, 76:4, 76:5, 78:1, 78:9, 80:1, 88:7, 92:17, 92:19, 92:22, 93:3, 93:4, 93:7, 93:10, 93:12, 100:13, 100:15, 100:16, 100:17, 100:20, 102:4, 102:7, 109:23, 109:25, 110:1, 114:25 sequences 10:4, 75:4, 75:10, 75:12, 78:4, 100:18, 102:6 services 132:25 session 3:4, 29:4 set 33:1, 95:1, 161:22 settings 128:15 several 11:22, 27:20,</p>	<p>32:11, 35:7, 38:8, 56:23, 59:11, 60:4, 71:17, 76:16, 76:18, 122:22, 135:15, 143:19, 148:7 shall 99:22 shanghai 1:11 share 139:14, 140:11, 140:12, 141:2, 142:3 sheppard 2:10 shorthand 2:3, 15:22, 69:10, 74:14, 91:16, 95:13, 120:12, 141:16, 152:14, 153:19, 161:6 should 5:9, 58:5, 58:7, 124:16, 153:9, 154:5 show 84:21, 86:22, 96:10, 122:10 showed 89:13 showing 65:1, 120:4, 151:8 shown 10:6, 96:17, 156:25 shows 120:22 sialoglycans 18:6, 19:12, 19:23 siblings 101:24, 104:3 side 8:16</p>	<p>side-effects 81:7 sign 158:13, 160:6 signaling 3:10, 34:7, 34:19, 127:24 signals 157:3 signature 160:25 signature-sc3 161:25 signed 11:12 significant 44:6, 44:7, 78:17, 85:24, 127:17, 135:5, 136:13, 136:16, 136:19, 136:23 significantly 97:20, 112:15 similar 109:19, 113:23, 114:14, 119:23 similarity 22:9, 101:25, 102:1 simplistic 32:14, 32:20, 32:22 simultaneously 18:9, 43:10, 50:12 since 64:16, 79:17, 146:19, 156:23 single 11:6, 40:6, 49:18, 50:3, 55:17, 104:25, 155:17 sister 91:24 site 25:3, 33:7, 138:18</p>
---	---	--	---

<p>site-specific 20:1</p> <p>situation 42:2, 47:10</p> <p>situations 39:2</p> <p>skill 8:25, 9:5, 14:14</p> <p>skin 71:4</p> <p>skips 94:19</p> <p>sleep 12:4</p> <p>slightly 6:24, 86:23</p> <p>slowly 5:6, 6:19</p> <p>small 58:8, 142:13</p> <p>smaller 70:6</p> <p>smoothly 5:5</p> <p>solid 4:28, 4:33, 70:2</p> <p>solve 147:2</p> <p>some 6:17, 10:12, 16:4, 17:25, 21:23, 24:8, 39:10, 49:22, 58:14, 59:13, 59:21, 60:3, 61:5, 67:10, 71:5, 76:7, 78:6, 79:11, 83:9, 83:20, 83:24, 85:25, 88:7, 89:17, 101:15, 112:21, 126:18, 132:6, 133:7, 134:2, 139:2, 146:1, 147:14, 150:15</p>	<p>something 17:12, 23:1, 43:2, 111:17, 147:17</p> <p>sometimes 41:1, 41:3, 41:13</p> <p>soon 134:8, 149:11</p> <p>sooner 66:7</p> <p>sophisticated 65:18</p> <p>sorry 6:22, 9:22, 10:14, 11:19, 15:3, 17:5, 20:17, 30:24, 34:3, 35:3, 38:21, 39:16, 39:22, 43:12, 46:19, 49:3, 50:14, 50:15, 52:17, 65:11, 67:8, 67:9, 72:3, 73:9, 82:9, 82:23, 84:1, 99:8, 102:6, 106:21, 107:12, 114:10, 130:16, 133:12, 134:11, 140:19, 157:5, 157:16</p> <p>sound 27:1, 31:17, 55:15, 73:8</p> <p>sounds 31:18, 73:16</p> <p>sources 61:23</p> <p>sparing 51:1, 51:9</p> <p>speak 5:6, 6:18, 64:25</p> <p>speaker 7:1</p> <p>speaking 5:12, 18:9,</p>	<p>29:8, 29:14, 43:10, 50:12</p> <p>species 21:21, 22:18, 146:6</p> <p>specific 33:11, 47:23, 48:4, 48:8, 48:9, 75:15, 93:19, 102:17, 124:25, 132:10, 132:17, 133:25, 134:19, 152:22</p> <p>specifically 21:22, 23:11, 34:15, 80:8, 90:15, 132:18, 133:20</p> <p>specification 13:1, 13:4, 13:7, 13:16, 13:22, 13:24</p> <p>specificity 39:18, 40:8, 40:24, 107:16, 108:8, 108:14, 113:23, 114:14, 115:2, 132:13, 132:15, 132:16</p> <p>specify 59:9, 160:6</p> <p>spectrum 107:22</p> <p>speculate 28:14, 53:15, 64:19, 88:6, 138:14, 147:13</p> <p>spelled 9:3</p> <p>spend 9:12, 12:5</p> <p>spent 12:13</p> <p>spike 42:5, 42:7, 42:11, 42:22, 42:23</p> <p>stabilities 79:12</p>	<p>stability 58:10</p> <p>stages 57:5</p> <p>staining 135:25</p> <p>stamp 120:16</p> <p>stamped 15:20, 140:4</p> <p>stand 131:17, 141:6</p> <p>standards 155:20, 155:21</p> <p>standing 158:18</p> <p>start 6:5, 64:9, 77:24</p> <p>started 6:9</p> <p>starting 125:2, 152:21, 152:25, 154:2</p> <p>starts 153:4</p> <p>state 2:3, 20:21, 20:25, 143:8, 144:17, 161:3, 161:7</p> <p>stated 68:23, 103:23, 126:2</p> <p>statement 37:9, 40:2, 72:23, 73:2, 84:25, 85:3, 85:4, 121:11</p> <p>statements 81:14, 81:16, 81:22</p> <p>states 1:1, 3:22, 4:34, 29:16, 76:24, 80:22, 81:4, 85:5, 144:17</p>
---	---	--	---

<p>status 129:3</p> <p>steady 144:17</p> <p>stenographer 5:18, 19:18, 21:7, 24:18, 25:7, 29:22, 29:24, 40:16, 40:21, 57:19, 59:18, 65:8, 106:11, 109:2, 109:11, 114:7, 127:4, 129:11, 131:9, 141:23, 151:12, 158:17</p> <p>stenographically 1:29, 5:20, 161:9</p> <p>step 48:24</p> <p>steps 60:24</p> <p>steric 42:13</p> <p>still 17:17, 32:11, 43:3, 43:19, 66:13, 66:14, 68:13, 87:15, 106:4, 106:5, 127:25, 128:5, 129:3, 131:17, 131:20, 132:7, 150:15</p> <p>stopping 124:14</p> <p>strategies 20:8</p> <p>strategy 53:1, 53:6, 53:9, 66:11, 106:10, 106:16, 106:17</p> <p>strike 28:17, 39:16, 49:3, 52:17, 71:19, 82:9,</p>	<p>91:11, 102:6, 105:15, 106:20, 130:16, 134:12, 157:5</p> <p>stronger 112:2, 112:13, 125:24, 126:8, 138:10</p> <p>structure 40:25, 41:3, 42:11</p> <p>studies 53:25, 65:1, 65:17, 151:3</p> <p>study 4:21, 4:31</p> <p>stylianos 1:21, 2:1, 3:21, 5:21, 74:3, 159:16, 160:8</p> <p>subclass 148:13</p> <p>subject 20:4, 26:18, 26:21, 81:8</p> <p>subscribe 159:9</p> <p>subset 98:12</p> <p>substantial 58:6, 87:14, 125:13</p> <p>substantially 80:2, 87:1, 101:19, 101:21, 103:25, 104:6, 104:18, 104:24, 104:25, 105:5, 105:13, 105:17, 105:25, 106:9, 106:14, 107:2, 107:9, 107:17, 107:25, 108:17, 108:20, 108:21, 108:22, 108:24, 109:1, 109:6, 109:15, 109:19,</p>	<p>112:20, 113:25, 114:17, 114:19, 114:22, 114:25, 115:8, 115:18, 126:14, 130:4, 149:25</p> <p>substantive 157:25</p> <p>substitution 77:25, 104:25</p> <p>success 55:25, 56:1, 56:3, 56:8, 56:11, 56:13, 56:14, 56:24, 56:25, 57:5, 57:7, 57:12, 57:24, 58:16, 59:10, 60:14, 60:25, 62:18, 68:25, 71:11, 131:7, 155:14, 155:17, 155:22, 155:23</p> <p>successful 60:9, 60:17, 64:21, 65:20, 71:6, 89:11, 89:19, 89:25, 90:9, 90:14, 90:24, 91:5, 98:22, 99:2</p> <p>successfully 73:7</p> <p>sufficient 49:18, 49:21, 49:23, 49:24, 50:4, 137:23</p> <p>sufficiently 144:19</p> <p>suggest 124:2</p> <p>suggests 14:14, 21:19, 31:23, 35:14</p> <p>suitable 60:12, 60:13, 60:14, 61:8,</p>	<p>63:4, 63:13, 63:20, 76:12, 156:20</p> <p>support 77:12, 81:20, 118:14, 119:11, 123:22, 150:19</p> <p>supports 77:20</p> <p>sure 6:15, 13:12, 15:9, 19:15, 31:16, 31:19, 32:8, 41:10, 45:20, 47:9, 47:14, 48:3, 51:4, 55:12, 61:6, 64:11, 72:6, 73:13, 75:9, 75:15, 82:22, 82:23, 84:24, 85:15, 92:11, 92:12, 93:1, 95:19, 102:1, 104:12, 113:11, 117:25, 122:20, 128:17, 128:19, 135:8, 137:3, 137:16, 142:14, 153:9, 155:9, 156:2, 158:3</p> <p>surface 41:17, 42:12, 42:16, 42:19, 44:5, 47:1, 47:19, 48:14, 50:2, 97:14, 97:18, 98:9, 134:6, 135:5, 136:6, 136:12, 137:12, 145:6, 147:8, 147:22</p> <p>surfaces 41:16, 42:18, 133:1</p> <p>surrogate 85:11</p>
--	--	---	--

<p>switching 53:20, 54:5 sworn 5:22, 74:4, 161:8 synthesis 19:25 sys 4:22, 151:4, 151:16, 154:14, 154:17, 155:14, 156:1, 156:8, 156:18, 157:12, 157:20 system 23:1, 47:10, 135:24 systems 148:5 sys↔syh 4:26</p>	<p>132:9 talk 5:6, 8:24, 47:16, 79:6, 134:19, 137:3 talking 19:16, 52:8, 52:10, 66:9 talks 45:25 target 25:23, 25:25, 33:11, 33:16, 35:8, 35:11, 37:25, 38:1, 39:5, 39:11, 40:8, 40:10, 40:11, 40:20, 43:24, 47:21, 48:1, 48:6, 48:20, 50:7, 51:14, 51:20, 52:4, 54:8, 54:11, 54:12, 58:8, 58:13, 60:12, 60:21, 61:14, 61:23, 62:22, 62:24, 63:1, 63:4, 63:8, 63:11, 63:19, 63:23, 63:24, 66:4, 66:23, 67:18, 70:1, 70:2, 71:12, 102:23, 107:5, 132:14, 137:13 targeted 33:8, 34:6, 47:24, 59:3, 67:21 targeting 39:12, 44:20, 48:17, 49:16, 50:21, 54:14, 67:16, 77:8 targets 66:6, 66:18,</p>	<p>99:6, 118:10, 143:23 taught 119:14, 119:17 teach 116:1, 116:8, 116:13, 117:22, 118:1, 118:7 teaches 116:5, 118:3, 125:15 teaching 116:16, 117:5, 117:6 technical-related 5:16 technician 2:30, 5:3, 139:14, 139:18, 139:24, 140:2, 140:6, 140:10, 140:17, 140:20, 140:23, 141:1 technologies 58:9, 60:22 tell 6:11, 61:1, 61:7, 102:9, 129:16, 135:19 ten 99:23 ten-minute 91:22, 158:8 term 9:3, 36:17, 44:9, 54:21, 54:22, 55:10, 55:14, 55:17, 56:3, 56:13, 56:25, 135:8, 152:25 terms 17:13, 38:10, 38:14, 55:20, 69:21, 71:22, 77:7, 114:25, 115:1, 128:4 terrific 158:22</p>	<p>tested 84:22, 87:3, 87:4, 91:10, 108:5, 148:23, 155:1 testified 5:23, 74:5, 90:3 testimony 7:13, 8:4, 8:6, 46:9, 81:12, 85:8, 87:7, 98:2, 104:20, 105:21, 107:13, 131:16, 160:3, 160:5, 161:9 testing 20:6 text 14:2 th 2:24 thank 5:3, 5:17, 7:3, 7:7, 15:24, 19:18, 21:5, 21:6, 40:21, 49:5, 94:15, 95:7, 99:21, 99:24, 153:16 thanks 16:8, 40:22, 48:16, 95:9, 117:21, 128:24 that'd 95:4 therapeutic 28:7, 37:12, 37:14, 54:14, 54:15, 54:19, 54:22, 54:25, 55:5, 55:11, 55:14, 55:19, 56:9, 66:5, 66:11, 67:3, 127:8 therapeutics 14:19</p>
T			
<p>table 83:2, 83:3, 83:4, 83:7, 83:14, 84:10, 84:12, 84:13, 84:14, 85:10, 85:18, 86:5, 86:12, 86:14, 87:8 tables 83:19 take 7:8, 7:9, 26:21, 37:23, 47:14, 48:24, 60:24, 67:11, 73:14, 80:13, 84:1, 84:19, 84:25, 99:20, 99:22, 105:23, 124:17, 127:20, 147:3, 155:4, 155:9, 158:2, 158:8 taken 2:2, 73:20,</p>			

<p>therapy 55:23, 64:1, 127:21, 127:22 thereafter 161:10 thereof 159:9 thing 22:23 things 6:9, 8:23, 10:11, 10:12, 83:1, 126:16 think 9:11, 14:7, 14:8, 16:3, 22:22, 27:6, 28:3, 28:13, 32:22, 33:7, 45:19, 48:19, 52:9, 60:3, 64:14, 64:20, 66:6, 67:25, 68:6, 70:22, 77:18, 80:9, 80:10, 81:19, 86:1, 87:18, 88:3, 88:11, 91:13, 96:11, 97:7, 99:16, 110:3, 129:5, 129:9, 137:7, 140:8, 144:24, 147:11, 153:9, 155:18, 156:4, 156:7 third 58:9 thought 147:21, 148:16 three 59:10, 68:24, 71:1 threshold 44:4, 44:8, 44:10, 44:15, 48:23, 49:7, 135:3, 135:7,</p>	<p>135:9, 136:9, 136:11 through 10:19, 11:22, 16:13, 20:1, 40:12, 41:11, 84:14, 143:2, 143:10, 143:18, 144:9, 145:12, 158:21 thursday 1:22, 2:4, 5:1, 74:1 tikhomirov 117:14, 117:17, 117:22, 118:1, 118:6, 118:8, 118:15, 118:25, 119:13, 119:16, 120:3, 120:16, 120:17, 122:16, 123:2, 123:15, 123:19, 124:3, 124:8 tikhomirov's 119:24, 123:7 time 2:5, 6:7, 9:12, 9:18, 12:13, 27:2, 30:21, 30:25, 31:4, 31:11, 31:15, 31:17, 47:13, 55:2, 55:8, 71:15, 73:17, 73:18, 78:8, 89:9, 99:23, 124:3, 124:6 timing 55:9 tissue 81:2, 130:10, 130:12, 130:19, 130:21, 130:22, 130:23, 130:25, 133:14 tissues 52:20, 54:7,</p>	<p>71:13, 97:20, 130:2, 130:5, 151:2 title 19:20, 19:22, 20:25 today 6:11, 6:14, 7:8, 7:14, 7:22, 8:1, 8:4, 8:10, 8:24, 27:23 today's 6:13 too-potent 54:6 too-toxic 54:7 tools 63:25, 147:2 top 18:21, 72:9 topic 27:23 total 12:13, 12:18, 12:21 toxic 33:3, 52:16, 52:18, 52:23, 52:25, 53:5, 53:10, 53:19, 54:7, 54:13 toxicity 53:2, 53:7, 53:14, 59:25, 119:2, 119:6, 119:10, 119:23, 120:2, 120:6, 120:25, 121:12, 122:1 trademark 1:1 transcribed 6:14, 161:10 transcript 5:14, 161:20 transcription 161:11</p>	<p>translated 100:21 transplantation 22:23 treat 55:3, 55:8 treated 81:8 trial 1:2, 4:26, 29:12, 29:15 trials 38:5, 154:25, 157:2, 157:3 tried 103:13 trigger 47:20, 47:25, 48:6, 137:13, 145:9 triggers 63:16, 63:19 true 28:6, 43:7, 77:15, 79:21, 103:23, 129:25, 131:20, 133:24, 161:12 truth 6:11 truthful 8:4 try 52:14, 73:19, 76:1, 76:20, 139:11 trying 64:4, 66:15, 142:16, 157:19 tumor 32:6, 32:10, 32:16, 32:19, 33:1, 33:7, 35:18, 36:21, 38:24, 39:3, 39:20, 50:25, 51:8, 51:20, 52:5, 53:12,</p>
---	--	--	---

<p>53:14, 58:6, 58:13, 67:20, 70:4, 70:7, 70:24, 72:5, 77:2, 77:8, 80:25, 83:10, 87:25, 88:1, 93:16, 93:21, 97:5, 97:10, 97:21, 97:25, 98:13, 98:14, 98:17, 115:17, 127:2, 128:10, 128:11, 129:1, 129:23, 129:25, 130:5, 130:8, 130:23, 131:2, 131:3, 132:8, 133:10, 135:18, 135:20, 148:19, 149:7, 149:14, 149:19, 149:24, 150:7, 150:16, 150:25 tumors 4:28, 4:33, 51:22, 52:6, 70:2, 70:17, 70:18, 93:19, 97:16, 97:18, 97:22, 98:10, 98:12, 127:20, 127:22, 128:3, 129:2, 150:21 turn 89:14 two 21:21, 25:17, 25:18, 25:19, 25:23, 38:6, 43:13, 70:23, 71:1, 83:19, 103:1, 103:3, 103:12, 107:6, 107:7, 108:16, 108:24, 110:8, 115:7, 122:23, 123:12, 126:16,</p>	<p>137:15, 137:18, 137:19, 137:22, 154:7 type 10:18, 111:7, 127:2, 128:11, 129:1, 143:2, 143:10, 143:25, 144:4 types 67:20, 98:14, 115:17, 130:7, 131:3, 134:2 typically 21:24, 44:4, 50:3, 57:13, 58:1, 136:9, 137:9, 138:20, 138:21 tyrosine 75:24 <hr/>U<hr/>uh-huh 14:3 unbinding 161:19 unclear 6:24, 14:8, 30:8, 37:1, 44:13 unconjugated 38:9, 38:24, 39:4, 128:14 under 6:10, 36:5, 36:19, 77:16, 77:17, 80:24, 81:1, 87:2, 159:1, 159:3, 159:4 understand 6:10, 6:18, 7:12, 7:16, 7:18, 9:4, 12:16, 13:19, 22:16, 26:10, 26:11, 31:2,</p>	<p>41:19, 45:21, 48:25, 54:21, 55:4, 55:18, 56:2, 56:7, 117:18, 128:17, 150:13 understanding 13:6, 14:6, 61:22, 81:24, 84:15 understood 7:24, 81:22, 82:4 undesirable 81:6 unedited 5:13 unique 45:13, 47:10 unit 85:14, 135:21, 137:5 united 1:1, 3:22, 4:34 units 84:24, 137:9 university 18:1 unless 7:17, 7:23, 16:4, 63:21, 115:6, 118:4, 134:8, 136:4 unmet 154:18, 155:11 unpredictable 72:18 unsealing 161:19 unstable 60:2 unsuccessful 59:14, 59:24 upload 74:11, 89:15, 94:22, 139:5, 139:23 uploaded 91:13, 94:22,</p>	<p>139:19, 139:20 urothelial 71:7 us0076232 94:6 use 9:3, 26:7, 26:24, 27:5, 33:3, 35:5, 36:23, 37:20, 61:1, 61:2, 61:7, 61:8, 62:4, 62:13, 63:13, 66:24, 68:1, 68:7, 80:7, 87:19, 116:4, 118:3, 123:15, 124:8, 136:7, 156:8, 156:21 useful 61:2, 63:25, 68:13, 68:15, 70:15 uses 116:23, 117:12, 157:20 using 15:25, 25:2, 29:3, 36:17, 75:24, 98:25, 116:8, 116:13, 116:16, 116:24, 117:5, 117:6, 124:6 usually 21:21, 22:6, 31:25 <hr/>V<hr/>vague 13:18, 22:15, 23:15, 23:22, 24:5, 26:8, 28:21, 28:24, 29:2, 29:16, 44:9, 56:13, 136:15</p>
--	---	---	---

<p>valent 137:17 value 85:13 values 87:10 variability 85:16 variable 40:25, 75:7, 88:15, 132:16, 146:2 variables 25:5 variant 75:23, 78:2, 86:3, 90:16, 99:9, 99:12, 99:14, 104:21, 104:22, 117:10, 117:11, 134:16, 134:21, 149:13, 149:16 variants 27:16, 27:18, 28:11, 28:16, 28:19, 30:5, 30:6, 30:10, 30:14, 30:15, 78:23, 78:25, 79:3, 79:4, 79:6, 79:19, 79:24, 80:11, 80:23, 84:22, 86:5, 89:22, 90:12, 90:19, 102:24, 104:6, 104:7, 104:16, 105:7, 108:12, 134:13, 134:16, 134:19, 150:9 variations 21:25, 101:1, 101:9 variety 72:20 vast 21:23, 146:8</p>	<p>vc 118:23, 118:24, 119:19, 120:24, 122:7 vcmmae 99:4, 120:6, 123:3, 124:6, 125:8 vcmmaf 99:4 vedotin 4:17, 38:7, 124:5 verbal 6:13 verbatim 148:16, 149:12 version 3:32, 4:10, 25:11, 25:12, 82:10, 83:16, 84:18, 100:24, 101:4, 145:19, 146:8, 147:19, 150:6, 150:23 versions 11:22, 28:1, 76:16, 79:14, 79:15, 106:14 versus 4:26, 37:10, 83:7, 83:14, 85:25, 86:5, 121:14, 128:14, 129:7, 138:9, 150:25 via 2:7, 33:11, 50:3, 140:21 video 5:11 videoconference 2:7 view 124:21, 146:20 virtue 81:4, 81:8 virus 144:21</p>	<p>vitro 17:18, 20:10, 123:13 vivo 17:18, 20:20, 65:1, 91:7, 91:9, 123:13, 151:1 void 161:21 vs 1:9</p> <hr/> <p style="text-align: center;">W</p> <hr/> <p>wang 18:20 want 9:10, 15:10, 16:24, 19:15, 28:4, 28:7, 28:16, 29:19, 37:21, 38:1, 45:21, 81:12, 86:15, 87:7, 89:14, 91:20, 92:12, 99:19, 99:20, 121:20, 122:3, 124:15, 128:8, 129:10, 139:15, 141:3, 142:18, 152:22, 158:3, 160:4, 160:5 wanted 73:12, 91:3, 140:14 wants 96:11 way 16:4, 25:6, 32:9, 32:20, 46:1, 46:15, 47:11, 49:13, 78:19, 110:14, 130:8, 136:7, 139:8, 139:13, 142:16, 144:15, 147:3, 147:15,</p>	<p>161:17 ways 61:1, 61:7, 61:10, 78:21, 135:15 we'll 73:19, 141:23, 143:24 we're 15:14, 15:25, 19:16, 142:16 we've 47:12, 89:7 weaker 84:23, 87:1, 112:2 wei 3:24, 74:8, 76:1, 76:6, 76:20, 76:24, 78:6, 78:25, 79:3, 79:6, 79:13, 79:18, 80:6, 80:11, 80:22, 81:4, 81:14, 81:17, 81:19, 81:21, 81:22, 82:1, 82:4, 82:10, 84:19, 84:21, 85:3, 85:4, 86:9, 87:23, 88:5, 89:7, 89:11, 89:17, 89:19, 89:21, 90:7, 90:12, 90:17, 90:19, 90:21, 90:24, 91:7, 102:22, 104:7, 104:9, 104:14, 104:15, 108:9, 108:13, 110:17, 111:9, 111:15, 112:25, 113:19, 116:14, 116:20, 117:8, 117:12, 119:14, 119:15, 119:17,</p>
--	---	--	---

<p>119:18, 119:20, 122:17, 123:4, 123:6, 124:4, 124:22, 125:7, 127:20, 134:25, 150:10, 151:3 wei's 74:17, 75:17, 75:21, 78:14, 90:3, 90:11, 101:20, 101:25, 102:3, 102:8, 102:14, 102:20, 103:6, 103:9, 103:15, 109:7, 109:16, 109:22, 110:1, 110:5, 110:13, 110:23, 111:1, 111:4, 111:13, 111:21, 111:24, 112:3, 112:7, 112:18, 112:24, 113:2, 113:5, 113:9, 113:14, 115:13, 116:16, 116:22, 117:4, 117:6, 119:22, 120:1, 125:5, 125:12, 125:19, 135:2, 150:5, 150:8, 150:14 went 11:22 whatever 136:7 whereas 70:17, 72:1, 87:12 whereof 161:22 whether 16:16, 30:17, 36:6, 45:21, 46:3, 49:12, 57:11, 57:23, 60:8, 60:11, 60:12, 60:13,</p>	<p>60:16, 61:2, 61:8, 62:4, 62:13, 62:24, 63:11, 63:12, 64:3, 72:18, 73:12, 93:9, 97:5, 110:21, 111:2, 111:11, 111:18, 112:1, 112:22, 113:3, 113:7, 113:12, 123:22, 124:15, 128:21, 130:11, 130:20, 131:12, 135:19, 137:8, 148:10, 148:24, 150:3, 151:1, 152:24 widening 54:15, 54:18, 55:4 wild-type 86:5, 86:23, 87:11, 129:3 window 54:15, 54:19, 54:22, 55:1, 55:5 wish 147:2 within 35:13, 86:8 without 33:5, 48:18, 48:19, 84:15, 85:23, 101:8, 121:22 witness 5:22, 10:17, 11:4, 11:20, 12:17, 13:9, 13:21, 16:8, 22:17, 23:16, 23:23, 24:6, 24:19, 25:8, 26:11, 28:22, 28:25, 29:25, 30:9, 30:21,</p>	<p>33:13, 34:5, 37:2, 39:25, 40:17, 40:22, 41:20, 43:23, 44:14, 44:23, 46:11, 46:18, 49:20, 50:7, 51:11, 51:24, 52:8, 54:18, 57:15, 58:3, 59:25, 61:20, 65:9, 69:8, 70:11, 77:10, 80:4, 82:13, 85:9, 89:1, 92:25, 95:3, 95:9, 96:13, 98:3, 101:11, 104:21, 105:9, 105:22, 107:14, 109:3, 109:17, 114:3, 114:19, 116:11, 116:19, 117:1, 117:8, 120:1, 123:10, 124:24, 126:2, 127:11, 130:14, 131:17, 135:7, 136:15, 139:10, 141:6, 141:11, 142:15, 142:21, 147:10, 149:3, 151:19, 153:13, 153:16, 153:21, 154:23, 155:9, 155:16, 156:11, 157:15, 157:25, 158:11, 158:13, 158:15, 159:9, 161:22 wo 3:27, 4:13, 93:7, 94:6 words 145:16, 160:4, 160:5 work 17:1, 63:7</p>	<p>worked 11:15, 16:18, 17:9, 17:19 working 31:8 works 32:21 world 3:25, 4:11 worse 83:18, 88:2, 123:23 wouldn't 8:3, 71:13, 97:21, 104:23, 147:16 writing 26:15 written 4:17 wrong 80:12, 99:12, 137:8 wrote 142:7</p> <hr/> <p style="text-align: center;">Y</p> <hr/> <p>yang 18:19 yd 74:17, 75:17, 75:21, 76:7, 76:14, 76:21, 77:6, 77:15, 77:22, 78:15, 78:17, 78:19, 80:7, 80:8, 82:4, 82:11, 82:19, 83:22, 85:5, 85:10, 89:12, 89:20, 89:22, 90:3, 90:8, 90:11, 90:22, 101:20, 102:3, 102:8, 102:15, 102:20, 103:9, 103:15, 103:24, 104:4,</p>
--	--	---	---

<p>104:15, 105:6, 106:23, 107:1, 108:3, 108:6, 108:9, 108:12, 109:7, 109:16, 109:22, 110:1, 110:6, 110:13, 110:23, 111:1, 111:4, 111:13, 111:21, 111:24, 112:3, 112:7, 112:24, 113:2, 113:5, 113:9, 113:14, 113:23, 114:14, 116:23, 117:5, 134:21, 135:2, 136:13, 137:11, 150:6, 150:14, 150:15, 150:18, 150:23 yd-mm 83:14 yd-mmae 83:7 yeah 11:15, 13:24, 14:3, 15:12, 15:18, 16:3, 16:11, 16:17, 16:24, 17:5, 18:4, 19:5, 19:11, 20:25, 29:20, 34:14, 35:3, 38:22, 47:14, 55:6, 56:18, 59:2, 61:20, 68:5, 68:21, 69:5, 69:8, 69:14, 73:5, 73:8, 73:9, 73:11, 73:13, 73:19, 74:21, 76:24, 80:19, 81:24, 83:4, 85:21, 89:13, 92:1, 92:12, 94:25, 95:4, 95:9,</p>	<p>95:11, 95:22, 96:7, 97:2, 97:17, 119:16, 125:3, 134:22, 134:24, 137:4, 137:5, 138:7, 139:18, 139:20, 140:25, 142:9, 142:21, 147:3, 152:24, 158:6, 158:20 year 11:5, 12:3, 26:25, 31:13 years 14:17, 17:25, 64:16, 66:25, 157:11, 157:19 yep 69:19, 80:17 yl 86:25 york 2:25 younes 4:18 yourself 11:17, 86:19, 97:1, 142:11, 153:5 <hr/> <p style="text-align: center;">Z</p> <hr/> z1 146:1 zero 44:16, 44:20, 124:1 zhang 18:19 zong 18:19 zoom 139:21, 139:23 <hr/> <p style="text-align: center;">.</p> <hr/> .2652 2:15 .7914 2:26</p>	<p style="text-align: center;">0</p> <hr/> 00 2:5, 5:2, 99:23 000062 4:13 003 157:8 00685 1:8 0071923 3:24 0076232 4:36 009 117:19 02 149:12 03 100:14, 100:15, 100:22, 101:6, 101:7, 101:11, 101:19, 101:25, 102:2, 102:7, 102:14, 102:20, 103:4, 103:8, 103:14, 103:24, 104:4, 104:8, 104:13, 104:15, 105:5, 105:11, 106:2, 106:23, 107:1, 108:2, 108:6, 108:7, 108:11, 109:6, 109:14, 109:21, 109:25, 110:5, 110:13, 110:21, 110:25, 111:2, 111:11, 111:18, 111:24, 112:1, 112:6, 112:10, 112:13, 112:22, 113:1, 113:3, 113:7, 113:12, 113:19, 113:20, 113:22, 114:13, 115:8, 115:11, 115:21, 115:24,	<p>116:1, 116:4, 116:8, 125:23, 126:9, 126:10, 126:11, 127:15, 129:14, 129:16, 133:13, 134:25, 135:3, 136:13, 137:11, 138:2, 138:9, 138:11, 138:12, 145:18, 145:25, 146:11, 146:13, 146:19, 146:20, 147:8, 147:14, 147:18, 148:22, 148:24, 149:6, 149:22, 149:23, 149:25, 150:3, 156:3, 156:7, 156:11, 156:19, 157:21 04 86:25 041319 93:7, 94:6 0994 86:13, 87:9 <hr/> <p style="text-align: center;">1</p> <hr/> 1 1:32, 73:10, 73:17, 92:23 1,000 137:9 10 73:20, 74:2, 144:13 10,792,370 1:11, 8:8 100 3:28, 4:6, 21:15, 26:14, 31:19, 64:5, 72:6, 75:9, 75:15, 93:1, 102:11, 105:24 1002 3:20, 15:13, 15:20, 15:21,</p>
---	---	---	---

Transcript of Stylianos Bournazos, Ph.D.
 Conducted on December 11, 2025

56:17, 68:19, 72:11, 80:14, 94:1, 103:18 1005 3:22, 74:8, 74:13 1006 3:25, 89:15, 91:13, 91:15 1007 3:28, 84:20, 100:7, 100:9, 100:18 1008 4:6, 84:20, 100:7, 100:9, 100:15 1009 4:11, 117:15, 117:16, 117:20, 120:9, 120:11 101 2:24 10178 2:25 102 86:9, 86:10 1021 4:14, 69:2, 69:4, 69:6, 69:9, 69:13, 69:15, 124:5 1024 84:11 103 105:11 103772504 3:31, 4:9 108 72:12 11 1:22, 2:5, 5:1, 74:1, 96:5, 96:7, 160:9 1100 154:4 1101 4:21, 153:14,	153:15, 153:17 1102 4:25, 153:10, 153:12, 153:17 1103 4:30, 153:7, 153:18 1118 83:12 12 100:21 120 4:11 128 83:9 13 94:13, 100:17, 100:21, 120:22, 121:3 13691 1:30, 2:2, 5:19, 161:7, 161:27 14 94:13 141 3:9 15 3:20, 96:20, 96:22, 96:25, 97:12, 98:7, 100:20 152 3:15 152199 3:27 153 4:21, 4:25, 4:30 1540 2:13 161 1:32 17 2:24 177 96:1, 96:2, 96:7	18 86:5, 161:23 187 103:17, 103:19, 108:21, 114:23 19 73:20, 100:19 1a 74:22, 74:23, 75:2, 75:5 1b 74:24 <hr/> 2 <hr/> 2 158:23 2-7 99:7 20 9:17, 64:16, 73:10, 73:17, 100:19 2000 31:15 2002 94:17 2003 94:17 2004 27:1, 27:5, 94:17 2005 94:18 2006 94:18 2007 94:18 2008 94:18 2009 94:18 2011 4:36, 93:7, 94:6, 94:18 20110076232 94:6 2012 4:19, 94:18	2013 94:18 2014 3:27, 94:19 2015 3:24, 4:13, 4:34, 14:23, 15:1, 31:5, 71:15, 94:9, 94:10, 95:2, 95:12, 95:17, 96:1, 96:21 2016 94:19 2017 142:7 2020 3:9, 139:5, 139:25, 140:1, 140:5, 141:15, 142:6 2021 18:5, 18:15, 18:20 2024 20:14, 20:22 2025 1:8, 1:22, 2:5, 5:1, 74:1, 159:10, 160:9, 161:23 2051 4:26 21 86:12, 86:14, 87:8 212.878 2:26 22 22:13, 100:20, 146:4 24 84:10, 84:12, 84:13, 84:14, 85:10, 85:18 246 75:1 26 158:6
---	---	--	---

<p>27 84:15 29 120:17 2c9 121:7, 122:18</p>	<p>83:4, 83:7, 121:4 44 83:14 45 152:17, 152:19, 153:1</p>	<p>7 7.4 84:23, 86:22, 87:1, 87:6, 87:10 74 3:4, 3:22</p>	
<p>3</p>	<p>5</p>	<p>79</p>	
<p>99:23</p>	<p>5</p>	<p>93:5, 93:25, 95:24</p>	
<p>3.3</p>	<p>75:8, 158:6</p>	<p>8</p>	
<p>86:6</p>	<p>5.07</p>	<p>8.33</p>	
<p>30</p>	<p>86:6</p>	<p>2:5, 5:2</p>	
<p>9:17, 69:16,</p>	<p>50</p>	<p>85:17, 85:25</p>	
<p>69:18, 69:21,</p>	<p>73:17, 84:22,</p>	<p>806</p>	
<p>69:25, 70:1,</p>	<p>85:10, 85:13,</p>	<p>96:10, 96:17</p>	
<p>70:3, 70:8,</p>	<p>85:17, 85:22,</p>	<p>86</p>	
<p>70:9, 70:16,</p>	<p>86:24, 87:2,</p>	<p>125:2</p>	
<p>70:23, 71:10,</p>	<p>116:7</p>	<p>9</p>	
<p>73:15, 73:16,</p>	<p>51</p>	<p>91</p>	
<p>120:15</p>	<p>74:2</p>	<p>3:25</p>	
<p>30.2</p>	<p>55</p>	<p>92</p>	
<p>85:22, 85:25</p>	<p>96:10, 96:17</p>	<p>161:25</p>	
<p>301</p>	<p>6</p>	<p>94025</p>	
<p>4:31, 151:5,</p>	<p>6.0</p>	<p>2:14</p>	
<p>151:16, 154:14,</p>	<p>84:23, 86:24,</p>	<p>95</p>	
<p>154:18</p>	<p>87:2, 87:5</p>	<p>4:34</p>	
<p>31</p>	<p>6.18</p>	<p>99</p>	
<p>120:8, 120:16</p>	<p>86:6</p>	<p>105:24</p>	
<p>33</p>	<p>6.5</p>	<p>994</p>	
<p>71:20, 71:22,</p>	<p>84:23, 86:24,</p>	<p>86:20</p>	
<p>71:25, 72:4</p>	<p>87:1, 87:6</p>		
<p>35</p>	<p>6010</p>		
<p>56:19, 57:9,</p>	<p>4:22, 4:26,</p>		
<p>58:4, 68:16,</p>	<p>151:4, 151:16,</p>		
<p>68:21, 158:23</p>	<p>154:14, 154:17,</p>		
<p>370</p>	<p>155:14, 156:1,</p>		
<p>8:11, 12:14,</p>	<p>156:8, 156:18,</p>		
<p>13:1, 13:14,</p>	<p>157:12, 157:20</p>		
<p>13:17, 14:6,</p>	<p>610717</p>		
<p>14:9, 72:17,</p>	<p>1:31</p>		
<p>72:24, 73:4,</p>	<p>62</p>		
<p>123:21, 124:21,</p>	<p>80:16, 80:22,</p>		
<p>125:5, 125:8,</p>	<p>81:10</p>		
<p>125:12, 125:14,</p>	<p>650.815</p>		
<p>125:16</p>	<p>2:15</p>		
<p>4</p>	<p>69</p>		
<p>42</p>	<p>4:14</p>		
<p>83:2, 83:3,</p>			